<!DOCTYPE html>

<html lang="en">


<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
        <link rel="prev" href="..">
      
      
        <link rel="next" href="../Oncology/">
      
      
      <link rel="icon" href="../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.5.3, mkdocs-material-9.5.12">
    
    
<title>Literature Survey (VPE)</title>

    
      <link rel="stylesheet" href="../assets/stylesheets/main.7e359304.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
  <!-- Add scripts that need to run before here -->
  <!-- Add jquery script -->
  <script src="https://code.jquery.com/jquery-3.7.1.js"></script>
  <!-- Add data table libraries -->
  <script src="https://cdn.datatables.net/2.0.1/js/dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/2.0.1/css/dataTables.dataTables.css">
  <!-- Load plotly.js into the DOM -->
	<script src='https://cdn.plot.ly/plotly-2.29.1.min.js'></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/buttons/3.0.1/css/buttons.dataTables.css">
  <!-- fixedColumns -->
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/dataTables.fixedColumns.js"></script>
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/fixedColumns.dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/fixedcolumns/5.0.0/css/fixedColumns.dataTables.css">
  <!-- Already specified in mkdocs.yml -->
  <!-- <link rel="stylesheet" href="../docs/custom.css"> -->
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/dataTables.buttons.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.dataTables.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/jszip/3.10.1/jszip.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/pdfmake.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/vfs_fonts.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.html5.min.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.print.min.js"></script>
  <!-- Google fonts -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <!-- Intro.js -->
  <script src="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/intro.min.js"></script>
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/minified/introjs.min.css">


  <!-- 
      
     -->
  <!-- Add scripts that need to run afterwards here -->

    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../assets/_mkdocstrings.css">
    
      <link rel="stylesheet" href="../custom.css">
    
    <script>__md_scope=new URL("..",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="Literature Survey for Swathi" class="md-header__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Literature Survey for Swathi
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Immunology
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
    <li class="md-tabs__item">
      <a href=".." class="md-tabs__link">
        
  
    
  
  Home

      </a>
    </li>
  

      
        
  
  
    
  
  
    <li class="md-tabs__item md-tabs__item--active">
      <a href="./" class="md-tabs__link">
        
  
    
  
  Immunology

      </a>
    </li>
  

      
        
  
  
  
    <li class="md-tabs__item">
      <a href="../Oncology/" class="md-tabs__link">
        
  
    
  
  Oncology

      </a>
    </li>
  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
                
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" hidden>
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="Literature Survey for Swathi" class="md-nav__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    Literature Survey for Swathi
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    Immunology
  </span>
  

      </a>
      
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../Oncology/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Oncology
  </span>
  

      </a>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
                
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  

  
  


  <h1>Immunology</h1>

<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
</head>

<body>
  <p>
  <i class="footer">This page was last updated on 2025-12-01 09:20:35 UTC</i>
  </p>

  <div class="note info" onclick="startIntro()">
    <p>
      <button type="button" class="buttons">
        <div style="display: flex; align-items: center;">
        Click here for a quick intro of the page! <i class="material-icons">help</i>
        </div>
      </button>
    </p>
  </div>

  <!--
  <div data-intro='Table of contents'>
    <p>
    <h3>Table of Contents</h3>
      <a href="#plot1">1. Citations over time on Immunology</a><br>
      <a href="#manually_curated_articles">2. Manually curated articles on Immunology</a><br>
      <a href="#recommended_articles">3. Recommended articles on Immunology</a><br>
    <p>
  </div>

  <div data-intro='Plot displaying number of citations over time 
                  on the given topic based on recommended articles'>
    <p>
    <h3 id="plot1">1. Citations over time on Immunology</h3>
      <div id='myDiv1'>
      </div>
    </p>
  </div>
  -->

  <div data-intro='Manually curated articles on the given topic'>
    <p>
    <h3 id="manually_curated_articles">Manually curated articles on <i>Immunology</i></h3>
    <table id="table1" class="display" style="width:100%">
    <thead>
      <tr>
          <th data-intro='Click to view the abstract (if available)'>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th data-intro='Highest h-index among the authors'>Highest h-index</th>
          <th data-intro='Recommended articles extracted by considering
                          only the given article'>
              View recommendations
              </th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f2918cad295af222dcbefbcbfa7b2c18903efa6" target='_blank'>
                Bispecific T cell engager therapy for refractory rheumatoid arthritis
                </a>
              </td>
          <td>
            Laura Bucci, M. Hagen, T. Rothe, M. G. Raimondo, F. Fagni, Carlo Tur, Andreas Wirsching, J. Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena Pachowsky, Markus Eckstein, S. Alivernini, A. Zoli, G. Krönke, S. Uderhardt, A. Bozec, Maria-Antonietta D’Agostino, G. Schett, Ricardo Grieshaber-Bouyer
          </td>
          <td>2024-04-26</td>
          <td>Nature Network Boston, Nature Medicine</td>
          <td>89</td>
          <td>47</td>

            <td><a href='../recommendations/8f2918cad295af222dcbefbcbfa7b2c18903efa6' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Background Mesenchymal stromal cell derived extracellular vesicles (MSC-EVs) are a promising therapeutic for neuroinflammation. MSC-EVs can interact with microglia, the resident immune cells of the brain, to exert their immunomodulatory effects. In response to inflammatory cues, such as cytokines, microglia undergo phenotypic changes indicative of their function e.g. morphology and secretion. However, these changes in response to MSC-EVs are not well understood. Additionally, no disease-relevant screening tools to assess MSC-EV bioactivity exist, which has further impeded clinical translation. Here, we developed a quantitative, high throughput morphological profiling approach to assess the response of microglia to neuroinflammation-relevant signals and whether this morphological response can be used to indicate the bioactivity of MSC-EVs. Results Using an immortalized human microglia cell-line, we observed increased size (perimeter, major axis length) and complexity (form factor) upon stimulation with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Upon treatment with MSC-EVs, the overall morphological score (determined using principal component analysis) shifted towards the unstimulated morphology, indicating that MSC-EVs are bioactive and modulate microglia. The morphological effects of MSC-EVs in TNF-γ/IFN-α stimulated cells were concomitant with reduced secretion of 14 chemokines/cytokines (e.g. CXCL6, CXCL9) and increased secretion of 12 chemokines/cytokines (e.g. CXCL8, CXCL10). Proteomic analysis of cell lysates revealed significant increases in 192 proteins (e.g. HIBADH, MEAK7, LAMC1) and decreases in 257 proteins (e.g. PTEN, TOM1, MFF) with MSC-EV treatment. Of note, many of these proteins are involved in regulation of cell morphology and migration. Gene Set Variation Analysis revealed upregulation of pathways associated with immune response, such as regulation of cytokine production, immune cell infiltration (e.g. T cells, NK cells) and morphological changes (e.g. Semaphorin, RHO/Rac signaling). Additionally, changes in microglia mitochondrial morphology were measured suggesting that MSC-EV modulate mitochondrial metabolism. Conclusion This study comprehensively demonstrates the effects of MSC-EVs on human microglial morphology, cytokine secretion, cellular proteome, and mitochondrial content. Our high-throughput, rapid, low-cost morphological approach enables screening of MSC-EV batches and manufacturing conditions to enhance EV function and mitigate EV functional heterogeneity in a disease relevant manner. This approach is highly generalizable and can be further adapted and refined based on selection of the disease-relevant signal, target cell, and therapeutic product.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e655e5284ada5880ec741fd1452f6a9e088a59" target='_blank'>
                Microglia Morphological Response to Mesenchymal Stromal Cell Extracellular Vesicles Demonstrates EV Therapeutic Potential for Modulating Neuroinflammation
                </a>
              </td>
          <td>
            K. R. Daga, A. M. Larey, Maria G. Morfin, Kailin Chen, S. Bitarafan, Jana Carpenter, Hannah M. Hynds, Kelly M. Hines, Levi B. Wood, Ross A. Marklein
          </td>
          <td>2024-07-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>

            <td><a href='../recommendations/a1e655e5284ada5880ec741fd1452f6a9e088a59' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e665b02560db74abd44a14d0e0ad225c2a41b63b" target='_blank'>
                Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors
                </a>
              </td>
          <td>
            Samarth Hegde, Bruno Giotti, Brian Y. Soong, Laszlo Halasz, J. Berichel, Assaf Magen, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Adam Marks, Meriem Belabed, Pauline Hamon, Theodore Chin, Leanna Troncoso, Juliana J Lee, Dughan Ahimovic, Michael J. Bale, Grace Chung, D. D’souza, K. Angeliadis, T. Dawson, S. Kim-Schulze, R.M. Flores, Andrew J. Kaufman, Florent Ginhoux, S. Josefowicz, Sai Ma, A. Tsankov, T. Marron, Brian D. Brown, M. Merad
          </td>
          <td>2024-06-28</td>
          <td>bioRxiv</td>
          <td>4</td>
          <td>134</td>

            <td><a href='../recommendations/e665b02560db74abd44a14d0e0ad225c2a41b63b' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c93b16e6c2ea8684026f637118f57acb1b437f" target='_blank'>
                Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection
                </a>
              </td>
          <td>
            H. Ichise, Emily Speranza, Federica La Russa, T. Z. Veres, Colin J. Chu, Anita Gola, Ronald N. Germain
          </td>
          <td>2024-07-07</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>11</td>

            <td><a href='../recommendations/d3c93b16e6c2ea8684026f637118f57acb1b437f' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. IgA+ PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia. One Sentence Summary Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA+ plasma cells and systemic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ab6d82fe97aac3e9bb88e1a47a346848d1ab7ff" target='_blank'>
                Gastrointestinal germinal center B cell depletion and reduction in IgA+ plasma cells in HIV-1 infection
                </a>
              </td>
          <td>
            F. Cossarini, Joan Shang, A. Krek, Z. Al-taie, Ruixue Hou, Pablo Canales-Herrerias, M. Tokuyama, M. Tankelevich, Adam Tillowiz, D. Jha, A. Livanos, L. Leyre, M. Uzzan, G. Martínez-Delgado, Matthew Tylor, Keshav Sharma, A. Bourgonje, Michael Cruz, G. Ioannou, T. Dawson, D. D’souza, S. Kim-Schulze, Ahmed Akm, Judith A. Aberg, Benjamin K. Chen, Sacha Gnjatic, A. Polydorides, Andrea Cerutti, C. Argmann, I. Vujkovic-Cvijin, M. Suarez-Farinas, F. Petralia, J. Faith, S. Mehandru
          </td>
          <td>2024-05-20</td>
          <td>bioRxiv</td>
          <td>3</td>
          <td>52</td>

            <td><a href='../recommendations/fc131532914bbcb165dc44342891066be53f33b0' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
          <th>View recommendations</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

  <div data-intro='Recommended articles extracted by contrasting
                  articles that are relevant against not relevant for Immunology'>
    <p>
    <h3 id="recommended_articles">Recommended articles on <i>Immunology</i></h3>
    <table id="table2" class="display" style="width:100%">
    <thead>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/412986be903d5b21c7f1774299fa7448e8984630" target='_blank'>
              Tissue-embedded CD4+ plasticity structures mucosal immunity in IBD-related inflammation
              </a>
            </td>
          <td>
            Q. Jiang, V. Merkus, C. Lindelauf, Nannan Guo, L. Ouboter, T. Höllt, P. Voorneveld, C. Meijer-Boekel, F. Koning, A.E. van der Meulen-de Jong, M. F. Pascutti, Vincent van Unen
          </td>
          <td>2025-11-13</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dfcb0c515a1fef2e5bd8d06a28f07486ae95bcfb" target='_blank'>
              Therapeutic remodeling of the tuberculosis granuloma with 1-methyl-D-tryptophan enhances CD8+ T cell-macrophage interactions
              </a>
            </td>
          <td>
            E. Mccaffrey, A. Delmastro, Bindu Singh, Annu Devi, Nadia A Golden, S. Khader, Michael Angelo, Deepak Kaushal, S. Mehra
          </td>
          <td>2025-10-04</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/49cdf4d2b06dc0c77173ce97caf0d6a3fa0e9a28" target='_blank'>
              Single-Cell Immune Profiling Reveals Non-classical Monocyte-Driven Immunodepression in Tuberculosis Treatment Non-Responders
              </a>
            </td>
          <td>
            Yang Che, Yiqun Xiong, Dongliang Zhang, Yahong Qu, Hao Shen, Weixin Wang, Junshun Gao, ZhenBo Wang, Yi Chen, Zhihong Shen
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/755725f1743ee5ddbe628ca1f1641cb9240f2088" target='_blank'>
              T-Cell Synaptosomes Orchestrate Long-Term Anti-Tumor Immunity via Proliferative and Metabolic Reprogramming
              </a>
            </td>
          <td>
            Sun-Kyoung Kang, Na-Young Kim, Sunghee Lee, Hyeonhee Lee, Won-Chang Soh, J. Park, Hee-Tae Kang, Jihwan Park, Sunjae Lee, Yujeong Shim, Joonha Kwon, Hye-Ran Kim, Chang-Duk Jun
          </td>
          <td>2025-11-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Chemokines and their receptors play a pivotal role in shaping the tumor microenvironment (TME) and modulating immune responses by orchestrating immune cell recruitment, spatial positioning, and facilitating cell-cell interactions. However, the exact mechanisms underlying chemokine signaling across different cell populations within the TME remain poorly understood. In this study, we utilized multiple-omics approaches to explore the relationship between CCR1+ macrophages, CD8+ exhausted T (Tex) cells, and immune checkpoint blockade (ICB) therapy response, as well as the role of chemokine signaling in the formation of CCR1+ macrophage and CD8+ Tex cell niches. We found that CCR1+ macrophages were closely associated with ICB outcomes in melanoma. Additionally, combination therapy with a CCR1 antagonist and anti-PD-1 monoclonal antibody significantly reduced tumor burden in melanoma mouse models, which was attributed to the substantial depletion of CD8+ Tex cells. Further, CCR1+ macrophages were found to co-localize with CD8+ Tex cells in human melanoma tissue, and the CCR1+ macrophage-CD8+ Tex cell niche was correlated with ICB treatment response in mice. Importantly, the CCR1-CCL3 axis was identified as a critical mediator in the formation of this niche. Overall, our study underscores the spatial relationship between CCR1+ macrophages and CD8+ Tex cells in ICB therapy, providing a promising strategy to overcome ICB resistance in melanoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a30817fcd20d9c5c0a1a97d6e2d28c75431189be" target='_blank'>
              Blocking CCR1+ macrophages overcomes resistance to immune checkpoint inhibitors in melanoma
              </a>
            </td>
          <td>
            Xinyu Su, Rong Huang, Donglin Kang, Jiayu Wang, Lin Li, Zhengyun Zou
          </td>
          <td>2025-11-03</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/063232094274864c9ecb7e230d62b1cabacbd418" target='_blank'>
              ETV4 restrains the formation of CD74+ cytotoxic exhausted CD8+ T cells
              </a>
            </td>
          <td>
            Dongwook Lee, Yewon Kim, Hyeonmin Gil, Jiyun Lee, Yoon Ha Choi, Minjung Kang, Yunjung Hur, Youngkwon Song, J. S. Park, K. Kim, Jong Kyoung Kim, Yoontae Lee
          </td>
          <td>2025-10-04</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Tissue-resident alveolar macrophages (AMs) rely on intrinsic stem-like programs for self-renewal and maintenance, yet the transcriptional networks that support these functions and their relevance to post-viral lung disease remain largely unknown. Here, we identify TCF4 (Tcf7l2) as a critical transcription factor that governs AM maturation and stemness. Loss of TCF4 impaired AM proliferation, shifted their identity toward a pro-inflammatory phenotype, and exacerbated host morbidity following influenza or SARS-CoV-2 infection. Conversely, enforced TCF4 expression promoted the expansion of mature AMs, and supported lung recovery, thereby protecting against severe acute viral disease. Mechanistically, TCF4 antagonized β-catenin-driven inflammatory transcription while preserving oxidative phosphorylation, defining a reciprocal regulatory axis essential for AM function. Notably, respiratory viral infections and exuberant interferon signaling suppressed TCF4 expression, which remains chronically reduced in murine and human lungs with post-COVID fibrosis. This downregulation is associated with persistent KRT8hi dysplastic epithelium and collagen deposition. Moreover, aging diminished TCF4 levels and enforced TCF4 expression dampened age-associated decline of AM self-renewal. Furthermore, in vivo TCF4 overexpression after viral clearance enhanced mature AM accumulation, promoted lung epithelium regeneration, attenuated chronic tissue fibrosis and restored pulmonary physiologial function in aged lungs in a model of persistent pulmonary fibrosis post-acute viral infection. These findings have established TCF4 as a key regulator of AM stemness and identified a promising therapeutic target for long COVID and related chronic lung diseases through the modulation of embryonic-derived macrophage regenerative capacity by targeting TCF4.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/65799dca4a24e6fbcd774c66d4741d26a7a006c5" target='_blank'>
              Targeting a macrophage stemness factor to mitigate diseases post respiratory viral infection
              </a>
            </td>
          <td>
            Mohd Arish, A. Chaudhuri, Janli Tang, H. Narasimhan, An Fang, Jinyi Tang, Xiaoqin Wei, Chaofan Li, I. Cheon, Wei Qian, Farha Naz, Gislane Almeida-Santos, Samuel Young, T. Parimon, Y. Shim, Robert Vassallo, Peter Chen, Jie Sun
          </td>
          <td>2025-10-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Tissue-resident memory CD4+ T cells (TRM) are key sentinels of the adaptive immune response that provide a rapid, robust inflammatory response upon reactivation in non-lymphoid tissues. While CD4+ TRM are highly protective during reinfections or tumor growth, they are also critical mediators of autoimmunity and allergic disease. Using transcriptional analysis and flow cytometry we profiled the heterogeneity of allergen-specific CD4+ TRM in the lungs following house dust mite exposure and observe two distinct populations of cells: a proinflammatory Th2 lineage and a progenitor TCF1+ lineage that can repopulate the Th2 branch. Confocal microscopy revealed that these two subsets occupied distinct anatomical niches in the inflamed lungs, with Th2 cells localized to the airways while TCF1+ cells localized within pulmonary tertiary lymphoid structures (TLS). Spatial transcriptomics affirmed the TLS as a tissue progenitor niche and highlight the transcriptional progression from progenitor to Th2 cell reflected in the TLS:airway axis. Manipulations to promote or ablate TLS development resulted in increased or decreased TCF1 expression among allergen-specific T cells, respectively. Finally, we identify the PD1 pathway as a critical signal localized to the TLS core and demonstrate that TCF1+ cells in the TLS are responsive to anti-PD1 treatment. Together, these data shape our understanding of tissue CD4+ T cell responses across space and time and highlight TLS as a critical therapeutic target that promotes the propagation of chronic inflammatory diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9a206f96029ea77d3f12043c80bdc9e380da94fc" target='_blank'>
              Tertiary lymphoid structures support the development of allergen-specific progenitor CD4+ T cells
              </a>
            </td>
          <td>
            Derek J. Bangs, Brian Hondowicz, Kathleen Abadie, Remi Savard, Madeleine Weiss, Triantafyllia Karakousi, Peter J. Skene, Amanda W. Lund, Ananda W. Goldrath, Maximilian Heeg, Marion Pepper
          </td>
          <td>2025-10-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>64</td>
        </tr>

        <tr id="Penile squamous cell carcinoma (PSCC) is a malignancy characterized by a poor prognosis and lack of reliable biomarkers, presenting considerable therapeutic challenges. Tertiary lymphoid structures (TLSs) are critical modulators of antitumor immunity; however, the immunological dynamics, particularly the roles of B cells and their interactions with naive T cells in PSCC tissues, remain inadequately understood. This study integrates transcriptomic approaches, including spatial transcriptomics, single‐cell sequencing (scRNA‐seq), and bulk RNA sequencing (bulk RNA‐seq), and immunohistochemistry to elucidate the immune architecture of and functional mechanisms within TLSs. The results reveal a positive correlation between TLS density and patient survival, with CD74⁺ B cells tending to be enriched during early TLS formation. These cells exhibit strong immune activation and a propensity to differentiate into plasma cells. By engaging with naive T cells through HLA‐DRA via ligand–receptor interactions, CD74⁺ B cells activate transcription factors, including NFKB1, NFKB2, NFATC1, NFATC2, FOS, and RUNX1, in naive T cells, thereby enhancing the immune response. Consequently, CD74⁺ B cells represent a compelling biomarker for and therapeutic target of PSCC, offering profound insights into the immunological mechanisms that drive PSCC progression and response to immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f775dcc4d8e646b4cd53d88e405d27443da1f7f" target='_blank'>
              Spatial Transcriptional Dynamics of CD74⁺ B Cells in Tertiary Lymphoid Structures Drive Immune Evolution in Penile Squamous Cell Carcinoma
              </a>
            </td>
          <td>
            Ting Xue, Chuangzhong Deng, Jingya Liu, Ru Yan, Jing Li, Xiheng Hu, Xueying Li, Xiao Xiao, Jietian Jin, Hongzhen Tang, Desi Chen, Zihan Zuo, Yujie Liang, Dongbin Wang, Bonan Chen, Hui Han, Zaishang Li
          </td>
          <td>2025-10-20</td>
          <td>Advanced Science</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/952046f90f3d6fd3b65c4bc71397ef55777b1e4f" target='_blank'>
              Albumin-STING Nanoagonist Reprograms HSPCs to Antitumor Neutrophils Enhancing MHC I–Mediated CD8⁺ T Cell Immunity
              </a>
            </td>
          <td>
            Jinsong Tao, Hong-Yi Zhao, Chengyi Li, Hanning Wen, Fang Ke, Qiuxia Li, Miao He, Bo Wen, Zhongwei Liu, Wei Gao, Duxin Sun
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Colorectal cancer (CRC) is a highly immunosuppressive malignancy characterized by limited therapeutic options and a poor prognosis. Within the CRC tumor immune microenvironment (TIME), tumor-associated macrophages (TAMs) represent the predominant immune cell population. This study aimed to characterize the specific macrophage subsets contributing to CRC progression and resistance to immunotherapy. Single-cell RNA sequencing (scRNA-seq) was used to identify the key macrophage marker genes. The clinical significance of death-associated protein kinase 1 (DAPK1), was evaluated in clinical CRC cohorts using immunohistochemistry, immunofluorescence, Kaplan-Meier plots and Cox Proportional Hazards Models. Cytometry by time-of-flight, RNA-seq, flow cytometry and an in vitro co-culture system were performed to explore the functional role of macrophage-derived DAPK1 in the TIME. Subcutaneous tumor models and splenic-liver metastasis models were constructed to assess the potential of DAPK1 inhibition to enhance immune checkpoint blockade (ICB) efficacy. scRNA-seq analysis revealed predominant DAPK1 expression in intratumoral macrophages of CRC TIME. Elevated macrophage-specific DAPK1 level was significantly associated with worse prognosis. DAPK1+TAMs exhibited immunosuppressive properties and inhibit CD8+T cells cytotoxicity. Pharmacological inhibition of DAPK1 enhanced the efficacy of anti-PD-1 therapy in murine models. DAPK1+TAMs infiltration was an independent risk factor for overall survival in patients with CRC. These DAPK1+TAMs exhibit an immunosuppressive phenotype and promote the establishment of the TIME with immune evasion. Targeting DAPK1 may represent a potential strategy for synergizing immunotherapy in CRC treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d25841457c8b6bc5218514a8ce08f04c9f270986" target='_blank'>
              DAPK1-positve macrophages facilitate immunosuppressive microenvironment and determine immunotherapy efficacy in colorectal cancer
              </a>
            </td>
          <td>
            Jiang Chang, Yuxu Niu, Shizhao Zhou, Ziqi Zhang, Weiying Zhu, Junchang Zhu, Haoran Xiu, Ke Shang, Q. Feng, Ye Wei
          </td>
          <td>2025-11-04</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7fde1e93aca554dff30d3a72e531050b06480632" target='_blank'>
              Bioengineered human tonsil organoids as an immuno-engineering platform for evaluating immune functions
              </a>
            </td>
          <td>
            Intan Rosalina Suhito, Donovan Eu Kum Chuen, Hong Sheng Cheng, Nguan Soon Tan, Zhe Zhang Ryan Lew, Kai Sen Tan, Justin Jang Hann Chu, Giselle G.K. Ng, Yvonne C.F. Su, G. Smith, Chee Wah Tan, Andy Tay
          </td>
          <td>2025-10-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Melanoma plasticity drives immune evasion and therapy resistance through dynamic cell-state transitions beyond genetic alterations. Epigenetic remodeling critically influences such processes, yet its role in reshaping the tumor ecosystem under therapeutic pressure remains unresolved. Here, we profiled longitudinal biopsies from melanoma patients treated in the phase Ib NIBIT-M4 epi-immunotherapy clinical trial (NCT02608437), testing the combination of a DNMT1 inhibitor with anti-CTLA4 using single-cell multiome and high-resolution spatial transcriptomics. Integrated analyses resolved seven malignant meta-programs, including a rare Wnt/β-catenin–driven melanocytic state and a de-differentiated neural crest–like state enriched in non-responders. Spatial modeling revealed that homotypic clustering stabilizes resistant programs, with neural crest–like cells forming compact, centrally localized niches, whereas Wnt/β-catenin subpopulations displayed a bimodal architecture, either cohesive clusters sustained by adhesion or dispersed, transcriptionally plastic cells. Responders exhibited progressive enrichment of an antigen presentation/interferon program and coordinated remodeling of the tumor microenvironment with T and B cell expansion, whereas tumors from non-responder patients maintained stable composition of neural crest–like clusters. Epigenetic therapy reactivated transposable elements, providing both regulatory signals that prime innate immunity within microenvironment and generating antigens that drive immunoediting and immunogenicity of Antigen presentation/interferon cell states in responders. Finally, NFATC2 emerged as a master regulator of neural crests–like transcriptional phenotypes and promoter of resistance to therapeutic interventions in melanoma patients. NFATC2 perturbation was able to shift tumor cells towards more differentiated and immunogenic states. These findings reveal how epigenetic-based immunotherapy reshapes melanoma ecosystems, provide mechanistic insights into how multiple transcriptional programs promote tumor plasticity and resistance to both combinatorial therapies and immune checkpoint blockade, identify spatial clustering as a principle stabilizing resistant niches, and highlight β-catenin and NFATC2 as actionable vulnerabilities to overcome resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc9320984fb7ca80afa8b2d49d724dd86390a378" target='_blank'>
              Transposable Elements and Homotypic Niches Drive Immune Dynamics and Resistance in Melanoma Epigenetic-based immunotherapy
              </a>
            </td>
          <td>
            Erika Ciervo, Francesco Ceccarelli, A. D. Di Giacomo, Piera Grisolia, A. Covre, Z. M. Besharat, Antonio De Falco, F. Caruso, Luigi Laezza, Luigi Ferraro, Gloria Mas Martin, M. F. Lofiego, Tommaso Sani, E. Ferretti, Yan Guo, Sean B. Holden, R. Mortarini, A. Anichini, M. Maio, T. Noviello, M. Ceccarelli
          </td>
          <td>2025-10-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="Background Pancreatic ductal adenocarcinoma (PDAC) is characterized by a profoundly immunosuppressive tumor microenvironment, which features a dense desmoplastic stroma enriched with cancer-associated fibroblasts (CAFs) that collectively impede the efficacy of immunotherapies. Although oncolytic viruses (OVs) have demonstrated promising potential in eliciting antitumor immunity, the mechanisms by which stromal components modulate OV efficacy remain poorly understood. Methods To investigate the interplay between immune and stromal components in PDAC following OV treatment, we employed murine and patient-derived tumor models. We characterized immune cell populations using single-cell RNA sequencing and flow cytometry. Functional studies included the engineering of a next-generation oncolytic herpes simplex virus expressing FLT3 ligand, OX40 ligand, and interleukin-12 (IL-12), combined with CD40 agonist antibodies to restore dendritic cell (DC) function and enhance T-cell responses. Results We identified a novel immunosuppressive circuit wherein monocytes, sensing damage-associated molecular patterns and pathogen-associated molecular patterns from OV-infected tumor cells, secrete interleukin-1β. This, in turn, triggers IL-6 production by CAFs, creating an IL-6-rich milieu that impairs DC maturation and co-stimulatory signaling, thereby attenuating T cell-mediated antitumor immunity and restricting OV therapeutic efficacy. Importantly, combination therapy with the engineered OV and CD40 agonist antibodies restored DC functionality and elicited robust tumor-specific T-cell responses in both murine and patient-derived models. Conclusion Our findings reveal a previously unrecognized monocyte-CAF-DC axis that mediates resistance to OV therapy through IL-1β and IL-6-driven suppression of DC function in PDAC. This study provides a mechanistically informed and translationally promising approach to overcome stromal immune suppression, restore effective antitumor immunity, and improve therapeutic outcomes for patients with PDAC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b3ad6676052a006d7f44e56422f87b86b5aaedd5" target='_blank'>
              Oncolytic virus-induced IL-1β+ monocyte-IL-6+ CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer
              </a>
            </td>
          <td>
            Fan Li, Jingru Chen, Yuanke Li, Wei Wang, Yi Yang, Jie Wang, Minghui Han, Han Wang, Feilong Zhou, Wenxuan Ma, Yi Wang, Zhaoyuan Zhang, Jufeng Yu, Zhen Zhao, Li Deng, Shiyu Liu, Yajuan Wan, Zhigang Zhao, Song‐Tao Xu, Jiangmei Li, Youjia Cao, Hongkai Zhang
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Background COVID-19, including its post-acute sequelae (Long COVID), is increasingly recognized as involving persistent immune dysregulation and chronic inflammation. Severe and prolonged disease states are often accompanied by sustained cytokine release, immune cell exhaustion, and ongoing cell-cell communication that shapes the inflammatory milieu. Among immune subsets, CD8+ T cells play a central role in antiviral defense, yet the molecular mechanisms linking their dysfunction to prolonged inflammation remain incompletely understood. Methods We analyzed 73,110 peripheral blood mononuclear cells (PBMCs) from individuals across four disease states (Healthy, Exposed, Infected, and Hospitalized) using single-cell RNA sequencing. Immune cell subsets were annotated, and T cell heterogeneity was profiled. Cytokine and inflammatory scores were calculated to assess immune activation. Differentially expressed genes (DEGs) underwent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Cell-cell communication was evaluated to map ligand-receptor networks. Additionally, nine machine learning models were trained on a bulk RNA-seq cohort, and the SHapley Additive exPlanations (SHAP) framework was applied to interpret key predictive genes. Results Progressive disease severity was associated with a decline in T cell proportions, enrichment of pro-inflammatory myeloid cells, and elevated cytokine expression, particularly IL-32. Memory CD8+ T cells showed increased exhaustion and inflammatory scores while maintaining a central position in MHC-I-mediated communication networks. Persistent activation of immune and metabolic pathways, including antigen presentation and oxidative phosphorylation, was observed in prolonged disease states. Seven genes (RPS26, RPS29, RPL36, RPL39, RPS28, RPS21, and CD3E) were identified as strong predictors of chronic immune dysregulation, with the XGBoost model achieving the highest AUC. SHAP analysis confirmed their contributions to disease classification. Conclusion This study maps the immune landscape of COVID-19 and Long COVID at single-cell resolution, revealing that persistent immune cell communication, particularly involving memory CD8+ T cells, may sustain chronic inflammation beyond the acute phase. The identified molecular signatures offer potential biomarkers and therapeutic targets for mitigating post-viral inflammatory syndromes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/536000d345ef1e6f7663efc28145b0e979e70e7b" target='_blank'>
              Immune cell communication networks and memory CD8+ T cell signatures sustaining chronic inflammation in COVID-19 and Long COVID
              </a>
            </td>
          <td>
            Hengrui Liu, Zewen Xu, Ilayda Karsidag, Panpan Wang, Jieling Weng
          </td>
          <td>2025-10-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Abstract Janus kinase inhibitors (JAKis) are widely prescribed for autoimmune diseases, but their use is associated with increased infection risk. The mechanisms underlying this susceptibility remain unclear. CD8 T cells play a central role in antimicrobial defense, yet little is known about how JAKis reprogram their activation and effector programs. Here, we investigated naïve and memory CD8 T cells from healthy donors stimulated in vitro with baricitinib, tofacitinib, or upadacitinib. Flow cytometry, SCENITH, transmission electron microscopy, and RNA-seq were used to evaluate metabolic and functional programs. We found that JAKis uncoupled phenotypic activation from metabolic reprogramming. Functionally, JAKi-treated CD8 T cells exhibited reduced activation and produced lower amounts of cytokines and cytotoxic molecules. Notably, even JAKi-treated memory CD8 T cells that upregulated CD69 and CD25 failed to engage glycolysis, showing decreased GLUT1 expression and glucose uptake. SCENITH profiling confirmed diminished glucose dependence and a shift toward mitochondrial reliance, despite reduced mitochondrial potential and structural alterations. Transcriptomic and protein analyses further revealed decreased mTOR activity and increased p53-associated transcripts, consistent with impaired growth and stress signaling. CD8 T cells from rheumatoid arthritis patients under JAKi therapy were analyzed ex vivo for translational validation. These cells showed similar metabolic and signaling alterations, underscoring their clinical relevance. Altogether, these findings identify JAKis as disruptors of metabolic and signaling pathways in CD8 T cells, providing a mechanistic link between impaired effector function and the increased infection risk observed in treated patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3631e94d8c181426251424980791a3b091872438" target='_blank'>
              Disruption of metabolic licensing by JAK inhibitors constrains CD8 T cell activation and effector function
              </a>
            </td>
          <td>
            Eva Acosta Rodriguez, Luisina Onofrio, Carolina Abrate, Ingrid Strusberg, Liliana Morales, Danilo Ceschin, Carolina Montes, Cinthia Stempin
          </td>
          <td>2025-10-27</td>
          <td>Research Square</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Immunotherapy has shown limited success in acute myeloid leukemia (AML), indicating an incomplete understanding of the underlying immunoregulatory mechanisms. Here we identify an immune evasion mechanism present in 60% of AML cases, wherein primitive AML cells aberrantly express the lymphoid surface protein SLAMF6 (signaling lymphocyte activation molecule family member 6). Knockout of SLAMF6 in AML cells enables T cell activation and highly efficient killing of leukemia cells in coculture systems, demonstrating that SLAMF6 protects AML cells from recognition and elimination by the immune system in a mode analogous to the programmed cell death protein–ligand (PDL1/PD1) axis. Targeting SLAMF6 with an antibody against the SLAMF6 dimerization site inhibits the SLAMF6–SLAMF6 interaction and induces T cell activation and killing of AML cells both in vitro and in humanized in vivo models. In conclusion, we show that aberrant expression of SLAMF6 is a common and targetable immune escape mechanism that could pave the way for immunotherapy in AML. Sandén et al. report that the ligand signaling lymphocyte activation molecule family member 6 protects acute myeloid leukemia cancer cells from T cell-mediated killing, leading to immune escape, and show that this can be targeted by a blocking antibody.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fcb36c82df5f2aa73980ffb55fa7d90a9dbee66e" target='_blank'>
              Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia
              </a>
            </td>
          <td>
            Carl Sandén, N. Landberg, Pablo Peña-Martínez, Hanna Thorsson, S. Daga, Noelia Puente-Moncada, Maria Rodriguez-Zabala, Sofia von Palffy, M. Rissler, Vladimir Lazarevic, Gunnar Juliusson, Mats Ohlin, Axel Hyrenius-Wittsten, Christina Orsmark-Pietras, H. Lilljebjörn, H. Ågerstam, T. Fioretos
          </td>
          <td>2025-10-03</td>
          <td>Nature Cancer</td>
          <td>0</td>
          <td>51</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8bf2e04bf6e2797aba3ea1f4f0aeb768b1def37b" target='_blank'>
              Memory Regulatory T Cells Reprogram into Protective Tfh-like Effectors in Recurrent Malaria
              </a>
            </td>
          <td>
            Nana Appiah Essel Charles-Chess, A. Ruberto, Carson Bowers, N. Obeng-Adjei, M. R. Hansen, Disha Bangalore Renuka Prasad, B. Traore, K. Klonowski, Peter D. Crompton, S. P. Kurup
          </td>
          <td>2025-10-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>47</td>
        </tr>

        <tr id="The immunosuppressive tumor microenvironment (TME) drives radioresistance, but the role of γδ T cells in regulating radiosensitivity remains incompletely understood. In this study, we found that γδ T cell infiltration in the TME substantially increased after radiotherapy and contributed to radioresistance. Depletion of γδ T cells enhanced radiosensitivity. Single-cell RNA sequencing revealed that γδ T cells in the post-radiotherapy TME were characterized by the expression of Zbtb16, Il23r, and Il17a, and served as the primary source of IL-17A. These γδ T cells promoted radioresistance by recruiting myeloid-derived suppressor cells and suppressing T cell activation. Mechanistically, radiotherapy-induced tumor cell-derived microparticles containing dsDNA activated the cGAS-STING/NF-κB signaling pathway in macrophages, upregulating the expression of the chemokine CCL20, which was critical for γδ T cell recruitment. Targeting γδ T cells and IL-17A enhanced radiosensitivity and improved the efficacy of radiotherapy combined with anti-PD-1 immunotherapy, providing potential therapeutic strategies to overcome radioresistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b1efdac109d7acd0476c2a995db227fa1bebc94" target='_blank'>
              IL-17-producing γδ T cells in the tumor microenvironment promote radioresistance in mice.
              </a>
            </td>
          <td>
            Yue Deng, Xixi Liu, Xiao Yang, Wenwen Wei, Jiacheng Wang, Zheng Yang, Yajie Sun, Yan Hu, Haibo Zhang, Yijun Wang, Zhanjie Zhang, Lu Wen, Fang Huang, Kunyu Yang, Chao Wan
          </td>
          <td>2025-10-07</td>
          <td>The Journal of clinical investigation</td>
          <td>1</td>
          <td>21</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/600eaa0907aa3323250a2afba50abb25ebe05bb3" target='_blank'>
              Repurposed endogenous virus-like vesicles mediate dendritic cell long-range antigen presentation and T cell activation for enhanced cancer vaccination
              </a>
            </td>
          <td>
            Wenchao Gu, Ruoxin Li, Hayleigh Goodrich, Dorin Artzi, Simian Cai, Aixin Shi, Irene Tsai, Guoting Qin, Ann Li, Evelyn Goldwasser, Nadine Elkasri, Sijin Luozhong, Shinji Kamada, Yizhou Wu, Vaibhav Upadhayay, Yu Zhao, Yating Yang, Justin Lau, Ella Sultan, Alexei Wirganowicz, Chenzhi Cai, Qiuming Yu, Shaoyi Jiang
          </td>
          <td>2025-11-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5268b5f8f5e67d2ca0369f9fa75cc7835efa85a7" target='_blank'>
              Anti-CD206 CAR T Cell Treatment Restores Fibrosis-Induced Loss of Dermal White Adipose Tissue
              </a>
            </td>
          <td>
            Chanhyuk Park, Asmaa O. Mohamed, Helen C. Jarnagin, Rajan Bhandari, Jason Gunn, Joana M. Murad-Mabaera, Noelle N Kosarek, Fred W. Kolling, Owen M. Wilkins, Yina H. Huang, Michael Whitfield, Patricia A. Pioli
          </td>
          <td>2025-10-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Abstract Introduction Synovial natural killer (NK) cells contribute to inflammation in arthritis by secreting cytokines and modulating synovial fibroblast activation. The aim of this study was to describe systemic versus local inflammatory changes of NK cell subsets as well as their physical cell-cell interactions in arthritis patients. Methods Spectral flow cytometry was used to compare paired peripheral blood (PB) and synovial fluid (SF) immune cells from patients with active inflammatory arthritis and healthy controls. Physical cell-cell interactions within tissues were studied by applying a recently developed cellular interaction mapping framework. Results Our paired approach revealed significant local enrichment of immature and activated NK cells in SF, characterized by elevated markers of early differentiation, immune-checkpoint regulation, and tissue-residency, highlighting tightly controlled immune activation at inflamed sites. Single-cell analysis confirmed heterogeneity within SF-NK cells, suggesting multiple co-existing activation states and developmental stages. PB-NK cells from patients differed profoundly compared to healthy controls, showing less immature NK cell subsets and an enrichment of mature, pro-inflammatory subsets indicative of systemic immune activation. Cellular interaction mapping revealed mainly NK/neutrophil interactions of patients’ NK cells, while interactions with B-cells, T-cells, or monocytes were negligible. T-cells also displayed profound local and systemic alterations. Cellular interaction mapping revealed that next to NK/neutrophil interactions, interactions between B-cells with monocytes and T-cells with neutrophils characterize joint inflammation. Conclusion This paired high-dimensional analysis revealed systemic and local alterations in NK cell subsets shaped by co-existing developmental stages and immune regulatory mechanisms. Cellular interaction mapping indicated that neutrophils are a main interaction-partner of NK cells in inflamed joints.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/33e0fc210c968311a194a2ca7566f89ed217a080" target='_blank'>
              Compartment-Specific NK Cell Phenotypes Reveal Distinct Maturation and Activation States in Inflammatory Arthritis
              </a>
            </td>
          <td>
            Franca Deicher, T. Exner, Maren Claus, S. Yousefian, Lea Rodon, Sophie Elisabeth Leonhardt, J. H. Distler, Carsten Watzl, Hanns-Martin Lorenz, Simon Haas, Daniel Hübschmann, Wolfgang Merkt
          </td>
          <td>2025-10-31</td>
          <td>Journal of Innate Immunity</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Harnessing the stimulator of interferon genes (STING) signaling pathway to trigger innate immune responses has shown remarkable promise in cancer immunotherapy; however, overwhelming resistance to intratumoral STING monotherapy has been witnessed in clinical trials, and the underlying mechanisms remain to be fully explored. Herein, we show that pharmacological STING activation following the intratumoral injection of a non-nucleotide STING agonist (i.e., MSA-2) results in apoptosis of the cytolytic T cells, interferon-mediated overexpression of indoleamine 2,3-dioxygenase 1 (IDO1), and evasion from immune surveillance. We leverage a noncovalent chemical strategy for developing immunomodulatory binary nanoparticles (iBINP) that include both the STING agonist and an IDO1 inhibitor for treating immune-evasive tumors. This iBINP platform developed by dual prodrug engineering and subsequent nanoparticle assembly enables tumor-restricted STING activation and IDO1 inhibition, achieving immune activation while mitigating immune tolerance. A systemic treatment of preclinical models of colorectal cancer with iBINP resulted in robust antitumor immune responses, reduced infiltration of regulatory T cells, and enhanced activity of CD8+ T cells. Importantly, this platform exhibits great therapeutic efficacy by overcoming STING-induced immune evasion and controlling the progression of multiple tumor models. This study unveils the mechanisms by which STING monotherapy induces immunosuppression in the tumor microenvironment and provides a combinatorial strategy for advancing cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c9daa26de0219c1ffe9646ad27a1bde9f47bf084" target='_blank'>
              Targeting STING-induced immune evasion with nanoparticulate binary pharmacology improves tumor control in mice.
              </a>
            </td>
          <td>
            Fanchao Meng, Hengyan Zhu, Shuo Wu, Bohan Li, Xiaona Chen, Hangxiang Wang
          </td>
          <td>2025-10-23</td>
          <td>The Journal of clinical investigation</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Tumor-infiltrating lymphocytes (TILs) are a promising autologous cell therapy to treat solid tumors. TILs are manufactured by expanding and reinfusing tumor-reactive T cells from tumor biopsies. Efficacy of TIL therapies has been limited by the heterogeneity of expanded TIL products and the high prevalence of dysfunctional exhausted CD8+ T cells (TEX). While a subset of CD8+ TILs co-expressing CD103 and CD39 are enriched for tumor-reactive TILs across multiple cancer types, these cells are often in the TEX state with low proliferative potential. To identify regulators of human TIL proliferation, we screened an open reading frame library encoding for all human transcription factors (TFs). RELB emerged as the dominant driver of human TIL expansion with a skew towards CD8+ cells. TCR diversity was maintained after multiple days of in vitro expansion driven by RELB. Transcriptome profiling of multiple RELB-expressing TIL subtypes revealed a shift towards a memory/costimulatory-like phenotype. Using a HER2-targeting CAR and tumor co-culture model, RELB conferred improved persistence after multiple tumor challenges in vitro and improved solid tumor control in mouse xenografts in vivo. Finally, co-culture of RELB-overexpressing TILs with patient-matched tumor organoids showed an increase in TIL product polyfunctionality, tumor reactivity, and tumor killing. Collectively these results support promoting RELB expression as a strategy for broadly enabling TIL therapy for treating solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e0439a6de8243c20d60a46c125842a0d34a0ceda" target='_blank'>
              RELB Reprograms Exhausted Tumor-Infiltrating Lymphocytes for Improved Adoptive Cell Therapy
              </a>
            </td>
          <td>
            Christian D. McRoberts Amador, Rachel E. Conover, Michael C. Brown, Liliana S. Lyniv, P. Noldner, Ying Zhou, Aretha R. Gao, Sean R. McCutcheon, S. Antonia, Charles A. Gersbach
          </td>
          <td>2025-10-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="ABSTRACT Chronic antigen exposure drives CD4⁺ T cell senescence, yet how autoimmunity and persistent viral infections differentially shape T cell differentiation and function remains unclear. Using cytomegalovirus (CMV) and rheumatoid arthritis (RA) as models of chronic immune activation, we performed high‐dimensional mass cytometry and functional assays to define their impact on CD4⁺ T cells. In CMV‐seropositive individuals, CD27−CD28− CD4⁺ T cells were abundant and exhibited a predominantly cytotoxic, nonproliferative phenotype. Only a minor fraction was CMV‐reactive, suggesting that bystander‐driven differentiation contributes to this subset. In the absence of CMV, senescent CD4⁺ T cells were infrequent and phenotypically distinct, though they still exhibited low proliferative capacity. EBV and HSV did not independently increase CD27−CD28− CD4⁺ T cell frequency. Similarly, RA had little effect on their abundance but instead tuned the functional quality of senescent cells. In CMV‐seropositive RA patients, senescent CD4⁺ T cells produced less pro‐inflammatory cytokines and showed impaired cytotoxic degranulation. Central memory CD4⁺ and CD27−CD28− CD8⁺ T cell functions were preserved, with no evidence for CMV reactivation, suggesting maintained viral control by unaffected T cell responses. These findings highlight distinct, nonredundant effects of CMV and RA on CD4⁺ T cell senescence and reveal RA‐specific functional defects in senescent CD4⁺ T cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3441dc9dbc45e96d9b0a98bad7c5d0ce97797b4d" target='_blank'>
              Divergent Effects of Cytomegalovirus and Rheumatoid Arthritis on Senescent CD4+ T Cells
              </a>
            </td>
          <td>
            Lea Williams, Ali O Saber, Silina Awad, Xi Su, Asgar Ansari, Ruozhang Xu, Hannah Jung, Anupama Shahane, Joshua F. Baker, Laura F. Su
          </td>
          <td>2025-11-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Background Tumor-associated macrophages (TAMs) can switch between immune-activating and cancer-promoting states; yet, the stress pathways that lock them into procancerous states remain obscure. Here we defined the role of transcription factor NRF2 as a mediator of procancerous macrophages. Methods We combined spatial transcriptomics, single-cell RNA sequencing, three-dimensional (3D) cell culture and in vivo tumor models to explore how NRF2 activation status in tumor-associated macrophages modifies responses to immunotherapy. Results In MC38 colon tumors, repeated anti-CD40 or radiotherapy created necrosis that split TAMs into peripheral Cxcl9+ and peri-necrotic Spp1+ subsets. Spatial transcriptomics, single-cell RNA sequencing, and Keap1-deficient mice showed that the latter are NRF2-imprinted “stress-TAMs”, with immunosuppressive and tumor-promoting activity. The same NRF2 activation gradient separates pro-inflammatory CXCL9+ and anti-inflammatory SPP1+TAMs across diverse human cancers. NRF2-imprinted TAMs silence IFN-STAT1 programs, lose major histocompatibility complex-II and chemokine expression, fail to expand T cells, drive tumor cell invasion in 3D co-cultures, and foster metastasis. Constitutive hematopoietic NRF2 activation accelerated the growth of therapy-naïve MMTV-PyMT breast tumors and markedly impaired the efficacy of agonistic anti-CD40 antibody therapy in MC38 subcutaneous and lung-metastasis models. Conversely, macrophage-specific Nrf2 deletion restored immunogenic TAMs and potentiated anti-CD40 and anti-programmed cell death protein-1 treatments. Conclusions Our data pinpoint a previously underappreciated cytoprotective mechanism, which inadvertently sustains immunosuppressive macrophages and confers therapy resistance. These results define stress-induced TAMs as an untapped driver of macrophage-based immune evasion. Inhibiting NRF2 activity alongside standard immunotherapies could restore a pro-inflammatory macrophage–T-cell amplification loop, potentially improving patient responses to T-cell—and macrophage-directed immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a3b564268f908e2668ba03acbe4a747ca42980a5" target='_blank'>
              Stress-NRF2 response axis polarizes tumor macrophages and undermines immunotherapy
              </a>
            </td>
          <td>
            Dominik J. Schaer, Nadja Schulthess-Lutz, Livio Baselgia, Kahrisan Kunasingam, R. Humar, K. Hansen, Melanie Eschment, Elena Duerst, F. Vallelian
          </td>
          <td>2025-10-31</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Massive immune cell infiltration and persistent inflammation in the central nervous system (CNS) are key hallmarks of multiple sclerosis. Here, we report a myeloid-derived suppressor cell (MDSC)–based therapeutic strategy, named CNS Immune Targeting Enabled by MDSCs (CITED), which uses surface-decorated MDSCs carrying rapamycin nanoparticles (NPs) for targeted multimodal immune reprogramming in CNS. We show that NP decoration enhances MDSC immunomodulatory function, facilitates their trafficking to inflamed CNS regions, and increases NP accumulation within CNS. In an experimental autoimmune encephalomyelitis model, CITED exhibited robust therapeutic efficacy, resulting in reduced disease progression, improved motor function, and diminished myelin damage. Mechanistic studies reveal that CITED exerts its therapeutic effects by targeted reprogramming of both innate and adaptive immune responses in CNS. Specifically, CITED inhibits immune cell infiltration, rebalances CD4 T cell phenotypes, and promotes the polarization of myeloid cells toward anti-inflammatory phenotypes. Collectively, CITED could provide a broadly effective approach for targeted immune restoration in multiple sclerosis and potentially other autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c8f24c23e0ed496fd13e4cd70e0bb4daac42d668" target='_blank'>
              Nanoparticle-boosted myeloid-derived suppressor cell therapy for immune reprogramming in multiple sclerosis
              </a>
            </td>
          <td>
            Endong Zhang, H. Algarni, Luyu Zhang, Chih-Jia Chao, Shan He, Aditi Upadhye, Qing Bao, Dahee Jung, Shubhi Srivastava, Edidiong Michael Udofa, Philana Phan, Dejan S. Nikolic, Steve Seung-Young Lee, Jalees Rehman, Zongmin Zhao
          </td>
          <td>2025-10-15</td>
          <td>Science Advances</td>
          <td>1</td>
          <td>5</td>
        </tr>

        <tr id="Epigenetic scarring of terminally dysfunctional (TDysf) CD8+ T cells hinders long-term protection and response to immune checkpoint blockade during chronic infections and cancer. We developed a faithful in vitro model for CD8+ T cell terminal dysfunction as a platform to advance T cell immunotherapy. Using TCR-transgenic CD8+ T cells, we found that 1-week peptide stimulation, mimicking conditions in previous models, failed to induce a stable exhaustion program. In contrast, prolonged stimulation for 2–3 weeks induced T cell dysfunction but triggered activation-induced cell death, precluding long-term investigation of exhaustion programs. To better mimic in vivo exhaustion, we provided post-effector, chronic TGF-β1 signals, enabling survival of chronically stimulated CD8+ T cells for over 3 weeks. These conditions induced a state of terminal dysfunction, marked by a stable loss of effector, cytotoxicity, and memory programs, along with mitochondrial stress and impaired protein translation. Importantly, transcriptomic and epigenetic analyses verified the development of terminal exhaustion-specific signatures in TDysf cells. Adoptive transfer of TDysf cells revealed their inability to recall effector functions or proliferate after acute lymphocytic choriomeningitis virus rechallenge. This tractable model system enables investigation of molecular pathways driving T cell terminal dysfunction and discovery of therapeutic targets for cancer or chronic infections.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc4dbe9ec01dc079f493706a4c9a1123f839c591" target='_blank'>
              Faithful modeling of terminal CD8+T cell dysfunction and epigenetic stabilization in vitro
              </a>
            </td>
          <td>
            Amira Yousif, Abbey A. Saadey, Ava Lowin, Asmaa M. Yousif, Ankita Saini, Madeline R. Allison, Kelley Ptak, Eugene M. Oltz, Hazem E. Ghoneim
          </td>
          <td>2025-10-08</td>
          <td>JCI Insight</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/739a87fd565af12d2e067e28eb04d43a769bbc0a" target='_blank'>
              Skin-derived G-CSF activates pathological granulopoiesis upon psoriasis
              </a>
            </td>
          <td>
            Tomson Kosasih, Tatsuya Morishima, Sohyeon Lee, Jungyeon Yoon, Kanako Wakahashi, Pilhan Kim, Aiko Sada, Hitoshi Takizawa
          </td>
          <td>2025-10-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="B lymphocytes exhibit a multifaceted and context-dependent role in tumor biology, acting as both promoters and suppressors of malignancy through dynamic interactions within the tumor microenvironment (TME). This review synthesizes current evidence on the dual functions of B cells in tumor immunity, highlighting their capacity to orchestrate antitumor responses via antigen presentation, antibody-dependent cytotoxicity, and tertiary lymphoid structure (TLS)-mediated T cell activation, while paradoxically driving immunosuppression through regulatory B cells (Bregs), pro-angiogenic signaling, and immune checkpoint modulation. Key mechanisms include TLS formation, which enhances cytotoxic T cell priming and correlates with improved immunotherapy outcomes, and Breg-mediated secretion of IL-10/TGF-β, which fosters T cell exhaustion and myeloid-derived suppressor cell recruitment. Tumor-type specificity is evident: TLS-rich malignancies like melanoma and Non-Small Cell Lung Cancer (NSCLC) show B cell-driven immune activation, whereas pancreatic and hepatocellular carcinomas demonstrate B cell functional plasticity influenced by metabolic and epigenetic reprogramming. Therapeutically, B cell-targeted strategies—including CD20 antibodies, CAR-T cells, and B cell epitope vaccines—demonstrate efficacy in hematologic and solid tumors, yet face challenges due to subset heterogeneity and sex-specific response disparities. Emerging approaches combine immune checkpoint inhibitors (ICBs) with TLS-inducing agents or exploit B cell-derived biomarkers for personalized therapy. Future directions emphasize deciphering B cell metabolic-niche crosstalk, optimizing combinatorial regimens, and leveraging spatial multiomics to resolve functional heterogeneity. By bridging mechanistic insights with clinical translation, this work underscores B cells as pivotal regulators of tumor immunity and advocates for precision strategies to harness their antitumor potential while mitigating pro-tumor plasticity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ebd579b54f9dae49f949806c09388f29afa2ecc8" target='_blank'>
              The dual immunomodulatory role of B cells in tumorigenesis: mechanisms, microenvironment crosstalk, and therapeutic implications
              </a>
            </td>
          <td>
            Zhuangwei Lv, Ruohao Yang, Kai Zhang, Ruihan Wang, Xiaoyu Shi, Jinhua Wu, Lulu Liu, J. Jiao
          </td>
          <td>2025-10-30</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/61f2942696de914b8ddcd3d63d15f096d71ddb29" target='_blank'>
              Progenitor T cells drive chronic pulmonary type 2 inflammation
              </a>
            </td>
          <td>
            Radomir Kratchmarov, Xiaojiong Jia, Jun Nagai, Hiroaki Hayashi, Kinan Alhallak, Juying Lai, Chunli Feng, Jakob von Moltke, Joshua A. Boyce, Patrick J. Brennan
          </td>
          <td>2025-10-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b26845defb7abdc1bf1c1d65b82acb78bc096a5c" target='_blank'>
              Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer
              </a>
            </td>
          <td>
            Chaitanya N. Parikh, Kelly D. DeMarco, Griffin I. Kane, Nikita Bhalerao, Ronnie W. Dinnell, Boyang Ma, Hadiya K. Giwa, Zhen Zhao, Lin Zhou, Katherine C. Murphy, Loretah Chibaya, Haruka Mori, Youwei Qiao, Brian Lewis, Wen Xue, Jason R. Pitarresi, Prabhani U. Atukorale, M. Ruscetti
          </td>
          <td>2025-10-14</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Immune checkpoint inhibitors have traditionally been understood to exert their effects primarily within the tumor microenvironment, particularly targeting CD8 + T cells. However, recent studies have highlighted a pivotal role of tumor-draining lymph nodes in mediating responses to immune checkpoint inhibitor therapy. This study aimed to elucidate the specific mechanisms by which tumor-draining lymph nodes respond to immune checkpoint inhibitor therapy and regulate the tumor microenvironment in human colorectal cancer. We performed single-cell RNA sequencing and T cell receptor sequencing on tumor-draining lymph nodes and tumor tissues from patients with colorectal cancer. Through in-depth analysis of the single-cell data, we established the connection between TDLNs and tumor, and explored the impact of immune checkpoint inhibitor therapy on the immune microenvironment of tumor-draining lymph nodes. In addition, we conducted animal experiments to validate these findings. Our findings revealed that immune checkpoint inhibitor treatment induced the expansion of tumor-specific CD8 + effector memory T cells within tumor-draining lymph nodes, which may serve as a source for the progenitor-exhausted CD8 + T cells in the tumor microenvironment. Moreover, conventional dendritic cells type 1 and macrophages within tumor-draining lymph nodes facilitated this process. We also observed that immune checkpoint inhibitor therapy promoted the expansion of tumor-specific CD4 + follicular helper T cells in tumor-draining lymph nodes, which may explain the increase of CD4 + follicular helper T cells in the tumor microenvironment after immune checkpoint inhibitor therapy. These hypotheses were corroborated through experiments in mice. Our findings delineate the critical regulatory function of tumor-draining lymph nodes in modulating the tumor microenvironment during Immune checkpoint inhibitor therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7b9de1a203560b665a61560f8094ade12f18f1b7" target='_blank'>
              Tumor-draining lymph nodes respond to immune checkpoint inhibition and orchestrate tumor immune remodeling
              </a>
            </td>
          <td>
            Jinzhu Zhang, Jian Ma, Yaru Niu, Jialiang Liu, Zhexue Wang, Jinyu Guo, Yongsheng Meng, Ruifang Sun, Zhen Zhang, Haiyi Liu, Juan Xu, L. Zan, Xu Guan, Xishan Wang
          </td>
          <td>2025-10-06</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="CNS infection by HIV-1 contributes to neuroinflammation, cognitive impairments, and the establishment of viral reservoirs. Although HIV-1 is known to enter the brain early in infection via “Trojan horse” leukocytes, including infected monocytes and CD4⁺ T cells, the specific cellular phenotypes facilitating this process during acute infection remain incompletely characterized. This study aims to characterize the roles of brain lymphocytes during acute infection and primary CD4 + T cell phenotypes seeding the SIV to the CNS. scRNA-seq was performed on brain and blood cells of three acutely SIV-infected rhesus macaques. The transcriptomic data were analyzed using bioinformatics approaches and validated through in vitro co-culture assays and re-analysis of a publicly available scRNA-seq dataset. scRNA-seq of brain and blood immune cells from acutely SIV-infected rhesus macaques revealed an expansion of proliferating CD4⁺ cytotoxic T lymphocytes (CTLs) in the blood, characterized by high CD4, CCR5, and adhesion molecule expression, indicating strong potential for CNS infiltration. In the brain, CD4⁺ CTLs, tissue-resident memory cells, and a unique Myeloid–T cell cluster were enriched for SIV⁺ cells. Integration of brain and blood data revealed transcriptomic maturation of CD4⁺ CTLs upon brain entry. To validate the biological relevance of the Myeloid–T cluster, we used a macrophage–T cell co-culture system, which reproduced similar dual-marker expression and identified chemokines (e.g., CCL3, CCL4) as potential markers of T cell–myeloid cell interaction. Our findings suggest that CD4⁺ cytotoxic-like T cells represent a key lymphocyte subset responsible for initiating SIV entry into the brain and triggering neuroinflammatory processes. Furthermore, interactions between infiltrating lymphocytes and brain-resident myeloid cells, potentially through chemokine signaling, may facilitate viral propagation within the CNS.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/72fbfac68579326979ef04a1dc07549f993cb4aa" target='_blank'>
              T cell-mediated SIV dissemination into the CNS: a single-cell transcriptomic analysis
              </a>
            </td>
          <td>
            Xiaoke Xu, Meng Niu, Benjamin G. Lamberty, Kathleen M. Emanuel, L. D. Estrella, Howard S. Fox
          </td>
          <td>2025-10-08</td>
          <td>Journal of Neuroinflammation</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/695c274c959b0fd1b92ee86ff6aa4f6baf9e49bd" target='_blank'>
              A multicenter spatial transcriptomics atlas of human tuberculosis and non-tuberculous mycobacterial disease
              </a>
            </td>
          <td>
            Xun Jiang, Leonard Christian, Yuesi Xi, Liang Zhou, Ahmed Alaswad, Xiaoyi Zheng, N. V. Unen, L. Neubert, Jana Dietrich, Jan C. Kamp, Moritz Kayser, Mark Kühnel, J. Hohlfeld, Hortense Slevogt, Marius M. Hoeper, N. Kaminski, Tobias Welte, Jan Fuge, F. Ringshausen, R. Homer, D.D. Jonigk, Chengbin Xu, Jonas C. Schupp, Yang Li
          </td>
          <td>2025-10-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Effective anti-tumor immunity critically depends on functional CD8+ T cells, yet in almost all solid tumors, these cells become dysfunctional, exhausted, or spatially excluded. This breakdown of immune surveillance arises not only from cell-intrinsic T cell exhaustion but also from multimodal communication among tumor, stromal, and immune cells within the tumor microenvironment (TME). This communication is mediated not only through direct receptor-ligand interactions but also through a suite of indirect mechanisms, such as metabolic competition, secretion of immunosuppressive metabolites and cytokines, extracellular vesicle exchange, and even mitochondrial transfer via tunneling nanotubes or membrane transfer through T cell trogocytosis. Together, these suppressive interactions impair CD8+ T cell metabolism, effector function, and persistence, thereby enabling tumor immune evasion. In this review, we summarize current understanding of how multimodal cell-cell communication, including immune checkpoints, metabolic reprogramming, and stromal crosstalk, cooperatively drive CD8+ T cell dysfunction. We also highlight emerging therapeutic strategies aimed at rewiring these suppressive networks, with emphasis on translational potential. A deeper understanding of the spatial, molecular, and metabolic context of CD8+ T cell suppression offers new avenues to enhance the efficacy of cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c5ae6993d7bfa10b0ab3f27994a45882bb6514da" target='_blank'>
              Multimodal cell-cell communication driving CD8+ T cell dysfunction and immune evasion
              </a>
            </td>
          <td>
            Liping Chen, Qianping Huang, Peipei Zhou
          </td>
          <td>2025-11-05</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Background Acute rejection is a significant cause of impaired graft survival in the early post-transplantation period, and the early-stage immune cell dynamics with local intercellular communication during this process require further elucidation. Methods We performed single-cell RNA sequencing (scRNA-seq) on CD45+ immune cells isolated from rat renal allografts during the early phase of acute rejection (days 0, 1, 3, and 7). Using unsupervised clustering, functional enrichment analysis, cellular trajectory inference, and intercellular communication network mapping, we delineated the immune cell dynamics and local communication networks at single-cell resolution. Our findings were subsequently validated through multiplex immunofluorescence and therapeutic intervention experiments. Results Macrophages constituted the dominant immune population during acute rejection. Sub-clustering analysis revealed a rapid expansion of the Isg15+Mac subset by post-transplant day 1, which persisted at elevated levels thereafter. Functional enrichment and trajectory inference demonstrated the pro-inflammatory properties of Isg15+Mac, implicating this subset in acute rejection. Cell-cell communication analysis identified Ccl3-Ccr5 ligand-receptor interactions between Isg15+Mac and T cells. Multiplex immunofluorescence confirmed abundance of Isg15+Mac within the allografts. Moreover, the acute rejection after kidney transplantation was alleviated by the FDA-approved Ccr5 blocker Maraviroc. Conclusions Our study establishes an in-depth, early-stage immune landscape of renal transplantation, revealed that the Isg15+Mac subset activates T cells via the Ccl3–Ccr5 axis and thereby serves as a critical driver of acute rejection. And indicating that Maraviroc may potentially be a therapeutic candidate for transplant rejection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0e9d767fb56923b15a4ac52a99263c253eebc577" target='_blank'>
              Single-cell transcriptomics unravels the early immune landscape of renal allograft rejection and nominates Ccl3-Ccr5 as a therapeutic target
              </a>
            </td>
          <td>
            Fanchao Wei, Zhaoxiang Wang, Ruochen Qi, Jingliang Zhang, Shichao Han, Changhong Shi, Tong Lu, Zhite Zhao, Zhengxuan Li, Lang Li, Weijun Qin, Shuaijun Ma, Lijun Yang
          </td>
          <td>2025-10-22</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Abstract Neutrophils and monocytes are persistently elevated in sickle cell anemia (SCA), yet the intrinsic mechanisms driving pathological myelopoiesis and inflammation remain poorly defined. Through single-cell RNA sequencing and functional assays, we demonstrate that hematopoietic stem and multipotent progenitor cells (HSPCs) in SCA are transcriptionally reprogrammed toward myeloid differentiation. This process is orchestrated by aberrant activation of type I interferon (IFN-I) signaling, which promotes premature myeloid commitment of hematopoietic stem cells. SCA progenitors further exhibit unexpected responsiveness to granulocyte colony-stimulating factor (G-CSF) through upregulation of CSF3R, resulting in skewed myelopoiesis toward the monocytic lineage. Importantly, hydroxyurea treatment attenuates IFN-I signaling in neutrophils, consistent with its therapeutic role in reducing excessive inflammation and granulopoiesis. Collectively, these findings uncover IFN-I–driven remodeling of hematopoiesis as a fundamental mechanism of leukocytosis and chronic inflammation in SCA, and establish a tractable therapeutic axis to mitigate innate immunity activation in this disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/381b70218da54c4009f797520df51073a0a3a2d8" target='_blank'>
              IFN-I-Mediated Transcriptional Reprogramming Drives Myeloid-skewed Hematopoiesis in Sickle Cell Anemia
              </a>
            </td>
          <td>
            Marion Serra, Marine Aglave, Mohammad Salma, Steven Akkaya, Patricia Hermand, Carine Lefevre, Romain Duval, Jade Merrer, Fallou Leye, Joelle Magne, Isabelle Plo, Lionel Blanc, Eric Soler, S. Azouzi, Bérengère Koehl
          </td>
          <td>2025-10-07</td>
          <td>Research Square</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="The co-inhibitory receptor TIGIT suppresses excessive immune responses in autoimmune conditions while also restraining antitumor immunity. In viral infections, TIGIT alone does not affect viral control but has been shown to limit tissue pathology. However, the underlying mechanisms are incompletely understood. Here we found TIGIT+ T cells to express not only an immunoregulatory gene signature but also a tissue repair gene signature. Specifically, after viral infection, TIGIT directly drives expression of the tissue growth factor amphiregulin (Areg), which is strongly reduced in the absence of TIGIT. We identified regulatory T (Treg) cells, but not CD8+ T cells, as the critical T cell subset mediating these tissue-protective effects. In Treg cells, TIGIT engagement after T cell antigen receptor stimulation induces the transcription factor Blimp-1, which then promotes Areg production and tissue repair. Thus, we uncovered a nonclassical function of the co-inhibitory receptor TIGIT, wherein it not only limits immune pathology by suppressing the immune response but also actively fosters tissue regeneration by inducing the tissue growth factor Areg in T cells. Joller and colleagues show that the co-inhibitory receptor TIGIT induces the expression of the tissue growth factor amphiregulin (Areg) in regulatory T cells and contributes to tissue repair in response to viral infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0b61dd16412c6f14fc56828dfe7806631ed84034" target='_blank'>
              The co-inhibitory receptor TIGIT promotes tissue-protective functions in T cells
              </a>
            </td>
          <td>
            C. Panetti, Rahel Daetwyler, A. Moncsek, Nikolaos Patikas, A. Agrafiotis, Adelynn Tang, F. Andreata, Valeria Fumagalli, Jean de Lima, Lifen Wen, Carolyn G King, Ajithkumar Vasanthakumar, Matteo Iannacone, Axel Kallies, A. Yermanos, M. Hemberg, Nicole Joller
          </td>
          <td>2025-10-15</td>
          <td>Nature Immunology</td>
          <td>1</td>
          <td>31</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8d8ac6d94dde3701e0cbe9646f9e4bb15f7423c5" target='_blank'>
              Synergistic targeting of MCL1 and caspases for enhanced anti-tumor immunity in breast cancer
              </a>
            </td>
          <td>
            Jae Kyo Yi, Ji-Sun Lee, Pilhan Kim, Leslie M. Shaw, Alexander Spektor
          </td>
          <td>2025-10-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Plasmacytoid dendritic cells (pDCs) mount powerful antiviral type I interferon (IFN-I) responses, yet only a fraction of pDCs produces high levels of IFN-I. Here we report that peripheral pDCs in naive mice comprise three subsets (termed A, B and C) that represent progressive differentiation stages. This heterogeneity was generated by tonic IFN-I signaling elicited in part by the cGAS/STING and TLR9 DNA-sensing pathways. A small ‘IFN-I-naive’ subset (pDC-A) could give rise to other subsets; it was expanded in STING deficiency or after the IFN-I receptor blockade, but was abolished by exogenous IFN-I. In response to RNA viruses, pDC-A showed increased Bcl2-dependent survival and superior IFN-I responses, but was susceptible to virus infection. Conversely, the majority of pDCs comprised the ‘IFN-I-primed’ subsets (pDC-B/C) that showed lower IFN-I responses and poor survival, but did not support virus replication. Thus, tonic IFN-I signaling decreases the cytokine-producing capacity and survival of pDCs but increases their virus resistance, facilitating optimal antiviral responses. Pucella, Maqueda-Alfaro and colleagues distinguish three developmentally related subsets of mouse plasmacytoid dendritic cells that differ in their ability to produce type I interferon and their susceptibility to virus.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d74835f8e845ea18beb20340e5bd3f281ac019ce" target='_blank'>
              Tonic type I interferon signaling optimizes the antiviral function of plasmacytoid dendritic cells
              </a>
            </td>
          <td>
            Joseph N. Pucella, Raul A Maqueda-Alfaro, Hai Ni, Fernando Bandeira Sulczewski, Anna Eichinger, E. Esteva, Ai C Ra, Annesa Das, Oriana A. Perez, Jue Feng, Marlon Stoeckius, Peter Smibert, Alireza Khodadadi-Jamayran, Igor Dolgalev, E. Ivanova, Stela Sota, Ken Cadwell, S. Koralov, Judy Zhong, Chetna Soni, Daniel B. Stetson, Stuart P Weisberg, Donna L. Farber, Juliana Idoyaga, Boris Reizis
          </td>
          <td>2025-10-14</td>
          <td>Nature Immunology</td>
          <td>1</td>
          <td>46</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d6db7c438373e1be32f3e8f8962c7eb002d2e0ff" target='_blank'>
              Single-cell profiling reveals that dynamic lung immune responses distinguish protection from susceptibility to tuberculosis
              </a>
            </td>
          <td>
            Fergal J. Duffy, M. L. Neal, Courtney R. Plumlee, Sarah Cohen, B. Gern, A. Diercks, Michael Y Gerner, K. Urdahl, J. Aitchison
          </td>
          <td>2025-10-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Background: HCC is a notably immunosuppressive malignancy with limited therapeutic options and poor prognosis. Macrophages, as major immune cell populations within the tumor microenvironment, significantly influence disease progression and therapy efficacy. We aim to identify pivotal macrophage subsets associated with HCC progression and resistance to immunotherapy. Methods: Immunotherapy-associated macrophage-specific marker genes were identified by single-cell RNA-sequencing analysis and transcriptome analysis. The clinical relevance of macrophages with heme oxygenase 1 (HMOX1) positive was assessed in HCC patients by immunofluorescence. The immune microenvironment of HCC and the functional phenotype of HMOX1+ macrophages were explored using cytometry by time-of-flight (CyTOF). Results: Single-cell RNA-sequencing analyses revealed that HMOX1 was predominantly expressed in intratumoral macrophages within the HCC microenvironment. Intratumoral HMOX1+ macrophages abundance was associated with worse prognosis and immunotherapy efficacy in patients with HCC. CyTOF analysis showed that the HCC microenvironment with high infiltration of HMOX1+ macrophages was characterized by high infiltration of CD4+ regulatory T cells (Tregs) and high expression of programmed death-1 (PD-1) in CD8+ T cells. Besides, HMOX1+ macrophages exhibited an immunosuppressive functional state. Pharmacological inhibition of HMOX1 by Znpp enhanced the therapeutic efficacy of anti-PD-1 antibody in the HCC mouse model. Conclusions: Macrophage-specific HMOX1 serves as a novel biomarker for predicting the efficacy of immunotherapy, and targeting HMOX1 has the potential to enhance the efficacy of anti-PD-1 therapy in HCC patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/20a58e4f02cc5693944528514521ad6b571bd6a6" target='_blank'>
              HMOX1+ macrophages determine immunosuppressive microenvironment and immunotherapy efficacy in hepatocellular carcinoma
              </a>
            </td>
          <td>
            Yabing Du, Wenxin Xu, Zhenkun Liu, Peihao Wen, Ruifeng Song, Weiwei Hao, Yating Liu, Xinlei Zhao, Meiying Gu, Jialei Weng, Wei He
          </td>
          <td>2025-10-14</td>
          <td>Hepatology Communications</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Lung mononuclear phagocyte (MNP) subsets differ in their ability to restrict Mycobacterium tuberculosis (Mtb) during chronic infection, yet the mechanisms underlying this difference are not well defined. Here, we show that CD11clo monocyte-derived cells (MNC1), the subset of lung cells that is most permissive for Mtb viability during chronic infection, express lower levels of interferon-gamma (IFNγ) signaling proteins, resulting in reduced responses to IFNγ compared to alveolar macrophages (AM) and CD11chi MNC2. Moreover, type I IFN signaling suppresses IFNγ-mediated MHC-II expression, impairing CD4 T cell activation by MNC1 cells. Importantly, prior immunity conferred by contained Mtb infection enhances IFNγ responsiveness of monocyte-derived cells, reducing bacterial burdens in lungs and within MNC subsets. Our findings indicate that heterogeneous IFNγ responsiveness is exploited by Mtb for persistence in vivo. Overcoming or bypassing impaired IFNγ responsiveness may guide the development of more effective TB vaccines and host-directed therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1185bf27cd38b33e534c27d9aa87381e2cd898fa" target='_blank'>
              Impaired IFNγ responsiveness of monocyte-derived lung cells limits immunity to Mycobacterium tuberculosis
              </a>
            </td>
          <td>
            Weihao Zheng, J. Limberis, Zachary P. Howard, Alexander Mohapatra, Enzo Takagi, J. Ernst
          </td>
          <td>2025-11-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Administration of IL-2 may promote the suppressive function and proliferation of Treg cells that cause immune tolerance in patients with cancer, which causes low-dose IL-2 to fail in achieving an optimal anti-tumor effect. Here, we designed an immunocytokine by fusing IL-2 and an anti-TIGIT monoclonal antibody, named αTIGIT-IL2, that targets Treg cells and promotes their fragility in the tumor milieu. These fragile-like Treg cells show impaired suppressive function and high IFN-γ production, triggering an immune-reactive tumor microenvironment. Such inflammation leads to the recruitment and functional reprogramming of intratumoral neutrophils, improving cross-talk between neutrophils and CD8+ T cells and enhancing the antitumor ability of CD8+ T cells. Combination therapy with αTIGIT-IL2 and PD-1 blocker could eliminate triple-negative breast cancer (TNBC) tumors resistant to immune checkpoint blockade (ICB) therapy. These findings provide the basis for developing a new generation of immunocytokines that target Treg cells and promote their fragility in the tumor milieu, resulting in robust antitumor immunity. Interleukin-2 (IL-2) and checkpoint inhibitors such as anti-TIGIT have been used individually as tumour therapies. Here the authors fuse IL-2 and anti-TIGIT in a combined therapeutic and show that this promotes Treg cell fragility in the tumour environment which in turn promotes neutrophil function to enhance CD8 T cell anti-tumour function in mouse models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a8f381b44371297ad7f4ba1f04d5155ffd6052c5" target='_blank'>
              αTIGIT-IL2 achieves tumor regression by promoting tumor-infiltrating regulatory T cell fragility in mouse models
              </a>
            </td>
          <td>
            Tianci Wang, Yupu Xu, Zhengfeng Zhang, Yaqi Wu, Long Chen, Xiaodong Zheng, Hui Peng, Qiang Zou, Rui Sun, Hongdi Ma, Haoyu Sun, Zhigang Tian, Xiaohu Zheng
          </td>
          <td>2025-10-17</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/929f5e64525cee92d0f3fab0ebf61c85bfdd0623" target='_blank'>
              The spatial landscape of infectious mononucleosis tonsils
              </a>
            </td>
          <td>
            Ciara I Leahy, Matthew Pugh, Aoife Hennessy, Nadezhda Nikulina, Stefan Dojcinov, Gerald Niedobitek, Graham S. Taylor, Paul G Murray, É. Fennell
          </td>
          <td>2025-10-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4e312c1a3a9dbed5ee9046577d5060ddafb93654" target='_blank'>
              Identifying the therapeutic potential of Niclosamide in overcoming IFN-gamma dependent cancer immune evasion in the Tumor Microenvironment
              </a>
            </td>
          <td>
            Yue Zhang, Sophia Peng, Hamid Akhbariyoon, Suzi Kim, Ellie Lai, En Cai
          </td>
          <td>2025-10-28</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="CD39 is an ectoenzyme in immune cells that regulates purinergic signaling by converting extracellular ATP into adenosine (ADO). Although first described on EBV-transformed B cells, CD39’s role in humoral immunity remains unclear. Using murine infection models and human samples, we confirm and extend previous findings showing that high CD39 expression identifies antibody-secreting cells (ASC) across differentiation stages, including ASC derived from memory B cells, and in various tissues, regardless of the infection phase. CD39 was resistant to enzymatic digestion, facilitating ASC identification in processed tissues. We found that while CD39 was not essential for B-cell differentiation into ASC, it remained functionally active as an ectoenzyme. ASC as well as germinal center (GC) B cells expressed ADO receptors, making them responsive to ADO signaling. Consistently, systemic ADO administration impaired GC reactions without altering the ASC number in infected mice. However, in vitro, ADO reduces antibody production both in ASC and in B cells undergoing differentiation and also impairs the differentiation of activated B cells. Finally, B cell–specific CD39 deficiency increased GC B-cell frequencies in infected mice, likely due to reduced ADO levels. These findings highlight the relevance of the purinergic pathway in B-cell biology.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/29ab4395fef7413edaeb4a4f893d031d065d8aea" target='_blank'>
              CD39 is an antibody-secreting B-cell marker that modulates germinal center and antibody responses during infection
              </a>
            </td>
          <td>
            L. Almada, Yamila Gazzoni, C. Beccaria, Facundo Fiocca Vernengo, Santiago Boccardo, Melisa Gorosito Serrán, Apurwa Trivedi, C. Vinuesa, Simon C. Robson, E. A. Acosta Rodríguez, Mauro Gaya, C. Montes, A. Gruppi
          </td>
          <td>2025-10-20</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>59</td>
        </tr>

        <tr id="Macrophages have a critical role in mucosal barrier immunity, demonstrating dynamic phenotypes that promote and resolve inflammation. However, the regulation of this polarization is not fully understood. Triggering receptor expressed on myeloid cells 2 (TREM2) is an immunoregulatory receptor expressed on macrophages. The role of TREM2 in mucosal immunity has not been previously studied. Our objective was to investigate TREM2 on macrophages during periodontal disease (PD), a chronic inflammatory condition affecting the oral mucosa. PD was induced using a ligature method in wild-type (WT) and TREM2−/− mice. Macrophages were isolated from oral mucosa and analyzed via flow cytometry. PD severity was assessed via quantification of bone loss and local inflammatory cytokine expression. Lastly, oral mucosal macrophages from WT mice and humans were analyzed via single-cell RNA sequencing (scRNA-seq). We demonstrated TREM2 expression on oral mucosal macrophages, and the proportion of TREM2+ macrophages significantly increased during resolution of PD and decreased during active PD. Analysis of TREM2−/− mice revealed a more severe PD phenotype with significantly increased tissue destruction and increased Il1b, Tnfa, and Il6 expression in the oral mucosa compared to WT. Transcriptional characterization of oral mucosal macrophages from mice and humans using scRNA-seq demonstrated subpopulations of TREM2+ macrophages characterized by similar gene signatures and pathways consistent with immunoregulatory functions. This study improves our understanding of macrophage polarization and introduces TREM2 as an important immunoregulator in the oral mucosa.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/962d98a853e2f7ac29c83c71bc0aa2dbf444bc5c" target='_blank'>
              Macrophage dynamics and the role of TREM2 at the oral mucosal barrier
              </a>
            </td>
          <td>
            Taiana C. Leite, Jiamiao Chen, A. Diacou, Sangmin Park, Andrew H Jheon, Jie Yin, Quinn T. Easter, Nicholas F. Fitz, K. Byrd, D. Clark
          </td>
          <td>2025-10-21</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Recent studies in murine disease models have identified Siglec-F+ neutrophils, which express a marker traditionally associated with eosinophils, as a functionally distinct population characterized by extended lifespans and context-dependent roles. While conventional neutrophils typically return to the bone marrow or undergo apoptosis at the site of inflammation, these cells remain in tissues for extended periods. These cells demonstrate remarkable functional plasticity, promote bacterial clearance and immune activation during infections, foster immunosuppression and tumor progression in cancer, and contribute to tissue remodeling in fibrotic diseases. In this review, we examine the key features governing Siglec-F+ neutrophil differentiation and function—including Siglec-F signaling, metabolic programming, and upstream cytokine cues—and explore how targeting these pathways may offer promising avenues for precision immunomodulation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f85d27981564af58b267b87dc5389351cceb464b" target='_blank'>
              Context-Dependent Roles of Siglec-F+ Neutrophils
              </a>
            </td>
          <td>
            Kisung Sheen, Taesoo Choi, Man S Kim
          </td>
          <td>2025-10-24</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="T cell responses are generally curtailed by suppressive mechanisms within the tumor microenvironment (TME) that prevent T cell infiltration and function. Consequently, T cell-based therapies for solid tumors have yielded limited and often non-durable clinical responses. Tumors develop a hostile TME, where tumor-associated macrophages (TAMs) that initially support T cells are converted into immune suppressive TAMs that facilitate tumor evasion from T cell control. In fact, immune suppressive TAMs represent a dominant fraction of immune cells within the TME and their presence is associated with poor prognosis and resistance to immunotherapy. Often in close contact with effector T cells, TAMs directly suppress CD8+ T cells through mechanisms involving metabolic mediators, co-signaling receptors, their ligands and/or cytokines. Here, we revisit molecular interactions behind TAM-mediated suppression of T cell responses and address the potential targeting of such molecules and pathways to re-boost anti-tumor T cell immunity. This perspective, focusing on molecular interactions between TAM and T cells, may aid the improvement of T cell-based therapies for solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8c01dfbcf193a83248342e1e2c8db14cdc37f598" target='_blank'>
              Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy
              </a>
            </td>
          <td>
            R. M. Coelho, R. Debets, Dora Hammerl
          </td>
          <td>2025-10-16</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="T-cell exhaustion is a terminal state of immune dysfunction characterized by impaired proliferation and effector functions, diminished cytokine secretion, and sustained expression of inhibitory receptors. In coronavirus disease 2019 (COVID-19), increasing evidence links exhausted T-cell phenotypes with poor clinical outcomes, including severe disease, delayed viral clearance, and persistent symptoms associated with Long COVID. Exhaustion results from prolonged antigenic stimulation and inflammatory signals and is marked by transcriptional reprogramming, metabolic and epigenetic dysregulation, and co-expression of inhibitory receptors such as programmed cell death protein-1 (PD-1), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Notably, exhausted phenotypes in COVID-19 frequently coexist with hyperactivation, raising the unresolved question of whether inhibitory receptor expression reflects transient activation or irreversible dysfunction. Emerging therapeutic strategies to reverse these dysfunctional states include immune checkpoint inhibitors, cytokine modulation, metabolic interventions, and epigenetic therapies, although their clinical translation remains at an early stage. Critical research gaps include the scarcity of longitudinal data, incomplete profiling of T-cell subsets across disease stages during COVID-19 and Long COVID-19, and contradictory evidence of vaccine-induced exhaustion with limited understanding of its consequences. This non-systematic literature review synthesizes current advances in COVID-19 immunopathology and therapeutic strategies, underscoring that understanding T-cell exhaustion is crucial to improving outcomes and shaping next-generation immunotherapies and vaccines.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fcda848fedb31d45bcaf7a6be07292887c93eed0" target='_blank'>
              T-cell exhaustion in COVID-19: what do we know?
              </a>
            </td>
          <td>
            Roderick Chen-Camaño, Rodrigo DeAntonio, S. López-Vergès
          </td>
          <td>2025-10-29</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/18d334efdd4d167f301eb6b862ccafe18092402f" target='_blank'>
              Localized immunomodulation with cytokine-producing cells to mitigate host immune rejection responses in rodents and a non-human primate
              </a>
            </td>
          <td>
            Boram Kim, Dilrasbonu Vohidova, A. Nash, Yuen San Chan, Samantha Fleury, Shravani Deo, Danna Murungi, Peter D Rios, Ira Joshi, Hafsa Nasir, Daisy Lopez, Mor Sela Golan, Cassidy Hart, Jose Oberholzer, H. C. Hodges, O. Veiseh
          </td>
          <td>2025-10-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Myeloid cells play critical roles as Fc effector cells in antibody‐mediated immunity. Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) is a pleiotropic cytokine that promotes the recruitment and activation of multiple myeloid populations and has been used in combination with vaccines/treatments against infectious diseases, inflammatory conditions and cancers. To evaluate GM‐CSF‐mediated kinetics of immune cell expansion and immune outcomes, we compared subcutaneous (subQ) and topical hypoosmolar (intravaginal/intrarectal) administration in vivo using rhesus macaques (RM), as they provide easy access to longitudinal mucosal tissue sampling and are a critical model species for vaccines/therapeutics development. While topical GM‐CSF did not result in a major change, neutrophils, eosinophils and monocytes were elevated within 1–3 days of subQ GM‐CSF administration, with peak eosinophil and neutrophil enrichment in blood at days 7 and 8, respectively. Corresponding elevations of neutrophils, eosinophils, total CD64+ and total CD32+ were observed at days 7 and 14 in rectal biopsies, indicating general Fc effector cell accumulation in these animals. Histological evaluations of vaginal biopsies showed myeloid cell infiltration at day 14 of subQ GM‐CSF treatment. Further, subQ GM‐CSF administration resulted in myeloid cell activation and trafficking, as evidenced by elevated levels of cytokines (CXCL13, MCP‐1, IL‐1RA). Importantly, neither subQ nor topical GM‐CSF administration induced overt systemic inflammation or adverse clinical impacts. Overall, our findings delineate the kinetics of systemic and mucosal myeloid cell expansion, activation and trafficking achieved by subQ GM‐CSF administration in RM. These findings will inform the use of GM‐CSF as an adjuvant in clinical applications where myeloid cell mobilization is advantageous.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/492d90767cafd39d09bc074bbefa23b57af9983b" target='_blank'>
              Myeloid cell recruitment and activation through systemic and mucosae‐directed cytokine therapy
              </a>
            </td>
          <td>
            C. Manickam, Rhianna Jones, Nihar R. Deb Adhikary, Kyle W. Kroll, Karen Terry, Hari Balachandran, Griffin Woolley, G. Tomaras, François J. Villinger, R. K. Reeves
          </td>
          <td>2025-10-07</td>
          <td>Immunology and Cell Biology</td>
          <td>0</td>
          <td>82</td>
        </tr>

        <tr id="Background The triple-negative breast cancer (TNBC) microenvironment (TME) undergoes progressive reprogramming, transitioning from an early immune-active state to a late immune-suppressed state. While tumor cell plasticity has been extensively studied, the molecular plasticity of T cells in vivo remains poorly defined. Objectives To characterize transcriptional changes in T cells during TNBC progression and identify stage-specific shifts in T cell function, polarization, and antigen-presenting cell (APC)-T cell interactions. Results Transcriptional analysis of T cells from BALB/c mice bearing 4T1 tumors at 1, 3, and 6 weeks revealed a decline in T cell-associated genes from 194 at 1 week to 156 at 6 weeks, with a significant late-stage loss of TCR diversity and contraction of natural killer T (NKT)- and γδ T cell-related transcripts. Cytokine and transcription factor dynamics reflected temporal T cell polarization: early (1 week) IL-12α/β-STAT4 signaling supports CD4+ type 1 T helper cell (Th1) and type 1 CD8+ cytotoxic T cell (Tc1) responses; intermediate (3 weeks) IL-21 and BCL6 expression suggest transient CD8+ cytotoxic follicular T cell (Tfc) skewing; and late (6 weeks) AhR and IL-1β induction reflect interleukin 17/22 producing CD8+ T cell (Tc17/Tc22) transition. Pro-inflammatory cytokines and chemokines increased over time, while immunosuppressive mediators (e.g., IL-10) declined significantly. Antigen-presenting cell (APC)-T cell crosstalk deteriorated at 6 weeks, characterized by a reduction in the expression of co-stimulatory and APC genes. Despite an early dominance of M1-like macrophage signals (e.g., IL-12α/β), persistent expression of arginase 1 (ARG1) and other M2-associated genes indicated a stable tolerogenic niche. Conclusions TNBC progression is characterized by progressive T cell functional decline, narrowing of TCR diversity, impaired APC-T cell interactions, and sustained macrophage-driven immunosuppression. These temporally coordinated immune shifts suggest tumor-driven adaptation toward immune evasion and identify potential windows for stage-specific immunotherapeutic intervention.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eb0d181b971ab9d5141b1475ee18608b8080d802" target='_blank'>
              Molecular Plasticity of T Cells Informs Their Possible Adaptation in 4T1 Tumors
              </a>
            </td>
          <td>
            Md. Iftehimul, Robert H. Newman, Scott H Harrison, Roshonda B. Jones, P. Muganda, Bryan L. Holloman, M. T. Hossain, C. J. Rorie, Misty D. Thomas, Joseph L. Graves, H. Kaufman, Dipongkor Saha
          </td>
          <td>2025-10-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3443903af73c8ea2603fc42506194395d5951dde" target='_blank'>
              Thrombospondin-1–CD47 signaling contributes to the development of T cell exhaustion in cancer
              </a>
            </td>
          <td>
            Chien-Huan Weng, Anais Assouvie, Lauren Dong, JC Beltra, S. Budhu, L. Mangarin, Yacine Marouf, Lucia Morgado-Palacin, Cailian Liu, Sébastien Monette, Jonathan F. Khan, Isabell Schulze, Dmitry Zamarin, Linda Hamadene, Fadi Samaan, Daniel Hirschhorn, S. Pourpe, David Schröder, R. Zappasodi, Pamela M. Holland, N. Anandasabapathy, E. Wherry, J. Wolchok, T. Merghoub
          </td>
          <td>2025-11-17</td>
          <td>Nature Immunology</td>
          <td>0</td>
          <td>170</td>
        </tr>

        <tr id="Stimulator of interferon genes (STING) is a cytosolic DNA sensor that activates type I interferon (IFN) signaling, which plays a key role in neuroinflammation. Although the role of STING in experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS), remains debated, its involvement in the development of CNS lesions, particularly within localized pathology, modeled here by targeting the corpus callosum, has yet to be explored. Using a focal EAE model, we compared the induction of lesions in wild-type and STING-deficient (STINGgt/gt) mice. Lesions were analyzed by immunohistochemistry, flow cytometry, and transcriptomics. STING-deficient mice had significantly larger demyelinated lesions, reduced ISG expression, and modified immune cell infiltration. STING signaling limits lesion severity in focal EAE by promoting IFN responses and regulating immune infiltration. These findings position STING as a potential target for MS therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4bf6c7ef661fd43e69e6cbc5a450148d7854f91e" target='_blank'>
              STING Signaling Deficiency Exacerbates Demyelination and Immune Infiltration in Focal EAE Lesions
              </a>
            </td>
          <td>
            M. Mørch, Line S Reinert, A. Benmamar-Badel, M. Dubik, M. Burton, M. Thomassen, T. Kruse, N. Asgari, S. R. Paludan, Trevor Owens, Reza Khorooshi
          </td>
          <td>2025-10-17</td>
          <td>NeuroSci</td>
          <td>0</td>
          <td>57</td>
        </tr>

        <tr id="Immune checkpoint inhibitor (ICI) resistance often stems from intratumoral T cell dysfunction. This review focuses on both tumor-intrinsic and tumor-draining lymph node (TDLN)-centric resistance mechanisms. We detail how specific defects within TDLNs - such as impaired dendritic cell migration and the establishment of immunosuppressive niches - initiate and perpetuate systemic immune dysfunction, ultimately leading to ICI resistance. To counter these challenges, we summarize the following TDLN-targeted strategies: (1) remodeling the TDLN immunosuppressive microenvironment to restore effective antigen presentation; (2) expanding the pool of progenitor exhausted T (Tpex) cells, with a focus on their primary reservoir in TDLNs; and (3) developing adoptive cell therapies using TDLN-derived Tpex cells to generate a robust, personalized antitumor response. By repositioning TDLNs as a central therapeutic target, recent findings suggest strategies aiming to overcome resistance at its source and improve ICI clinical outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0c7e16289ee16f5e53cf880372e73eefd67132cd" target='_blank'>
              Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update
              </a>
            </td>
          <td>
            Jianan Lu, Jiangnan Yu, Tuo Xu, Yina Li, Shuxian Chen, Qian Zhou, Lei Wang
          </td>
          <td>2025-10-24</td>
          <td>Cancer Drug Resistance</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Abstract Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that accumulate under pathological conditions such as cancer, where they contribute to immune evasion, tumor progression, and resistance to therapy. These cells exert potent immunosuppressive effects by inhibiting T cell activation, inducing regulatory T cells, modulating antigen-presenting cells, and shaping an immunosuppressive tumor microenvironment (TME). Their suppressive functions involve multiple mechanisms, including amino acid depletion, production of reactive oxygen and nitrogen species, expression of immune checkpoint ligands, and secretion of immunoregulatory cytokines such as IL-10 and TGF-β. Besides these immune-related roles, MDSCs also promote tumor growth through non-immunological mechanisms, including the stimulation of angiogenesis and undergoing metabolic reprogramming. These adaptations support their survival and function in the hostile TME. Given their multifaceted role in cancer, MDSCs represent a promising target for therapeutic intervention. Furthermore, their abundance and dynamic modulation during treatment confer them tremendous potential as biomarkers to monitor therapy efficacy and stratify patients. This review provides a comprehensive overview of MDSC biology, their mechanisms of action, and their emerging clinical relevance as biomarkers and therapeutic targets. We also explore current strategies aimed at targeting MDSCs, including their depletion, inhibition of recruitment, functional blockade, and promotion of their differentiation into mature myeloid cells. Integrating these approaches with existing cancer therapies holds great promise for enhancing antitumor immunity and overcoming resistance in both solid tumors and hematologic malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d195f524c3054c9a1106fbc8581ac237b69c234e" target='_blank'>
              Emerging Role of MDSCS as Novel Biomarkers and Therapeutic Targets for Cancer Immunotherapy
              </a>
            </td>
          <td>
            S. Silva-Romeiro, Rocio del, Carmen Flores-Campos, M. L. Sánchez-León, V. Sánchez-Margalet, L. Cruz-Merino, María, Luisa Sánchez-León
          </td>
          <td>2025-11-01</td>
          <td>ImmunoTargets and Therapy</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Background The efficacy of immunotherapy is often hindered by the suppression of immune responses via the tumor microenvironment (TME). The presence of cancer cells forces other proximal non-cancerous cells to support tumor growth and persistence. A clear example of this cancerous-to-non-cancerous communication is represented by the accumulation of myeloid-derived suppressor cells (MDSCs) within the TME. Several studies have convergently shown that the overexpression of DNA-methyl-transferase-1 (DNMT1) in these cells results in protection from necroptosis and enhanced accumulation in vivo. Conversely, targeting DNMT1 through hypo-methylating agents has shown promising therapeutic potential by not only reducing the levels of MDSCs but also enhancing cancer immunogenicity and the efficacy of immune checkpoint inhibitors (ICI). Methods Murine 4T1 (triple-negative breast cancer (TNBC)) and CT26 (colon carcinoma) cell lines were cultured under standard conditions and used to generate tumor models in BALB/c mice. An oncolytic adenovirus expressing a DNMT1-targeting short hairpin RNA (OAd.shDNMT1) was engineered and validated for DNMT1 knockdown and genome-wide methylation reduction. Small extracellular vesicles (sEVs) were isolated from virus-infected cancer cells and characterized for RNA content and uptake by MDSCs. MDSC differentiation and suppressive function were assessed in vitro using flow cytometry and co-culture assays with murine splenocytes. In vivo, tumor-bearing mice received intratumoral OAd.shDNMT1, systemic decitabine, or immune checkpoint inhibitors (anti-Programmed cell Death protein-1), and tumor growth, immune infiltration, and systemic MDSC levels were evaluated. Results In this study, we report that, by using virally infected TNBC murine cells as a source for shDNMT1-loaded sEVs, OAd.shDNMT1 successfully reduced MDSC levels in vitro and in vivo. Furthermore, the co-administration with ICI resulted in a significant tumor growth reduction in mice bearing poorly immunogenic TNBC 4T1 cells. Also, our treatment promoted antitumor immunity, prolonged survival, and complete tumor eradication in modestly immunogenic colon CT26 cancer cells. Conclusion This multifaceted strategy, based on OV-mediated immune stimulation and reduction of MDSC levels via sEVs, may improve clinical outcomes and the success of immuno-based regimens for patients facing MDSC-rich and highly aggressive cancer subtypes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/854d707af7ff1d7731b63579e115f89b9c83b43b" target='_blank'>
              Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy
              </a>
            </td>
          <td>
            Salvatore Russo, Yvonne Giannoula, S. Feola, Justin Cerioni, Firas Hamdan, Jacopo Chiaro, Anja Thu Ha Dang, Paolo Bottega, Michaela Feodoroff, M. Fusciello, Virpi Stigzelius, Carmine D'Amico, Carmen Caiazza, Gabriella Antignani, Federica D'Alessio, Milda Sakalauskaite, Julia Petryk, J. Bell, C. Ilkow, M. Grönholm, Vincenzo Cerullo
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Cancers are a risk factor for active tuberculosis (TB), and anti-cancer drugs can independently cause TB progression. To understand the underlying mechanisms, mice infected with Mycobacterium tuberculosis (Mtb) were treated with gemcitabine (Gem), cisplatin, or paclitaxel. These treatments delay Mtb-specific T cell responses, increase bacterial loads, and cause hyperinflammation with permissive neutrophils in the lungs. However, depleting Mtb-permissive neutrophils reduce bacterial levels and G-CSF production, thereby attenuating lung immunopathology. Additionally, Mtb-specific T cell responses generated by BCG vaccination inhibit bacterial growth and neutrophil infiltration even after Gem treatment. Gem induces granulocyte-biased generation in the bone marrow via G-CSF signaling, which led to lung neutrophil inflammation. However, pre-existing Mtb-specific T cell responses from BCG vaccination normalizes granulopoiesis by restricting G-CSF production. These findings show the mechanism of anti-cancer drug-induced neutrophilic lung inflammation in TB and highlight the role of Mtb-specific T cell responses in maintaining balanced hematopoiesis against Gem-induced TB immunopathogenesis. Anti-cancer drugs could independently promote TB progression. Here, the authors show using mouse models, that anti-cancer drug treatments could induce delayed Mtb-specific T cell responses, followed by G-CSF dependent neutrophil manifestation in the lungs, leading to TB exacerbation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c8a2b78a64e7e259f4ab9a6f5256f8cca0ff830d" target='_blank'>
              Mycobacterium tuberculosis-specific T cells restrain anti-cancer drug-induced neutrophilic lung inflammation in tuberculosis
              </a>
            </td>
          <td>
            Kee Woong Kwon, T. Kang, Jii Bum Lee, Eunsol Choi, Hagyu Kim, Minchul Park, S. Choi, Kyungmin Kim, Hyeong Woo Kim, Su Jin Jeong, H. R. Kim, Sung Jae Shin, Sang-Jun Ha
          </td>
          <td>2025-10-06</td>
          <td>Nature Communications</td>
          <td>1</td>
          <td>17</td>
        </tr>

        <tr id="Mucosal‐associated invariant T (MAIT) cells are a highly conserved population of immune cells that can be activated via the major histocompatibility complex class I‐related protein pathway or cytokine pathways, playing a central role in immune surveillance. This review provides comprehensive information on their thymic developmental origin, tissue‐specific distribution, and microbial regulatory networks, with a focus on analyzing the bidirectional regulatory mechanisms in diseases. In infectious diseases, MAIT cells eliminate pathogens through the rapid release of cytokines; however, sustained antigen exposure leads to functional exhaustion. In autoimmune diseases, their migration disorders and proinflammatory cytokine secretion of MAIT cells exacerbate tissue damage. In the tumor microenvironment, they play a paradoxical role, being capable of mediating antitumor effects while also being reprogrammed into a protumor phenotype. Based on their tissue targeting ability and functional plasticity, we discuss novel strategies for targeted therapy, including engineering chimeric antigen receptor–MAIT cells to enhance tumor killing, blocking exhaustion pathways to reverse functional impairment, and regulating the microbiota–metabolic axis to reprogram cell activity. This review integrates cutting‐edge evidence, reveals the translational potential of MAIT cells as a cross‐disease regulatory hub, and provides a theoretical framework for precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b35d66b0d36f247e296da89c6cdd92c5b6962ca6" target='_blank'>
              Mucosal‐Associated Invariant T Cells: Origins, Biological Functions, Diseases, and Therapeutic Targets
              </a>
            </td>
          <td>
            Cheng Zhu, Qian Huai, Yishan Du, Xingyu Li, Fumin Zhang, Yongkang Zhang, Mengwei Wu, Ying Dai, Xiaolei Li, Hanren Dai, Hua Wang
          </td>
          <td>2025-11-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7e104f926b9fda3602b303271493c55d2937a852" target='_blank'>
              Neuro-Immune Crypt-Associated Cells Drive Colorectal Carcinogenesis via REST-Mediated Phenotypic Reprogramming: Implications for Tumorigenesis and Viral Susceptibility
              </a>
            </td>
          <td>
            D. Díaz-Carballo, Adrien Noa-Bolaño, Udo Rahner, A. Acikelli, Sahitya Saka, Jacqueline Klein, Flevy D’Souza, S. Malak, Anne Höppner, Annabelle Kamitz, Carla Casula, Lalitha Kamada, Andrea Tannapfel, Jens Christmann, Sarah Albus, Enrico Fruth, Daniela Gerovska, Marcos J. Araúzo-Bravo, M. Senkal, Crista Ochsenfarth, D. Strumberg
          </td>
          <td>2025-10-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Immunotherapy is currently effective in less than half of patients with solid tumors, and most responders develop secondary progression. High infiltration of the tumor microenvironment (TME) with CD8+ cytotoxic T cells (CTLs) and low infiltration with regulatory T cells (Treg) predicts the patients’ responses to immunotherapy and long-term outcomes. To identify the mechanisms regulating long-term stability of CTL infiltration, we analyzed the impact of CTL-produced cytokines on the TME by co-culturing patient-isolated ascites cells with activated T cells. Unexpectedly, we observed that activated CTLs selectively induce cytotoxic T cell-attracting chemokines but not chemokines that attract T regulatory cells in ovarian cancer TME and tumor-associated myeloid cells, resulting in recruitment of additional CTLs without Tregs. This selectivity resulted from the unique dependence of CCL22 induction on both canonical and alternative NF-κB and the suppression of alternative NF-κB signaling by T cell-released IFNγ. Our data demonstrate that T cell-produced IFNγ suppresses alternative NF-κB signaling in TME-associated myeloid cells, allowing for the induction of CTL-attracting chemokines with the concomitant suppression of Treg-attracting CCL22. These novel functions of IFNγ and activated T cells in regulating the balance between canonical and alternative NF-κB signaling in myeloid cells provide new opportunities to enhance and stabilize the selective CTL influx in the TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e5a5a14adab24415a821ab9194596f9d27a53e37" target='_blank'>
              IFNγ-mediated suppression of alternative NF-κB in tumor-resident myeloid cells promotes selective recruitment of cytotoxic but not regulatory T cells
              </a>
            </td>
          <td>
            Adam Brinkman, Ravikumar Muthuswamy, Bowen Dong, Robert P Edwards, Pawel Kalinski
          </td>
          <td>2025-10-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e655b3f34a47917eb0c1eab5cc8dbd65bd366140" target='_blank'>
              P2RY2 is a purinergic immune checkpoint linking extracellular ATP to immune evasion and adaptive resistance to immunotherapy
              </a>
            </td>
          <td>
            Zhaoqing Hu, Hitoshi Matsuo, Shangce Du, Cecilia Berzain Battioni, L. Jassowicz, Rafael Carretero, Melanie Sator-Schmitt, Xiyue Zhao, Beiping Miao, Cansu Eris, Helena Engel, Mohamed A.A. Mahmoud, Elke Laport, Yanling Xiao, Ilse Hofmann, Christel Herold-Mende, Chong Sun
          </td>
          <td>2025-10-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Immune checkpoint blockade (ICB) therapy has made remarkable advances in cancer treatment. However, the overall response rate remains limited. Here, we aim to explore the role of histone 3 lysine 4 mono‐methyltransferase KMT2D in tumor immune response and improve the efficacy of ICB. We developed a patient‐derived urologic tumor fragment (PDUTF) platform comprising 56 tumors and constructed three major urological tumor tissue microarrays from 356 patients. Analyzed using the PDUTF platform and tissue microarrays (TMAs), we found that tumors with KMT2D deficiency were associated with enhanced T‐cell activation in response to anti‐PD‐1 therapy and exhibited increased T‐cell infiltration. Subsequently, T‐cell migration and T‐cell‐mediated tumor cell killing assays revealed that the deletion of KMT2D in cancer cells promoted CD8+ T‐cell migration and cytotoxicity against tumor cells. Mechanistically, the loss of KMT2D enhanced antitumor immunity by promoting chemokine‐mediated recruitment of T cells both in vitro and in vivo. Finally, the small‐molecule inhibitor MI‐503 combined with anti‐PD‐1 therapy suppressed tumor growth on the PDUTF platform. Collectively, KMT2D deficiency sensitizes tumor cells to ICB, and inhibiting KMT2D may represent a promising approach in combination with ICB to improve patient prognosis. © 2025 The Pathological Society of Great Britain and Ireland.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/302b8c8dc4634e08a8e9cc4f4bba94194b56d64a" target='_blank'>
              KMT2D deficiency potentiates antitumor immunity and sensitizes immune checkpoint blockade in urologic cancers
              </a>
            </td>
          <td>
            Yuedian Ye, Yuanpeng Liao, Yifan Zhang, Jianqiang Zhang, Mayao Luo, Qiao Yang, Qiliang Zhai, Zhuofan Xu, Yutong Wang, Haoran Wen, Chenwei Wu, Yang Qiu, Shidong Lv, Qiang Wei
          </td>
          <td>2025-10-06</td>
          <td>The Journal of Pathology</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="The efficacy of anti-CD20 therapies places B cells and their interaction with T cells at the center of attention for multiple sclerosis (MS) pathogenesis. Follicular T helper cells (Tfh), which guide B cell maturation in germinal centers within lymph nodes (LNs), are elevated in the circulation and cerebrospinal fluid of patients with MS (pwMS). However, the LN spatial landscape has remained largely without investigation for pwMS. Using cyclic immunofluorescence, we assessed cell abundance and spatial connections in FFPE LNs of 33 pwMS and 35 non-MS controls. The presence of EBV was analyzed through EBER immunostaining and multiplex quantitative PCR. Our analysis showed that Tfh cells were expanded in LNs of pwMS and accumulated especially in the mantle zone and B cell follicles compared with controls. The Tfh/T follicular regulator ratio was increased in pwMS, while B cell ratios were similar between the cohorts. The interaction of Tfh cells with follicular B cells was higher in pwMS. Interestingly, Tfh accumulation was also observed in 5 prediagnostic MS cases. No signs of EBV latency were detected in either group. These findings highlight LNs as a site of early and persistent immune activation in pwMS, with therapeutic implications to be further addressed.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c6205960882a96d4371faf48c5e9cbddf440c57b" target='_blank'>
              Intranodal expansion of follicular T helper cells in patients with multiple sclerosis
              </a>
            </td>
          <td>
            Joona Sarkkinen, E. Kekäläinen, Leo Hannolainen, Ada Junquera, Johannes Dunkel, Maria Perdomo, Mikko I. Mäyränpää, S. Laakso
          </td>
          <td>2025-10-08</td>
          <td>JCI Insight</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Stem-like CD8⁺ exhausted T cells (Tex) sustain antitumor immunity, whereas TGFβ signaling acts as a major immunosuppressive pathway. In patients with colorectal liver metastases, we observe that elevated TβRI expression in peri-metastatic hepatocytes correlates with poor prognosis. We therefore investigate whether disrupting hepatocytic TGFβ signaling can reinvigorate stem-like CD8⁺ Tex cells to restrict liver metastasis. In support of this hypothesis, mice with hepatocyte-specific TβRI depletion exhibit reduced liver metastatic burden across multiple tumor models. Mechanistically, hepatocytic TβRI blockade suppresses Galectin-9 secretion, which reshapes the transcriptional program of intra-tumoral CD8⁺ T cells. This reprogramming promotes a phenotypic transition from terminal exhaustion toward stem-like and effector states, yielding T cell subsets with enhanced metastasis-control capacity. Importantly, this axis functions independently of macrophages and CD4⁺ T cells. Furthermore, therapeutic delivery of Galunisertib using choline-modified lipid nanoparticles synergizes with αPD-1, fostering the conversion of exhausted CD8⁺ T cells into responsive Ly108⁺CX3CR1⁺ subsets and suppressing liver metastases. Collectively, our results identify hepatocyte TGFβ signaling as a targetable checkpoint against liver metastases. How TGF-β regulates liver metastasis remains further investigation. The authors here find that TβRI blockade in hepatocytes decreases liver metastatic progression via revitalizing stem-like CD8⁺ Tex subsets, and an LNP encapsulated with the TβRI inhibitor Galunisertib synergizes with αPD-1 to ameliorate liver metastasis">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8539be173ace8a0b4d35310e7d3ebf922993bf40" target='_blank'>
              Targeting hepatocytic TβRI ameliorates liver metastatic outcomes by revitalizing stem-like CD8+ Tex subsets
              </a>
            </td>
          <td>
            Hao Wang, Yan Zhou, Yuanyu Tu, Junxiong You, Baogui Gao, Kun Yuan, S. Zhong, Changjie Huang, Qinrui Han, Yu Dai, Ye Ma, Qingyuan Zhang, Xinyi Yan, Junjiang Wang, Xiaorui Wang, Liang Zhao, Xuegang Sun
          </td>
          <td>2025-11-27</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Intestinal stem cells (ISCs) promote tissue repair after genotoxic or immune-mediated injury. However, ISCs are particularly sensitive to various stressors and primary targets of overwhelming immune responses, such as interferon γ (IFNγ)-mediated killing. In mouse models of radiation therapy-induced gut damage and in biopsies from patients who underwent allogeneic hematopoietic stem cell transplantation, we observed IFNγ expression by intestinal Treg cells. Treg cells leverage combined IFNγ and interleukin 10 (IL-10) stimulation of ISCs to nurture the growth of intestinal organoids through the activation of the mTORC1 and Myc pathways. Similarly, Treg cells or the combined addition of recombinant IFNγ and IL-10 promoted the regeneration of organoids after irradiation, and both cytokines were essential for ensuring epithelial regeneration following acute intestinal tissue injury in vivo. The exposure of organoids to growth factor-free culture conditions revealed distinct EGF-like properties of IFNγ and Wnt-like properties of IL-10. While IFNγ rapidly induced epithelial proliferation, it depleted the pool of ISCs in vitro. Only the combination of IFNγ and IL-10 led to epithelial proliferation and organoid growth while simultaneously ensuring ISC maintenance over time. Our results reveal a context-dependent role of inflammatory signaling in ISCs, through which Treg cells promote epithelial repair following therapy-induced injury.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d94b1c2ecbf09b8eb96b76cf6ccb45e0eb507208" target='_blank'>
              Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury
              </a>
            </td>
          <td>
            J.C. Fischer, Sascha Göttert, Maximilian Giller, Paul Heinrich, Kaiji Fan, Omer Khalid, C. Walther, Maria Drießlein, S. Nefzger, Gabriel Eisenkolb, V. R. Timnik, S. Jarosch, Lena Klostermeier, T. Engleitner, Nicholas Strieder, C. Gebhard, Sarah Diederich, Nicole A. Schmid, Laura Lansink Rotgerink, Laura Joachim, Sakhila Ghimire, E. Vonbrunn, M. Büttner-Herold, Marianne Remke, Katja Steiger, R. Öllinger, R. Rad, Daniel Wolff, Markus Feuerer, Petra Hoffmann, Matthias Edinger, Michael Rehli, Markus Tschurtschenthaler, O. Kepp, Guido Kroemer, Erik Thiele Orberg, Stephanie E. Combs, Wolfgang Herr, Florian Bassermann, Dirk H. Busch, Ernst Holler, S. Heidegger, H. Poeck
          </td>
          <td>2025-11-26</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>121</td>
        </tr>

        <tr id="Adoptive T cell therapies (ACT) have revolutionized the management of hematologic malignancies; however, their efficacy in solid tumors remains limited. Accumulating evidence implicates the tumor microenvironment (TME) - a highly complex and immunosuppressive niche as a major barrier to their effectiveness. In this review, we propose that the next generation of ACT will require a fundamental shift from a reductionist focus on T cell engineering alone to an integrated approach that considers the interactions between immune cells and the TME. A comprehensive literature review identified several emerging strategies to enhance the efficacy of ACT, including reprogramming tumor vasculature, repolarizing immunosuppressive myeloid and stromal cells, leveraging oncolytic viruses to remodel antigen presentation, inducing acute sterile inflammation, and targeting the physical properties of the extracellular matrix. While many of these approaches remain in early-stage development, some have already progressed to clinical trials, indicating their potential for clinical translation. Additionally, we found that conventional therapies, such as surgery, chemotherapy, and radiotherapy, can be strategically integrated with ACT to improve therapeutic outcomes. These findings highlight a shift in the field toward more integrative approaches. Future advances will likely depend on reprogramming the TME to support T cell persistence and functions. Addressing these interconnected challenges will require closer collaboration between immunology, oncology, and bioengineering disciplines.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5845940292899bbb8a96147c6b79326179c978e6" target='_blank'>
              Reprogramming the tumor microenvironment to boost adoptive T cell therapy
              </a>
            </td>
          <td>
            Maria Fernanda Meza Pacheco, Lee-Hwa Tai
          </td>
          <td>2025-10-23</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9bc60307b76a4b412a3e65454da49927d8bd70ac" target='_blank'>
              Viral replication and interferon responses in bronchial epithelia is enhanced by Th17 cells
              </a>
            </td>
          <td>
            Weston T. Powell, T. Janczyk, P.C. Dela Cruz, Basilin Benson, Elizabeth R. Vanderwall, C. Gates, Lucille M. Rich, M. White, N. Samanas, Kourtnie Whitfield, Gail H. Deutsch, T. Hallstrand, Matthew C. Altman, J. Debley
          </td>
          <td>2025-10-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>45</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c7fdd50ef3604bb5496e43d50c930df247607fa0" target='_blank'>
              Adenosine-specific transcriptional programs in murine connective tissue type mast cells
              </a>
            </td>
          <td>
            Qihua Liang, Volodymyr Tsvilovskyy, Anouar Belkacemi, Merima Bukva, Christin Richter, Nicole Ludwig, Andreas Keller, M. Freichel
          </td>
          <td>2025-11-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Background: Chronic lymphocytic leukemia (CLL) is characterized by malignant B lymphocyte accumulation and progressive immune dysfunction. The immune checkpoint molecule TIM-3 and its ligand galectin-9 (Gal-9) contribute to T cell exhaustion, impairing anti-tumour immunity. Interleukin-27 (IL-27) has pleiotropic immunomodulatory properties, but its impact on TIM-3 and Gal-9 expression in CLL remains unclear. Methods: Peripheral blood mononuclear cells (PBMCs) from 20 treatment-naive CLL patients were cultured with or without IL-27 (100 ng/mL) for 72 h. Flow cytometry assessed TIM-3 and Gal-9 expression on CD4+, CD8+, and CD19+ cells. Results: IL-27 stimulation significantly increased TIM-3 expression on CD8+ T cells (2.18 ± 0.32% vs. 3.09 ± 0.49%, p = 0.009), a hallmark of T cell exhaustion. IL-27 also modestly increased intracellular Gal-9 levels in total lymphocytes (93.91 ± 1.17% vs. 96.55 ± 0.67%, p = 0.005). Additionally, IL-27 reduced CD4+ T cell proportions (26.71 ± 4.19% vs. 22.01 ± 3.23%, p = 0.010). Although numerically modest, these changes may be biologically pertinent in the context of checkpoint-mediated CD8+ T-cell exhaustion. Conclusions: IL-27 may enhance immunosuppressive mechanisms in CLL by modulating immune checkpoint expression, potentially contributing to disease progression. These ex vivo findings in PBMCs from CLL patients indicate the IL-27-associated modulation of checkpoint expression under the conditions tested. In the absence of parallel healthy-donor controls, CLL specificity cannot be established in this study.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/58d00c9f01ecefffef026fe6257bcd71c012fd04" target='_blank'>
              Expression of TIM-3 and Gal-9 Immune Checkpoints in Chronic Lymphocytic Leukemia: The Potential Role of Interleukin-27
              </a>
            </td>
          <td>
            E. Wędrowska, Tomasz Wandtke, Bartosz Ulaszewski, E. Cichocka, R. Dębski, Piotr Kopiński, Jan Styczyński, Grzegorz Przybylski
          </td>
          <td>2025-10-23</td>
          <td>Current Issues in Molecular Biology</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Glioblastoma (GBM) harbors a highly inflammatory microenvironment driven predominantly by activated innate immune cells, despite being classified as an immunologically cold tumor due to limited T cell infiltration. Tumor-associated macrophages (TAMs) are key contributors to disease progression, in part through their production of interleukin-1β (IL-1β), a pro-inflammatory cytokine with tumor-promoting functions. However, the precise role of IL-1β⁺ TAMs in GBM remains incompletely understood. This study aimed to elucidate the functional contributions of IL-1β⁺ TAMs to GBM malignancy and to explore their therapeutic relevance. Single-cell RNA sequencing (scRNA-seq) analysis revealed that IL-1β⁺ TAMs were enriched in GBM tissues compared to normal brain tissue, with their elevated infiltration correlating with aggressive tumor phenotypes and poor prognosis. Functionally, IL-1β stimulated GBM cells to secrete inflammatory mediators such as PGE2 and TNFα. These mediators, in turn, upregulated C/EBPβ expression in macrophages, thereby enhancing IL-1β transcription. Mechanistically, tumor-derived PGE2 and TNFα synergistically activated C/EBPβ via EP4 receptor signaling, initiating a self-sustaining IL-1β-PGE2/TNFα-EP4-C/EBPβ-IL-1β feedback loop that amplified pro-inflammatory crosstalk between GBM cells and TAMs. Disruption of PGE2/EP4 signaling effectively suppressed IL-1β+ TAM generation and attenuated tumor growth in preclinical models. Our finding highlights how GBM cells induce macrophages to secrete IL-1β through the synergistic action of PGE2 and TNFα via the EP4 receptor and C/EBPβ activation. This feedback loop between tumor cells and macrophages fosters a pro-inflammatory TME that drives GBM progression. Targeting the PGE2/EP4-C/EBPβ signaling axis may therefore present a promising immunotherapeutic strategy to disrupt tumor-TAM crosstalk and suppress GBM progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/79403f7ff1eae47b3c3514d50ed4afe7c020a741" target='_blank'>
              IL-1β+ tumor-associated macrophages accelerate glioblastoma progression by amplifying the PGE2-EP4 signaling
              </a>
            </td>
          <td>
            Hao Liang, Qunying Yang, Biling Zhong, Dan Li, Feima Wu, Jian Zhang, Chongqi Guo, Zhengquan Zhu, Min Feng, Yong Zhang, Hui Peng
          </td>
          <td>2025-10-14</td>
          <td>Journal of Neuroinflammation</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Dendritic cells (DCs) are professional antigen‐presenting cells (APCs) that play a central role in regulating immune responses by linking innate and adaptive immunity. In recent decades, substantial progress has been made in understanding the development, classification, and diverse functions of DCs. However, a comprehensive overview integrating recent advances in the biology and therapeutic targeting of DCs remains lacking. This review systematically summarizes the origin, developmental pathways, and subset heterogeneity of DCs, including classical type 1 and 2 DCs, plasmacytoid DCs, monocyte‐derived DCs, and Langerhans cells. Moreover, it further details the core biological functions of DCs, including antigen capture, migration, and maturation; antigen presentation; activation of adaptive immunity; induction of immune tolerance; and modulation of innate immune responses. The pathological roles of DCs in diseases such as cancer, diabetes, and infectious diseases are discussed, highlighting emerging DC‐based therapeutic strategies. Importantly, this review provides a summary of both preclinical studies and clinical trials involving DC‐targeted therapies, offering a translational perspective. This work aims to deepen the understanding of DC immunobiology and to provide a valuable foundation for the development of novel DC‐based immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f0e677608689fc4d137f5dd944e3591ee29e3ed6" target='_blank'>
              Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential
              </a>
            </td>
          <td>
            Fangfang Jin, Lingxiang Xie, Hongqi Zhang, Xiang Fan, Jiaxing Tian, Wei Liu, Yang Xiao, Xinrong Fan
          </td>
          <td>2025-11-01</td>
          <td>MedComm</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Regulatory T cells (Treg cells or Tregs), a subset of CD4⁺ T cells with immunosuppressive properties, are essential for immune homeostasis and self-tolerance. Characterized by their immunosuppressive capabilities and reliance on the transcription factor Foxp3 (Forkhead box protein P3), Tregs employ multiple mechanisms, including cytokine secretion, metabolic control, and cell contact inhibition, to restrain excessive immune activation to prevent autoimmunity while maintaining tissue repair processes. However, dysregulation in their frequency or function—whether deficiency or hyperactivity—is implicated in diverse pathologies, spanning autoimmune disorders, cancer progression, transplant rejection, and emerging associations with neurological and cardiovascular diseases. Thus, Treg-targeted strategies represent a promising approach for restoring immune balance under various conditions. This review synthesizes current knowledge on Treg biology, from their discovery and definition of markers to their new regulatory mechanisms. We further explore the roles of Tregs across diseases, emphasizing their context-dependent therapeutic potential. Strategies to deplete or inhibit Tregs in cancer immunotherapy contrast with approaches to expand or stabilize their function in autoimmunity and transplantation. However, challenges persist, including achieving tissue-specific targeting, ensuring the functional stability of engineered Tregs, and minimizing off-target effects. By integrating mechanistic insights with translational innovations, this review provides a roadmap for advancing Treg-based therapies, ultimately aiming to restore immune equilibrium in a disease-specific manner.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4664303d5c8731e32a24c5f6aff938bbbbb96dc7" target='_blank'>
              Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential
              </a>
            </td>
          <td>
            Lingling Wang, Ying Liang, Chunxia Zhao, Peijun Ma, Shulin Zeng, Dongen Ju, Minggao Zhao, Min Yu, Yun Shi
          </td>
          <td>2025-10-14</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>3</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/64023140f5e7a3e5fa3e9f72f99117f80751143f" target='_blank'>
              Rapid expansion of podoplanin-positive fibroblasts following radiation limits the anti-tumour CD8+ T-cell response to radiotherapy
              </a>
            </td>
          <td>
            Anna Wilkins, S. Makris, M. Green, S. Hooper, Anna Mikolajczak, Giovanni Giangreco, Srinivas Allanki, E. Nye, Emma Connick, Richard Mitter, Sam Cooper, Emily Durie, Malin Pedersen, Amy Burley, Katie O'Fee, Ben O'Leary, Daniel Shewring, Zoe Ramsden, A. Melcher, Kevin Harrington, N. Somaiah, Sophie E. Acton, E. Sahai
          </td>
          <td>2025-10-07</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Memory T cells endow the mammalian host with an essential form of adaptive immunity that generates durable and rapid protection following re-exposure to an infectious pathogen or a cancerous transformation1–4. How naive CD8⁺ T cells develop into memory T cells that bifurcate into long-lived central (TCM) versus effector (TEM) subsets after such an antigen encounter remains ill-defined at the molecular level. To address this gap, here we dissect the functional T-cell receptor (TCR) repertoire of 242 murine CD8⁺ TCRαβ clonotypes specific for the peptide-major histocompatibility complex molecule (pMHC) comprising an immunodominant influenza A virus (IAV) oligopeptide epitope NP366–374 presented by H-2Db 5,6. Using single-cell transcriptomics with TCR sequencing, biophysical measurements of force-dependent TCR-pMHC interactions, in vivo memory development, and structural analyses, we integrate these data to define relationships between signaling polarity and memory fate. We find that TCM and TEM polarities are reflected in distinct subunit-related mechanotransduction biases: TCM-associated TCRs favor TCRβ-driven pMHC engagement, whereas TEM-associated TCRs preferentially favor TCRα-driven pMHC engagement. Moreover, “bipolar” clonotypes (TBP) capable of generating both memory subsets exhibit more balanced signaling, the largest average clonal expansions, and broadest heterosubtypic crossreactivities. By contrast, variegated TCM TCR sequences foster mostly clonal singlets with the greatest IAV mutant recognition potential within the overall memory repertoire, thus revealing two complementary memory niche crossreactivity strategies. Weak, force-sensitive TCR bonds are pervasive for this entire repertoire, being most conspicuous amongst TCM clonotypes. At the atomic level, highly nuanced variation in TCRαβ bonding to either peptide and/or MHC modulates mechanical load transmission across the holoreceptor’s ectodomains, transmembrane segments, and CD3 cytoplasmic tails to differentially influence downstream tyrosine phosphorylation and memory development. Collectively, TCR diversity anticipates epitope-specific pathogen evolution, whereas divergent TCR signaling regulates memory fate with implications for adoptive T-cell immunotherapies seeking to maximize persistence and minimize functional exhaustion.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/47c5e8a658084ff1675ec010b34b843ae8e69de3" target='_blank'>
              Atomistic TCR-ligand interactions instruct memory T-cell differentiation
              </a>
            </td>
          <td>
            A. Akitsu, Kemin Tan, R. J. Mallis, Matthew A. Booker, J. Duke-Cohan, K. Brazin, Evan H. Kirkpatrick, Andrew N. Parkins, Sarita Aryal, V. Cinella, Jonathan J Lee, Kaveri I. Uberoy, Jenna K. Koenig, Matthew Biddle, Cameron M. Messier, P. Lizotte, M. Tolstorukov, Wonmuk Hwang, Matthew J Lang, Ellis L. Reinherz
          </td>
          <td>2025-11-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Chimeric antigen receptor (CAR)-T cell therapy has achieved significant progress in the treatment of hematologic cancers but continues to face major obstacles in solid tumors, including antigen heterogeneity, limited infiltration, and an immunosuppressive tumor microenvironment (TME). Oncolytic viruses (OVs) have emerged as promising tools to reshape the TME and improve CAR-T cell activity, yet many OVs encounter translational hurdles due to human seroprevalence and safety concerns. Newcastle disease virus (NDV), a naturally tumor-selective avian paramyxovirus, offers unique advantages as a non-integrating, non-pathogenic platform with a longstanding veterinary safety record and minimal pre-existing immunity in humans. NDV mediates direct oncolysis and immunogenic cell death, while simultaneously activating dendritic cells, repolarizing macrophages, and enhancing immune cell recruitment, thereby creating a TME that is more permissive to CAR-T cell therapy. Recent advances have enabled NDV to deliver immunostimulatory payloads locally within tumors, offering synergistic combinations to address CAR-T cell exhaustion and persistence. Looking ahead, further engineering efforts may expand the potential of this combined approach. This review summarizes the biological rationale, preclinical evidence, and translational prospects for integrating NDV with CAR-T cell therapy to improve outcomes in solid tumors. Newcastle disease virus (NDV) offers low human seroprevalence and strong safety as an oncolytic platform. NDV kills tumor cells and remodels the microenvironment to improve CAR-T cell efficacy. Engineered NDV can deliver local cytokines, chemokines, and checkpoint inhibitors to overcome CAR-T cell exhaustion. Synthetic biology may further expand NDV–CAR-T cell combination strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/24757618f894f679c2162b5de9b2d0b9a4a2ccd2" target='_blank'>
              Engineering the tumor microenvironment: oncolytic NDV to facilitate CAR-T cell therapy
              </a>
            </td>
          <td>
            Mei Wang, Ke Jiang, A. Aicher, Christopher Heeschen
          </td>
          <td>2025-11-19</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>56</td>
        </tr>

        <tr id="Type I interferon (IFN) has long been known as a critical component of the molecular machinery that first responds to viral infection in multicellular eukaryotes. More recently, type I IFN signaling has also emerged as a common process in the microenvironment of naturally developing neoplasms, as well as tumors responding to (immuno)therapy. In this setting, robust, acute but ultimately resolving type I IFN responses appear to support natural and therapy-driven cancer immunosurveillance by a number of mechanisms, including an accrued propensity of malignant cells to arrest their proliferation and undergo apoptotic cell death, as well as broad immunostimulatory effects on CD8+ cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, dendritic cells (DCs) and tumor-associated macrophages (TAMs). Conversely, weak, indolent and ultimately non-resolving type I IFN responses de facto facilitate tumor progression, not only by promoting stemness in malignant cells (which is associated with increased metastatic dissemination and resistance to therapy), but also by favoring the establishment of a highly immunosuppressive lymphoid and myeloid tumor microenvironment. Here, we provide a critical discussion of the context-dependent impact of type I IFN signaling on cancer progression and response to treatment, focusing on the tumor-intrinsic and extrinsic factors that may account for such a heterogeneity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d2e617f9f9711708567426eb2cf65f4ef606f0b6" target='_blank'>
              Context-dependent impact of type I interferon signaling in cancer
              </a>
            </td>
          <td>
            Ainhoa Ruiz-Iglesias, Emma Guilbaud, Lorenzo Galluzzi, Santos Mañes
          </td>
          <td>2025-10-30</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Exosomes, nanoscale extracellular vesicles secreted by various cell types, play pivotal roles in intercellular communication. In cancer, tumor-derived exosomes—referred to as cancer-derived exosomes (CDEs)—have emerged as critical regulators of immune evasion, tumor progression, and therapy resistance within the tumor microenvironment (TME). CDEs modulate immune cell function through the transfer of immunosuppressive proteins, cytokines, and non-coding RNAs, ultimately reprogramming immune surveillance mechanisms. This review provides an in-depth analysis of how CDEs influence major immune cell subsets—including T cells, B cells, NK cells, dendritic cells, macrophages, and myeloid-derived suppressor cells—thereby establishing an immunosuppressive TME. We also explore the potential of immune cell-derived exosomes (IDEs) as emerging immunotherapeutic tools capable of counteracting the suppressive effects of CDEs. Furthermore, we highlight exosome engineering strategies aimed at improving therapeutic cargo delivery, tumor targeting, and antitumor immune activation. Finally, we discuss how exosome profiling offers promise in liquid biopsy diagnostics and how integration with 3D tumor models and advanced bioengineering can accelerate the clinical translation of exosome-based cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eae1e39741f5db67d36338284089286232d39875" target='_blank'>
              Cancer-derived exosomes: mediators of immune crosstalk and emerging targets for immunotherapy
              </a>
            </td>
          <td>
            Ridwan Mahamed, Bernice Monchusi, Clement Penny, S. Mirza
          </td>
          <td>2025-10-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="The tumor microenvironment (TME) constitutes a highly complex and dynamic ecosystem wherein diverse leukocyte subsets engage in intricate cross-talk that ultimately dictates the balance between tumor progression and suppression. This review provides a comprehensive analysis of the dualistic functions of key immune cell populations-including natural killer (NK) cells, effector T cells, regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs)-within this milieu. Particular emphasis is placed on the Nigerian context, where unique genetic backgrounds, such as the high prevalence of sickle cell trait, and environmental factors, including endemic infections, significantly shape immune phenotypes and cancer pathogenesis. We explore how cutting-edge single-cell technologies are revolutionizing our understanding of the spatial architecture, functional plasticity, and cellular heterogeneity of these leukocytes in patient cohorts, revealing mechanisms of both immune surveillance and tumor-promoting immunosuppression. The paradoxical roles of these cells elucidate the variable clinical outcomes observed with immunotherapies and underscore the critical need for precision medicine strategies that are tailored to individual immune landscapes. Finally, we discuss emerging therapeutic modalities aimed at selectively depleting pro-tumor subsets like Tregs or MDSCs while activating anti-tumor effectors such as NK cells, which hold substantial promise for reshaping the TME and improving oncology outcomes both in Nigeria and across the globe.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/85d4138591bf3dda987df758be78f378fdcee1f4" target='_blank'>
              Leukocyte Subset Dynamics in the Tumor Microenvironment: Dual Roles, Single-Cell Insights, and Implications for Cancer Immunotherapy in Nigeria
              </a>
            </td>
          <td>
            Okluchi Hartumu
          </td>
          <td>2025-11-25</td>
          <td>Hematological Disorders in the Single-Cell Era</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e8782e43d5a359ec11f1397979fbb249cbe9fbe7" target='_blank'>
              Adoptive cell therapy using T cell receptors equipped with ICOS yields durable anti-tumor response
              </a>
            </td>
          <td>
            Alexandre Marraffa, C. Berrevoets, Margherita Mosiello, R. Wijers, Daphne Roelofs, Mandy van Brakel, Kim Kroese, Marlies J. W. Peeters, Wim Dik, A. Kunert, Rachel Judith Mary Abbott, Dora Hammerl, C. Schliehe, R. Debets
          </td>
          <td>2025-10-15</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Mesenchymal stromal cell (MSC) transplantation has achieved significant clinical benefits for many diseases, such as systemic lupus erythematosus (SLE) and inflammatory diseases. However, the detailed therapeutic mechanism of MSCs is not fully understood. Here, in the SLE treatment, we show that MSC transplantation triggers recipient bone marrow neutrophil aggregation to generate an endogenous extracellular vesicle (EV) storm in the circulation via the TNFα/ICAM-1/Rab11b axis. Interestingly, blockade of the EV storm abolishes the MSC-mediated therapeutic effect for SLE. The level of EV storm is positively associated with the therapeutic effect of MSCs in SLE patients. Mechanistically, aggregated neutrophils-derived EV storms equalize Th17 and T-regulatory (Treg) cells to promote immune tolerance and disease remission via the DHA/LILRB4/STAT5/STAT3 pathway in the MSC treatment for SLE. Taken together, our findings reveal a new immune-modulating function of MSCs through the induction of endogenous neutrophil aggregation in the bone marrow, which results in the secretion of EV storms for immune tolerance in SLE mice and patients. In addition, this study revealed a previously unknown role of the recipient EV storm in determining the therapeutic effect of MSC in SLE, and the recipient EV storm can be used to predict the therapeutic efficacy of MSCs in SLE therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/95b613d65045593441abfdbbf4cbbb2a0630d4f2" target='_blank'>
              Mesenchymal stromal cells induce neutrophil aggregation and extracellular vesicle storms for systemic lupus erythematosus
              </a>
            </td>
          <td>
            Qianmin Ou, L. Niu, Dandan Wang, Genhong Yao, Qianhui Ren, Zhengshi Li, Xueli Mao, Wei Teng, Zetao Chen, Andy Peng Xiang, Songtao Shi, Lingyun Sun
          </td>
          <td>2025-10-13</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="The tumor microenvironment in breast cancer is typically immunosuppressive. Combined neoadjuvant chemotherapy and immunotherapy is the standard of care for high-risk, triple-negative breast cancer patients, but it is not routinely applied to other breast cancer subtypes. Somatic mutation of STK11 (serine/threonine kinase 11), a tumor suppressor, occurs in the MSK-IMPACT platform in 1.9% of 3116 breast cases. A potential link between inactivation of STK11 and immune response regulation has been suggested in breast cancer, but the impact of STK11 suppression on tumor–immune interactions remains under investigation. In this study, we established Stk11-knockout (Stk11-KO) mouse breast cancer cell lines, performed RNA sequencing and cytokine array analysis to assess alterations in gene expression and cytokine profiles. Our results revealed significant enrichment of several immune-related pathways and a marked increase in C-X-C motif chemokine ligand 1 (Cxcl1) expression in response to Stk11 knockout. Moreover, analysis of breast cancer patient samples showed an inverse association between the plasma CXCL1 levels and STK11 expression. To evaluate the in vivo effects of STK11 loss, we established an orthotopic breast cancer model in immunocompetent female mice. Tumors derived from Stk11-KO mouse breast cancer cells demonstrated greater tumorigenicity. In addition, mice-bearing Stk11-KO tumors exhibited elevated levels of circulating polymorphonuclear myeloid-derived suppressive cells. In summary, STK11 suppression enhances immune-related pathways and promotes Cxcl1 expression, correlating with the expansion of immunosuppressive MDSC populations. Our findings suggest that targeting STK11-associated immunosuppressive mechanisms may provide a novel therapeutic option for STK11-deficient breast cancer patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c31d86f908d14d37e2803389cd1c9e71bee4f15b" target='_blank'>
              Suppression of STK11 induces expansion of polymorphonuclear myeloid-derived suppressive cells and activation of immune signaling in breast cancer
              </a>
            </td>
          <td>
            Tzu-Hui Wei, Chi-Che Hsieh, Zhu-Jun Loh, Wei-Pang Chung, Kuo-Ting Lee, Yi-Ling Chen, Hui-Ping Hsu, Che-Hung Shen
          </td>
          <td>2025-10-06</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Trained immunity is reshaping our understanding of host defense by demonstrating that innate immune cells once thought to lack memory can be reprogrammed to mount heightened responses to subsequent challenges. Unlike tolerance, differentiation, or priming, trained immunity relies on epigenetic and metabolic rewiring of resident myeloid cells, particularly in mucosal barriers such as the skin, gut, and lungs, where these cells provide continuous protection against toxins and pathogens. Here, we review recent advances showing how an initial stimulus endows monocytes and macrophages with long-lasting functional changes that can be either protective or maladaptive upon re-exposure. We highlight therapeutic opportunities that harness trained immunity to boost vaccine efficacy and discuss strategies to modulate this program in cancer and hyper-inflammatory disorders. Finally, we propose new directions for enhancing or dampening trained immunity to promote human health.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/57f6e83421893f19b268537080a2332361f2582c" target='_blank'>
              Innate immune memory: The evolving role of macrophages in therapy
              </a>
            </td>
          <td>
            Payal Damani-Yokota, Kamal M. Khanna
          </td>
          <td>2025-11-14</td>
          <td>eLife</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Fungal communities in the gut influence host immunity, yet most studies have focused on cell wall components rather than genetic materials. Here, we explore how fungal genomic DNA (gDNA) from Candida albicans, Saccharomyces cerevisiae, and Cryptococcus neoformans modulate immune responses in human CD4+ T cells, murine splenocytes, and THP-1-derived macrophages. We find that C. albicans gDNA promotes the development of regulatory T cells and increases IL-10, fostering immune tolerance and preserving CD4+ T cell viability in an inflammatory setting. S. cerevisiae gDNA induces moderate Treg responses with restrained effector T cell expansion and higher checkpoint gene expression, entirely consistent with its commensal nature. In contrast, C. neoformans gDNA elicits a strongly inflammatory profile, promoting Th1/Th17 cells and driving high cytokine production. Mechanistically, C. albicans and S. cerevisiae gDNA dampen DNA-sensing pathways and enhance immune checkpoint molecules that act as brakes against overactivation, while C. neoformans gDNA robustly activates innate sensing pathways with limited checkpoint induction. These species-specific signaling profiles reveal that fungal gDNA itself can influence whether the immune system adopts a tolerant or inflammatory response toward fungi. This discovery highlights fungal genomic DNA as a previously underappreciated regulator of host–fungus interactions, offering new insight into commensal persistence, pathogenic invasion, and the potential for DNA-based antifungal interventions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc70eaeb8599dabbca9b1f79f2645699f524d2e1" target='_blank'>
              Divergent Immunomodulatory Roles of Fungal DNA in Shaping Treg and Inflammatory Responses
              </a>
            </td>
          <td>
            Dongmei Li, Idalia Cruz, Yahui Feng, Maha Moussa, Jie Cheng, Digvijay Patil, Alexander Kroemer, Joseph A. Bellanti
          </td>
          <td>2025-10-22</td>
          <td>Journal of Fungi</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="T-cell based immunotherapies such as chimeric antigen receptor T (CAR-T) cell therapy face substantial hurdles when confronting solid tumors such as ovarian cancer, where metabolic constraints in the tumor microenvironment limit T cell infiltration and function. In particular, T cells exposed to nutrient deprivation and hypoxia upregulate autophagy, a lysosomal degradation pathway that negatively regulates effector responses. Here, we used CRISPR-Cas9 to target a folate receptor alpha (αFR) CAR expression cassette into the locus of the essential autophagy gene ATG5, thereby generating autophagy-deficient CAR-T cells in a single editing step. Targeted metabolite profiling revealed that deletion of ATG5 induced widespread metabolic reprogramming characterized by increased glucose and amino acid uptake. Functionally, ATG5-knockout CAR-T cells maintained high cytolytic activity when assayed in patient-derived ascites in vitro, and exhibited superior and long-lasting tumor control against ovarian tumors in vivo. Taken together, our results suggest that deletion of ATG5 metabolically primes CAR-T cells for enhanced cytotoxicity in immune-suppressive conditions, thereby improving the therapeutic potential of αFR CAR-T cells for ovarian cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8e4d37620ca392d7a89bb01813d9698710108a7a" target='_blank'>
              Autophagy disruption primes CAR-T cell metabolism for sustained rejection of ovarian tumors
              </a>
            </td>
          <td>
            G. Carleton, Sébastien Levesque, Lauren G. Zacharias, João S. Patrício, Tracey Sutcliffe, Peter H Watson, R. DeBerardinis, Yannick Doyon, Julian J. Lum
          </td>
          <td>2025-10-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Head and neck squamous cell carcinomas (HNSCCs) rank seventh among the most prevalent malignancies globally. The immune response in cancer conditions governs the course of the disease and clinical outlook. Interferons (IFNs) are a key part of the innate immune system and are essential in modulating the tumor microenvironment (TME). Additionally, IFNs could influence proliferation and affect differentiation, emigration, and death of cancer cells. The cGAS–stimulator of interferon genes (STING) signaling identifies cytosolic DNA and triggers an immune response. Aberrant induction of the cGAS–STING signaling may lead to excess and sustained release of type-I IFN, leading to imbalanced aggregation in various tissues or organs. It is noteworthy that STING signaling has shown a dual role, both promoting tumor resistance and antitumor immunity. Moreover, STING agonists have been investigated in recent studies; however, challenges such as toxicity should be addressed. IFNs have also been used as monotherapy or adjuvant treatment before chemotherapy to increase efficacy against HNSCC tumors. The present review briefly describes IFN signaling with a focus on the STING pathway, and discusses its role in modulating immunotherapy and chemotherapy effects in HNSCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ec33bf70e5cd102c2226fc113e2c801da17d53cb" target='_blank'>
              Interferon signaling and STING pathway in head and neck cancers: unlocking immune secrets and therapeutic frontiers
              </a>
            </td>
          <td>
            Kosar Zolfaghari, Mohammad Yazdi, Shaghayegh Mohammadioun, Fatemeh Tajafrooz, Hesam Malekfarnood, Kiarash Saleki, N. Rezaei
          </td>
          <td>2025-10-03</td>
          <td>Cancer Cell International</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="
 Immunotherapy has revolutionized cancer treatment but remains ineffective against glioblastoma (GBM), where the immunosuppressive tumor microenvironment (TME) limits therapeutic success. While B-cells influence immune checkpoint blockade (ICB) responses in peripheral tumors, their role in GBM remains poorly understood. Here, we demonstrate that myeloid-derived TGFβ signaling drives B-cell dysfunction in GBM, and dual blockade of αVβ8-mediated TGFβ activation and PD-1 synergistically enhances anti-tumor immunity. Using spatial transcriptomics and multiplex immunofluorescence, we identified myeloid-B cell crosstalk via TGFβ as a key immunosuppressive axis in GBM. Myeloid cells, particularly bone-derived macrophages, localized near B-cells and induced TGFβ1-dependent suppression, impairing B-cell expansion and function. Genetic (Tgfbr2 knockout in B cells) or pharmacological (αVβ8 blockade) TGFβ inhibition expanded intratumoral B-cells and synergized with PD-1 blockade, achieving 60% tumor eradication in murine GBM models—an effect entirely dependent on B-cells, as their depletion abolished therapeutic efficacy. Mechanistically, dual therapy rescued B-cell function, reducing their suppression of CD8⁺ T-cell cytotoxicity and promoting plasmablast differentiation. Notably, surviving mice developed immunological memory, which was lost upon B-cell depletion, highlighting their role in sustained anti-tumor immunity. Dual αVβ8/PD-1 blockade uniquely enhanced CD8⁺ T-cell proliferation and granzyme B expression while fostering a Th17-polarized CD4⁺ T-cell response. Intratumorally, plasmablast differentiation increased without systemic effects, suggesting localized immune reprogramming. Partial efficacy in RagKO mice indicated ancillary innate immune contributions, but B-cells were the dominant mediators of therapeutic response. Our findings establish TGFβ inhibition as a strategy to reverse B-cell dysfunction in GBM and demonstrate that dual αVβ8/PD-1 blockade reinvigorates anti-tumor immunity through coordinated B and T-cell activation. This work positions B-cells as pivotal targets for improving immunotherapy in GBM and supports clinical translation of integrin-based combination therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0f92e9df002b9f4c1e4b3d01b295b43d6dc46434" target='_blank'>
              TMIC-81. Targeting TGFβ-mediated B cell suppression enhances anti-PD-1 efficacy in glioblastoma
              </a>
            </td>
          <td>
            D. Hou, Si Wang, Brandyn Castro, Joshua Katz, Mark Dapash, V. Arrieta, G. Vázquez-Cervantes, Hanxiao Wan, Leah K. Billingham, Rebecca Du, Alina R Murphy, Aurora Lopez-Rosas, Yu Han, R. Patel, Tzu-yi Chia, C. Dmello, Peng Zhang, Dean Sheppard, A. Sonabend, J. Miska, M. Lesniak, D. Heiland, Catalina Lee-Chang
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>43</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b5bcb6ae407b6468805f3b43958f785ac3821d33" target='_blank'>
              Inhibition of neutrophil degranulation by Nexinhib20 delays the development of radiation-induced pulmonary fibrosis
              </a>
            </td>
          <td>
            Stefanie Ruhland, Konstantina Nikolatou, Victoria Bridgeman, Tatiana Rizou, E. Sahai, Jayanta Bordoloi, Emma Nolan, Alberto Elosegui-Artola, I. Malanchi
          </td>
          <td>2025-10-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>33</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/20f65e1524ffb4190a28bef066a656c7fa921b4e" target='_blank'>
              B-cell Follicles in the Secondary Lymphatic Tissues Act as a Critical Microanatomical Niche for Sustained Viral Replication, Virus-host Interaction and Damage During Chronic SIV Infection of Rhesus Macaques
              </a>
            </td>
          <td>
            Yilun Cheng, Miaoyun Zhao, Jackson Chen, Subhra Mandal, Mark G. Lewis, Qingsheng Li
          </td>
          <td>2025-11-20</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Adoptive T cell therapy has transformed cancer treatment, with chimeric antigen receptor (CAR) T cell therapy demonstrating remarkable clinical success in hematological malignancies. By genetically engineering a patient’s own T cells to recognize and attack cancer cells, CAR T therapy has achieved durable remissions in several blood cancers. However, its efficacy in solid tumors remains limited, largely due to the immunosuppressive tumor microenvironment (TME), which impairs T cell infiltration, persistence, and function. To address these challenges, innovative strategies are being developed to reprogram T cell signaling within the hostile TME. One promising class involves chimeric non-antigen receptors (CNARs), which modulate T cell activity independently of direct antigen recognition. Among these, chimeric switch receptors (CSRs) convert inhibitory checkpoint signals into activating cues, while inverted cytokine receptors (ICRs) redirect suppressive cytokine signals to promote T cell activation. In this review, we provide a focused overview of the design principles, mechanistic functions, and therapeutic potentials of CSRs and ICRs as adjuncts to CAR T therapy in solid tumors. We also discuss key considerations regarding safety, specificity, and clinical translation to inform future advancements in engineered receptor strategies for cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0543afc911285b890c5cf262ad504cbe1ca634d6" target='_blank'>
              Chimeric switch and inverted cytokine receptors in T cell therapy: reprogramming T cells to overcome immune suppression in the solid tumor microenvironment
              </a>
            </td>
          <td>
            Riley Rane, Fengqiao Li, Alexis Williams, Avaneesh Jayadev, Nhan L. Tran, J. Winkles, Gloria B. Kim
          </td>
          <td>2025-10-08</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>56</td>
        </tr>

        <tr id="The tumor microenvironment (TME), comprising malignant and non-transformed cells like immune cells, endothelial cells, and cancer-associated fibroblasts, significantly affects tumor growth and progression. Tumor cells manipulate the TME by releasing chemokines and inhibitory cytokines, reprogramming surrounding cells to support their survival and evade immune detection. Innate immune cells within the TME play dual roles, either promoting or inhibiting tumor progression, impacting immunotherapy outcomes. Recent studies highlight the influence of innate immune cells in shaping the TME and the pivotal role of tumor-derived microRNAs (miRNAs) in modulating these cells. miRNAs regulate gene expression and enhance tumor immune evasion, angiogenesis, drug resistance, and invasion. Their tumor-specific expression patterns suggest potential as biomarkers and therapeutic targets. This study focuses on how miRNAs affect innate immune cells like macrophages, dendritic cells, myeloid-derived suppressor cells, and natural killer cells, contributing to immunosuppressive or immunogenic environments. Understanding miRNA-mediated interactions between cancer and immune cells opens new possibilities for improving targeted immunotherapy and advancing cancer treatments.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e85aa9b654355b3e4b7e9a3784ef3b6054fa10e" target='_blank'>
              Ambivalent roles of miRNAs in cancer development via modulating tumor-associated innate immune cells
              </a>
            </td>
          <td>
            Bahar Naseri, Amirhossein Mardi, N. Shekari, Neda Shajari, Samin Abdolzadeh, Hossein Khorramdelazad, Amirhossein Hatami-Sadr, Milad Taghizadeh Anvar, Mohammad Reza Javan, Amirhossein Heibatollahi, Javad Masoumi, Farid Ghorbaninezhad, B. Baradaran
          </td>
          <td>2025-10-04</td>
          <td>BioImpacts</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Background Chimeric antigen receptor (CAR) T cells targeting CD19 achieve remarkable remissions in refractory B cell malignancies, yet deleterious side effects such as cytokine release syndrome (CRS) limit their broader application. Current preclinical assays on manufactured cell products do not predict human clinical function. We hypothesized that variability in the CAR proximal protein interaction networks that mediate CAR signal transduction may correlate with patient-to-patient differences in toxicity. Methods Using banked, preinfusion 41BB–CD3ζ CAR T cell products with known clinical outcomes, we applied quantitative multiplex co-immunoprecipitation (QMI) to profile ∼200 binary interactions among 21 key signaling proteins following CD19 stimulation. Bioinformatic analysis clustered interactions into functional modules, and correlated protein interaction patterns with clinical outcomes. Results Correlation network analysis, which clusters interactions into coregulated modules, identified a stimulation-responsive module with similar behavior in all products, and a second module that correlated with the presence of CRS. The CRS module was enriched for interactions among CD28, FYB, and the SRC family kinases LCK and FYN. In a head-to-head validation cohort, a similar CD28–FYB–kinase module again correlated with the presence of CRS. Using a combined dataset, a machine learning classifier trained on top QMI features retrospectively identified CRS samples with high accuracy. Conclusions These data indicate that subtle, batch-to-batch differences in CAR signalosome assembly may correlate with CRS, and they support the further development of a preinfusion proteomic assay to forecast CRS risk in CAR T cell products.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/17efcf9a76f9233541576eecccf77b8453a7d369" target='_blank'>
              CD28 signaling complexes are correlated with patient outcomes in anti-CD19 41BB-costimulation CAR T cell therapy
              </a>
            </td>
          <td>
            Isabella Draper, William Selke, Samuel A. Ritmeester-Loy, Felicia Harsh, Colleen Annesley, Corinne Summers, Rebecca Gardner, Wooyoung Kim, Stephen Smith
          </td>
          <td>2025-11-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3f43905ab0c3ef05ee0c7aeabe0b704f94916fcb" target='_blank'>
              Reduced CSF1R expression in myeloid cells has limited impact on chronic lymphocytic leukemia progression
              </a>
            </td>
          <td>
            Natascha Rosen, Guillermo Rodriguez-Real, Viktoria Kohlhas, T. Truong, A. F. V. Stein, M. Koch, Sebastian Reinartz, Sumiya Iqbal, S. Ilyas, Sanjay Mathur, Nina Reinart, Phuong-Hien Nguyen, Michael Hallek
          </td>
          <td>2025-10-07</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Peripheral immune cell infiltration plays a key role in the excessive intracranial inflammatory response during sepsis, contributing to cognitive dysfunction and increased mortality. This study aims to elucidate the immune inflammatory status of hippocampal tissue in septic mice, providing potential targets for treatment and prevention. Male C57BL/6J mice underwent cecal ligation and puncture (CLP) or sham surgery. Twenty‐four hours post‐surgery, hippocampal tissues were harvested for transcriptome sequencing and immunofluorescence analysis. Immune cell infiltration was assessed using the xCell package, and structural changes in brain microvessels were evaluated by transmission electron microscopy. Flow cytometry and immunofluorescence confirmed immune cell presence in the hippocampus. Hub genes related to immune responses were identified using protein–protein interaction networks, weighted gene co‐expression network analysis, and enrichment analysis of immune‐related biological processes. In CLP mice, microvessel endothelial cells were separated, with swelling and damage to tight junctions. Significant infiltration of myeloid immune cells, including dendritic cells, monocytes and neutrophils, was observed in the hippocampus. Seven immune‐related hub genes (Fcer1g, Fcgr2b, Fcgr3, Icam1, Itgb2, Ptprc and Slc11a1) play a pivotal role in mediating immune responses. Fcer1g, Fcgr2b and Slc11a1 were positively correlated with monocytes and neutrophils, suggesting their involvement in the recruitment of immune cells to the brain. This study enhances our understanding of peripheral immune cell infiltration in sepsis and provides novel insights into potential therapeutic targets for sepsis‐associated encephalopathy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/245a88b1e684b6e2b4373d4be2ee46cd6cf621de" target='_blank'>
              Peripheral Immune Cell Infiltration in the Hippocampus of Sepsis Mice
              </a>
            </td>
          <td>
            Hui Zhang, Meixian Zhang, Yanan Gao, Qian Chen, Qiang Liu, Fanbing Meng, Xiaoxiao Sun, Miaomiao Fei, Cheng Li, Lize Xiong
          </td>
          <td>2025-10-31</td>
          <td>Journal of Cellular and Molecular Medicine</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Background/Objectives: Extracellular vesicles (EVs) are key mediators of intercellular communication and are implicated in the neuropathogenesis of HIV-associated brain injury (HABI). However, their direct effects on glial cells, particularly in the context of antiretroviral therapy (ART), remain incompletely understood. Methods: In this study, we investigated how EVs from naïve, Simian Immunodeficiency Virus (SIV)-infected, and SIV-infected ART-treated rhesus macaques impact primary mixed glial cultures. Results: Through multiple, sequential applications mimicking chronic exposure, we found that EVs from SIV-infected animals significantly reduced glial expansion and induced a simplified, reactive astrocyte morphology indicative of neuroinflammatory stress. In contrast, EVs from naïve animals supported glial health. EVs derived from ART-treated animals provided partial protection from SIV-induced effects, yet still suppressed glial proliferation and failed to fully restore normal morphology. Furthermore, cytokine profiling revealed that both SIV and SIV + ART EVs induced a sustained proinflammatory secretory phenotype, characterized by elevated IL-6, IL-8, and IFN-γ. Conclusions: Our findings demonstrate that systemically circulating EVs in SIV infection are potential drivers of glial dysfunction. The persistence of these pathogenic EV effects despite ART suggests a vesicle-mediated mechanism that may contribute to chronic neuroinflammation and cognitive impairment in virally suppressed individuals.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/67fab60169c13d075bcfdc8d7c00be88b51107c6" target='_blank'>
              Simian Immunodeficiency Virus-Derived Extracellular Vesicles Induce a Chronic Inflammatory Phenotype in Healthy Astrocytes Unresolved by Anti-Retroviral Therapy
              </a>
            </td>
          <td>
            Alison R. Van Zandt, Miranda D. Horn, Ryan P. McNamara, Tiffany A. Peterson, N. Maness, Blake Schoest, Elise M. Frost, Yijun Zhou, Matilda J. Moström, D. P. Dittmer, Andrew G. MacLean
          </td>
          <td>2025-10-24</td>
          <td>Pharmaceutics</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="Natural killer T (NKT) cells play a complex role in hepatocellular carcinoma (HCC) progression. Using a diethylnitrosamine (DEN)-induced HCC mouse model, we observed a significant reduction in NKT cells within malignant liver tissue due to apoptosis, with the remaining cells exhibiting impaired cytokine production and cytotoxic potential. CD1d-deficient mice, which lack NKT cells, showed delayed tumor initiation and fewer tumors, yet the tumors that did form were larger and exhibited enhanced proliferation and immunosuppression. Notably, adoptive transfer of healthy NKT cells after tumor establishment reduced tumor burden, suggesting a protective role in later disease stages. These findings indicate that NKT cells contribute to early tumor development but may help control tumor progression in later stages. Their functional impairment in HCC underscores the need for strategies to restore their anti-tumor activity. Understanding the dual role of NKT cells in liver carcinogenesis may pave the way for novel immunotherapeutic approaches to improve HCC treatment and patient outcomes. In HCC, NKT cells promote early tumor development but restrain later growth. Adoptive transfer of healthy NKT cells after tumor establishment reduces tumor burden, highlighting their potential as immunotherapeutic targets in HCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a90f2e66dfb37d54c65e9f253685e5ee9a14d1c9" target='_blank'>
              Dual regulatory role of natural killer T cells during development of hepatocellular carcinoma
              </a>
            </td>
          <td>
            Maria Papanastasatou, Marianthi Gioulbasani, Evangelia Nakou, A. Galaras, Teresa Rubio-Tomás, I. Talianidis, Aristides G. Eliopoulos, P. Hatzis, Mihalis Verykokakis
          </td>
          <td>2025-10-20</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>42</td>
        </tr>

        <tr id="Long COVID has emerged as a major global health concern, yet the long-term trajectory of immune recovery and its contribution to persistent symptoms remain to be elucidated. Here, we conducted a three-year longitudinal follow-up of the 47 COVID-19 patients and applied single-cell RNA sequencing (scRNA-seq) and multiplex cytokine profiling to comprehensively characterize the peripheral immune landscape during convalescence. We observed persistent immune dysregulation up to three years post-infection, characterized by chronic inflammation and impaired restoration of naïve CD4⁺ T cells, naïve CD8⁺ T cells, and SLC4A10⁺ MAIT cells—features reminiscent of immunosenescence. Notably, Th17 cells, rather than monocytes, emerged as key drivers of chronic inflammation beyond one year. We identified two distinct Th17 subsets: RORC⁺ Th17 cells and LTB⁺ Th17 cells. While RORC⁺ Th17 cells were negatively correlated with inflammatory cytokine levels, LTB⁺ Th17 cells showed proinflammatory features and were positively associated with long COVID symptoms. Sustained elevation of S100A8 and IL-16 in follow-up patients may contribute to the persistent presence of LTB⁺ Th17 cells. Together, our study provides an in-depth longitudinal map of immune remodeling in COVID-19 convalescents, revealing key cellular and molecular drivers of sustained inflammation up to three years post-infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f682ef5df5972e318b0093c3cf2459508e92d089" target='_blank'>
              T cell-driven sustained inflammation and immune dysregulation mimicking immunosenescence for up to three years post-COVID-19
              </a>
            </td>
          <td>
            Tian Zheng, Ru Gao, Yiwei Liu, Ye-ming Wang, Chao Wu, Li Guo, Lan Chen, Xinming Wang, Yan Xiao, Jingchuan Zhong, Rongling Zhang, Ying Wang, Xianwen Ren, Bin Cao, Lili Ren, Jianwei Wang
          </td>
          <td>2025-11-20</td>
          <td>Immunity & Inflammation</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Metastatic cancer remains the leading cause of cancer-related mortality, largely owing to the limitations of conventional treatments such as chemotherapy, radiotherapy, and targeted agents that are challenged by tumor heterogeneity, acquired resistance, and systemic toxicity. In contrast, immunotherapy has emerged as a transformative modality, harnessing the power of the immune system to selectively target and eradicate tumor cells. This review systematically examines key immunotherapeutic strategies ranging from immune checkpoint inhibitors (ICIs) and monoclonal antibodies to cancer vaccines, oncolytic viruses, and adoptive cell therapies (such as CAR-T and TCR-engineered T cells). Of particular interest are personalized approaches, including neoantigen-based vaccines and tumor-infiltrating lymphocyte (TIL) therapies, which hold promise for tailored treatment but also present significant logistical and translational challenges. Central to therapeutic outcomes are factors like immune resistance, the suppressive tumor microenvironment, and the identification of predictive biomarkers including PD-L1 expression and tumor mutational burden (TMB) that can guide patient selection and efficacy. As the field progresses, future breakthroughs will hinge on deepening our understanding of metastasis immunobiology, refining biomarker-driven precision approaches, and developing novel immunological targets and delivery platforms to improve outcomes and accessibility.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6d36a9b7bf90cbf380458cb586d2addbafaad0aa" target='_blank'>
              Immunotherapeutics in metastatic cancer management
              </a>
            </td>
          <td>
            Manisha Shukla, Poorna Shri, Sunil Kumar Mahobiya, R. K. Vishwakarma
          </td>
          <td>2025-11-14</td>
          <td>Discover Oncology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Background/Objectives: T cell dysfunction represents a fundamental barrier to effective cancer immunotherapy. Although immune checkpoint blockades and adoptive cell transfer have achieved clinical success, therapeutic resistance remains prevalent across cancer types. Thymopentin (TP5), a synthetic immunomodulatory pentapeptide (Arg-Lys-Asp-Val-Tyr), has demonstrated immunostimulatory properties, yet its anticancer potential remains unexplored. The aim of this study was to investigate TP5’s antitumor efficacy and underlying immunological mechanisms. Methods: We evaluated TP5’s therapeutic effects in multiple murine tumor models, including B16-F10 melanoma, MC38 colorectal carcinoma, Hepa 1-6, and LM3 hepatocellular carcinoma. Immune cell populations and functional states were characterized using flow cytometry, ELISAs, and immunofluorescence analyses. The potential of TP5 as an adjuvant for T cell-based therapies was also systematically assessed. Results: The TP5 treatment markedly suppressed tumor growth across caner models through strictly T cell-dependent mechanisms. Critically, TP5 promoted thymic rejuvenation under immunocompromised conditions, restoring the thymus–tumor immunological balance and revitalizing peripheral T cell immunity. TP5 functionally reprogrammed T cell states, preserving effector function while ameliorating exhaustion. Furthermore, TP5 demonstrated synergistic efficacy when combined with adoptive T cell therapies, enhancing both proliferation and effector functions. Conclusions: TP5 represents a promising immunomodulator that addresses fundamental limitations of current T cell therapies by simultaneously enhancing T cell function and reversing thymic involution under immunocompromised conditions. Our findings provide compelling evidence for TP5’s clinical translation in cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/33660023e865ee9b3b9111ce1cf65d89f507510c" target='_blank'>
              Thymopentin Enhances Antitumor Immunity Through Thymic Rejuvenation and T Cell Functional Reprogramming
              </a>
            </td>
          <td>
            Md Amir Hossain, Ye Zhang, Li Ji, Yumei Chen, Yue Luan, Yaxuan Si, Yuqing Fang, Junlan Qiu, Zhuo Wang, Guilai Liu
          </td>
          <td>2025-10-01</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Background: Inflammation plays a central role in the formation of peptic ulcers, yet the contribution of cellular immunity remains poorly defined. This study aimed to clarify the contribution of cellular immunity to acute gastric mucosal injury. Methods: BALB/c mice received 80% ethanol via oral gavage to induce acute gastric injury. Stomachs were examined macroscopically and histologically, and gastric tissues were analyzed by qPCR, ELISA, and flow cytometry for cytokine expression, immune cell infiltration, and apoptosis. Results: Administration of ethanol exacerbated acute gastric injury in mice, as evidenced by extensive macroscopic lesions and severe disruption of mucosal architecture. This damage was accompanied by marked infiltration of CD11c+ dendritic cells, together with an increased frequency of CD86-expressing and IL-12-producing dendritic cells. In addition, there was greater accumulation of both CD4+ and CD8+ T lymphocytes, including elevated numbers of CD4+ and CD8+ cells producing IFN-γ and IL-17, as well as CD8+CD107a+ cytotoxic cells. Alongside these cellular alterations, ethanol exposure was accompanied by elevated levels of pro-inflammatory cytokines (IL-1β, TNF-α, IL-17, and IFN-γ) in gastric tissue. In parallel, ethanol exposure also promoted epithelial cell apoptosis, further contributing to mucosal deterioration. Conclusions: Our findings reveal for the first time that both CD4+ and CD8+ T cells participate in sterile ethanol-induced acute gastric injury, emphasizing cellular immunity as an important yet insufficiently studied contributor to mucosal damage and highlighting the necessity for further mechanistic and translational research.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4ecfeda669eef5fb7228297765fc9783652ca1f6" target='_blank'>
              T Helper and Cytotoxic T Cells Play an Important Role in Acute Gastric Injury
              </a>
            </td>
          <td>
            Irfan F Corovic, Jelena Pantić, Isidora Stanisavljević, Sladjana M. Pavlovic, N. Jovicic, Ivan P Jovanović, G. Radosavljević, Bojana J. Simovic Markovic
          </td>
          <td>2025-11-01</td>
          <td>Diseases</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a0fb447bcefcdb90c4999356e9caf6fb1b2e1509" target='_blank'>
              Proinflammatory circulating extracellular vesicles from type 1 diabetes patients contribute to beta cell cytotoxicity and disease pathogenicity
              </a>
            </td>
          <td>
            Nagesha Guthalu Kondegowda, Zelda Cisneros, Daniel Roeth, Jeong-su Do, Joanna Filipowska, Rosemary Li, Shihong Zhang, Selassie J. Ogyaadu, C. S. Jayasena, Tijana Jovanovic-Talisman, Clive Wasserfall, Yate-Ching Yuan, Helena Reijonen, Markus Kalkum, Carol Levy, Fouad Kandeel, Susmita Sahoo, R. Vasavada
          </td>
          <td>2025-10-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="The roles of eosinophil extracellular traps (EETs) in cancer have not been investigated. This research aims to unearth the association between EETs and clinical outcomes in pan-cancer. From the Cancer Genome Atlas (TCGA) program, a 28-gene EETs score was constructed. Overall, higher EETs scores indicated shorter overall survival. EETs were significantly correlated to various pro-tumor processes, including extracellular matrix remodeling, IL-17 signaling, M2 macrophage polarization, and Treg differentiation. Immune suppressive M2 macrophages infiltrated more in the tumor microenvironment (TME), while cytotoxic cells (CD8 T and NK cells) were fewer. EETs-gene expression correlated with multiple T cell co-inhibitors. Target molecules of immune checkpoint inhibitors (ICIs) were not in proximity to the EETs disease module. Drugs against IL-5, IL-5RA, CCL-11 and IL-33 scored highly in perturbation of the disease module. Therefore, the EETs formation was coordinated with the adverse clinical outcomes and TME alternations in cancer. The role of EETs and anti-eosinophil therapy in cancer deserve further investigation in the era of immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3b598a846eb03bb4801110e2bd62531abd6b5070" target='_blank'>
              Eosinophil extracellular traps formation is correlated with cancer prognosis by tumor microenvironment remodeling
              </a>
            </td>
          <td>
            Jingdai Zhang, Yu Qiu, Yifan Liu, Shengwei Mo, Muwen Nie, Hui Zhang, Xiaohang Liu, Wei Chen
          </td>
          <td>2025-11-17</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2d337f9005b90e93fdf29316d67b193863ed97ca" target='_blank'>
              CAR T-cells dysfunction in the central nervous system is mediated by BBB-induced activation-induced cell death
              </a>
            </td>
          <td>
            Yarden Aharony-Tevet, O. Ravid, A. Yanir, Amilia Meir, Hadar Levi, Daniel Burstein, Aviya Amram, Tamar Feuerstein, S. Izraeli, Itzik Cooper, E. Jacoby
          </td>
          <td>2025-10-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>28</td>
        </tr>

        <tr id="Natural Killer (NK) cell-based immunotherapy is rapidly emerging as a promising modality for cancer treatment. As pivotal players in the innate immune system, cells independently recognize and eliminate malignant cells without prior sensitization, offering distinct advantages over other cell-based therapies. This review highlights the current landscapes of NK cell adoptive therapy, from fundamental biology to cutting-edge clinical applications. It highlights how advancing NK cell sources, including peripheral blood, umbilical cord blood, established cell lines, and the increasingly significant induced pluripotent stem cells (iPSCs), are driving wider, more standardized therapeutic use. The multifaceted strategies employed to enhance NK cell efficacy are being explored, including advanced expansion protocols and sophisticated genetic engineering techniques such as the introduction of Chimeric Antigen Receptors (CARs) and modifications to bolster antibody-dependent cellular cytotoxicity. Additionally, it also addresses the significant hurdles that remain, primarily the immunosuppressive tumor microenvironment (TME), and discusses innovative strategies being developed to overcome these challenges. By synthesizing preclinical data and results from the latest clinical trials, this review highlights the remarkable progress and bright future of NK cell therapy as a safer, effective, and more accessible cornerstone of cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/907e688bbe5ee6289ded49ffbefb7a3664df42bb" target='_blank'>
              Harnessing the Innate Effector: A Narrative Review of Advancing Strategies in CAR Engineering, Metabolic Reprogramming, and TME Resistance of Natural Killer Cells for Cancer Immunotherapy
              </a>
            </td>
          <td>
            Rita Agustina, Endah Agustina Lestari, Husni Ahmad Sidiq, M. A. Nazar
          </td>
          <td>2025-10-13</td>
          <td>International Journal of Cell and Biomedical Science</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7bcfd3df2c5d1e60c0a8518093894d3b787fd6a7" target='_blank'>
              Azvudine remodels the local immunosuppressive microenvironment and exhibits sustained anti-tumor effects in combination with anti-PD-1 therapies.
              </a>
            </td>
          <td>
            Limin Jia, Zhaoyang Wang, Jinfa Du, Zhigang Ren, Jiandong Jiang, Pan Li
          </td>
          <td>2025-11-24</td>
          <td>Frontiers of medicine</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Faust Akl et al. revealed in Nature a paradigm-shifting mechanism distinct from myeloid-driven immunosuppression, whereby glioblastoma induces T-cell apoptosis via tumor-derived IL-11, prompting astrocytes to reprogram into immunosuppressive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)+ effectors, thereby establishing astrocytes as active immunomodulators. Therapeutically, herpes simplex virus type 1 (HSV-1) (anti-TRAIL) achieves a dual therapeutic effect, offering novel strategies to overcome glioblastoma (GBM)'s evasion tactics.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3ee38de781ba115c0898771e91e1d944adf21efa" target='_blank'>
              Beyond Passive Bystander: Glioblastoma-Educated Astrocyte Suppressing T Cell.
              </a>
            </td>
          <td>
            Yuan-Yuan Wang, Weilin Jin
          </td>
          <td>2025-10-31</td>
          <td>Frontiers in bioscience</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="
 Although immunotherapy has transformed cancer treatment, glioblastoma (GBM) remains stubbornly resistant due to multiple immunosuppressive mechanisms. Our previous work identified polyamine metabolism as a key driver of this immunosuppression, with difluoromethylornithine (DFMO) improving survival in a T and B cell-dependent manner. However, DFMO alone, or in combination with PD-1/PD-L1 blockade, failed to yield durable benefits. This suggests the emergence of adaptive resistance mechanisms. To investigate this, we performed single-cell RNA sequencing (scRNA-seq) on DFMO-treated tumors, revealing increased T-cell inflammation and IFN-γ-driven gene expression. Surprisingly, the most upregulated gene was apolipoprotein D (ApoD), a lipid transport protein that sequesters arachidonic acid (AA). AA is an inflammatory lipid essential for T-cell-induced IFN-γ-STAT1-dependent ferroptosis of tumor cells during immunotherapy. Notably, this STAT1-ApoD axis was also acutely induced in response to other immunotherapies in murine GBM models. We therefore hypothesized that IFN-γ–induced ApoD expression represents a potential mechanism of tumor immune evasion. Our preliminary findings show that ApoD overexpression protects tumor cells from AA-induced lipotoxicity and ferroptotic cell death, decreasing survival in GBM mouse models, which was dependent on intact adaptive immunity. ApoD-overexpressing tumors displayed a higher myeloid-to-CD8⁺ T cell ratio and increased expression of immune checkpoints and suppressive markers, indicating a more immunosuppressive microenvironment. Collectively, our study demonstrates ApoD as a critical adaptive responder to inflammatory stress in GBM. Ongoing research will further explore ApoD-targeted interventions, including lipid nanoparticle-mediated siRNA delivery. We will investigate the intrinsic role of ApoD in controlling tumor cell susceptibility to ferroptosis, and, in parallel, examine its extrinsic effects as a secreted factor that reshapes the immune microenvironment by suppressing T cell function and promoting myeloid immunosuppression. This may lead to future therapies that enhance immunotherapy efficacy in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/002ee8adc2baa74e88b71b10cd71ff6d47d4f268" target='_blank'>
              TMIC-82. Sequestration of inflammatory lipids as an immune evasion mechanism in glioblastoma
              </a>
            </td>
          <td>
            Tzu-yi Chia, Chao Wei, Leah K. Billingham, Suzi Delay, Lauren Boland, Nishanth S. Sadagopan, Jay Subbiah, Si Wang, Hanxiao Wan, Jiawei Huo, J. Duffy, Alina R Murphy, Rebecca Du, Joshua Katz, Aurora Lopez-Rosas, Yu Han, G. Vázquez-Cervantes, Hardik Shah, Peng Zhang, Irina V Balyasnikova, M. Lesniak, Catalina Lee-Chang, J. Miska
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="Melanoma, the deadliest form of skin cancer, poses a significant challenge due to its genetic heterogeneity and high metastatic potential. While cytotoxic T cell (CTL)‐based immunotherapies have made remarkable progress in recent years, the therapeutic potential of natural killer‐(NK) cells is increasingly recognized. However, resistance mechanisms to both CTL‐ and NK‐cell‐mediated immunotherapies hinder effective treatment. To evaluate the exclusive role of NK‐cells in anti‐melanoma immunity, we performed 2D and 3D co‐culture‐based cytotoxicity assays under varying conditions. Our findings revealed a protective phenotype in melanoma cells following prolonged exposure to primary NK‐cells. By combining experimental data with bioinformatic analyses, we identified key genes and pathways involved in melanoma cell adaptation to NK‐cell‐mediated killing (NKmK). We found that cytokines such as IFNγ play a major role in suppressing NKmK with MHC II surface expression being a critical factor. Targeting the master regulator CIITA, which governs MHC II expression and is affected by IFNγ, significantly reduced melanoma cell resistance to NKmK. This study provides potential strategies to overcome resistance to NK‐cell‐based immunotherapies and offers novel insights into melanoma immune escape mechanisms.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5764eda312a5162e966ee86f3fed7809fb2be1df" target='_blank'>
              The IFNγ‐CIITA‐MHC II axis modulates melanoma cell susceptibility to NK‐cell‐mediated cytotoxicity
              </a>
            </td>
          <td>
            Lena C M Krause, Rixa-Mareike Köhn, Christian Ickes, Julia Lenger, Jonas Fischer, Sabrina Cappello, Ivan Bogeski
          </td>
          <td>2025-10-13</td>
          <td>Molecular Oncology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/541160e8b435b526009e3e42eef754f3da87a632" target='_blank'>
              Hiltonol and Protamine-RNA stimulation induce an immune-activating transcriptome profile in cDC1s
              </a>
            </td>
          <td>
            Georgina Flórez-Grau, Till S. M. Mathan, Mihaela B. Mihaylova, Tom van Oorschot, G. Schreibelt, D. Sancho, I. Melero, Carl G. Figdor, I. M. D. de Vries, Johannes Textor
          </td>
          <td>2025-10-14</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>43</td>
        </tr>

        <tr id="Glioblastoma (GBM) secrete extracellular vesicles (EVs) which play a pivotal role in brain tumor progression by mediating intercellular communication within the inflamed tumor microenvironment (TME). EVs’ cargo transports biomolecules that promote tumor progression, immune evasion, and resistance to therapies. While Hippo inhibitors play a significant role in mitigating cancer inflammation, their specific impact on EVs cargo remains unknown. Human grade IV U87 GBM-derived cells were cultured and EVs isolated from the conditioned media of tumor necrosis factor (TNF)α-primed cells. Total RNA was extracted using TRIzol™, and differential gene expression assessed through gene arrays and validated by RT-qPCR. Protein cell and EVs lysates were used for immunoblotting. 3D mesenchymal stem/stromal cells (MSC) in vitro vasculogenic mimicry (VM) was assessed using Cultrex matrices. Our study shows that U87 cells are responsive to pro-inflammatory stimulation by TNFα as the phosphorylation status of ERK, IκB, and NFκB increased. Among the Hippo pathway inhibitors tested, VT107 inhibited both the TNFα-induced phosphorylation, induction of the downstream Hippo pathway CYR61, and cargo of secreted EVs as assessed upon gene array screens. Pro-inflammatory genes that were reduced by VT107 in EVs included, among others, COX2, IL6, IL1B, and several members of the CCL, CXCL, and Interleukin/Interleukin receptors family. EVs isolated from VT107-treated TNFα-primed U87 cells had decreased paracrine regulation of MSC in vitro VM. By inhibiting the Hippo pathway and TNFα-induced pro-inflammatory cargo of GBM-derived EVs, our data support VT107 as a potential candidate to inhibit tumor-promoting processes involved in therapy resistance such as paracrine induction of MSC-mediated VM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fa05d80e4910bdac3b9b63c9272d09c39377ebb6" target='_blank'>
              Hippo pathway suppression reprograms TNFα-primed glioblastoma extracellular vesicles transcripts cargo to drive mesenchymal stem/stromal cells vasculogenic mimicry
              </a>
            </td>
          <td>
            Rosalie Zilinski, Angélique Sabaoth Konan, Alain Zgheib, N. Eliopoulos, Luc H. Boudreau, B. Annabi
          </td>
          <td>2025-10-14</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>43</td>
        </tr>

        <tr id="Ferroptotic tumor therapy is of highly significance to treat malignancies. Nevertheless, immune cells within the tumor immune microenvironment (TIME) are particularly susceptible to ferroptosis upon exposure to ferroptotic inducers, leading to the immunosuppression of TIME. In the present work, we report a dual activation strategy to initially pre-activate the T cells within TIME using genetically engineered cytolysin A-expressing outer membrane vesicles (OMVs) to enhance the interferon-γ (IFN-γ) production. We then deliver the homologous tumor cell membrane-hybridized liposomal nanovesicles containing arachidonic acid (MLipoAA) to the tumor cells for IFN-γ-potentiated ferroptosis. The combination treatment of OMVs and MLipoAA results in significant tumor destruction in colon CT26 tumor xenografts. This approach is also effective in combating tumor recurrence and metastasis. Mechanistically, the produced IFN-γ synergizes with arachidonic acid to trigger Acsl4-mediated tumor ferroptosis. The present work provides prominent immunopotentiations followed by selective tumor ferroptotic strategy with high effectiveness and biocompatibility, presenting a robust therapeutic strategy to conquer the immunosuppression drawback during in vivo ferroptotic therapy. Pre-Activation of T cell Immunity Potentiates Tumor Ferroptotic Cell Death Pre-Activation of T cell Immunity Potentiates Tumor Ferroptotic Cell Death">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5ea8aabf479b70bf359a2e32d2d9662ee7569509" target='_blank'>
              Pre-activation of T cell immunity potentiates ferroptotic cell death through arachidonic acid hybridized nanovesicles
              </a>
            </td>
          <td>
            Qi Lyu, Chang Liu, Shaoyue Li, Dandan Shan, Hong Han, Liying Wang, Huixiong Xu
          </td>
          <td>2025-11-18</td>
          <td>Journal of Nanobiotechnology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, characterized by rapid proliferation, diffuse infiltration, and resistance to conventional therapies. Despite advances in surgery, radiotherapy, and chemotherapy, the prognosis remains dismal, with median survival rarely exceeding 15 months. The immunosuppressive and heterogeneous tumor microenvironment (TME), along with profound tumor-intrinsic resistance mechanisms, contributes significantly to treatment failure. Cardiotonic steroids (CTS), such as ouabain, have recently gained attention for their pleiotropic effects beyond Na+/K+-ATPase inhibition, including modulation of intracellular signaling, induction of cell death, and immune regulation. In GBM, ouabain has been shown to reduce tumor cell viability, impair migration, disrupt angiogenesis, and alter different signaling pathways. Although direct evidence of ouabain’s effects on the GBM immune microenvironment is limited, findings from other models suggest that it can modulate both innate and adaptive immune responses, affecting T cells, regulatory T cells, dendritic cells, monocytes, and NK cells. While previous reviews have explored the anticancer and pharmacological aspects of cardiotonic steroids, the immunological dimension of ouabain’s activity remains underrepresented. This review integrates current evidence on ouabain’s dual actions in tumor biology and immune regulation, emphasizing its emerging therapeutic potential and the need for deeper investigation within high-grade glioma models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5c73049935628c7b64bd22cf222eb78736095626" target='_blank'>
              From hormonal immunomodulation to glioblastoma therapy: the emerging role of Ouabain
              </a>
            </td>
          <td>
            Arthur Gomes de Andrade, D. Carvalho, Daniel Wilson Arruda Magalhaes, A. C. de Queiroz, M. S. Alexandre-Moreira, Sandra Rodrigues-Mascarenas, L. H. A. Cavalcante-Silva
          </td>
          <td>2025-11-07</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, thus, there is an urgent need to develop more effective therapeutic options for this dismal condition. Tumor-infiltrating lymphocytes (TILs) are associated with improved response to immune checkpoint blockade in HCC, but their low abundance in most cases limits their therapeutic efficacy. Here, we demonstrate, in mice, that low-dose intratumoral immunovirotherapy with the trivalent measles, mumps, and rubella vaccine (MMR) induces superior tumor-growth delay and extended host survival compared to individually administered vaccines for measles, mumps, or rubella viruses. Further, our results show that MMR therapy synergizes with PD-1 and CTLA-4 blockade to reprogram the tumor microenvironment, resulting in increased CD8+ TIL infiltration and reduced PD-1 expression on TILs, among other effects. These changes in the immunological landscape translated into greater survival and more durable tumor-specific and memory immune responses for hosts. Comprehensive toxicology analysis revealed no evidence of MMR-induced liver or kidney toxicity after intrahepatic administration. This work reinforces an unrecognized role of MMR plus ICB in reprogramming the immune landscape in HCC through multimodal immune activation, providing a strong rationale for further development of MMR-based therapies for HCC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a0ee9f74230079389edd57b51b6b1e849660e18a" target='_blank'>
              Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
              </a>
            </td>
          <td>
            M. Tesfay, Aleksandra Cios, K. U. Ferdous, Randal S. Shelton, Bahaa Mustafa, Camila C Simoes, Murat Gokden, I. Miousse, Kimberly J. Krager, Marjan Boerma, Alicja Urbaniak, Anuradha Kunthur, S. Obulareddy, Joshua M. Eichhorn, Steven R Post, J. C. Chamcheu, Omeed Moaven, C. Chabu, D. Duda, Matteo Conti, Bruno Nardo, Rang Govindarajan, M. Fernandez-Zapico, Lewis R. Roberts, M. Borad, Martin J Cannon, Alexei G. Basnakian, B. Nagalo
          </td>
          <td>2025-10-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>63</td>
        </tr>

        <tr id="Despite the success of immune checkpoint inhibitors in cancer, many patients do not respond or relapse following treatment. Therefore, new approaches to augment existing immunotherapies are needed. CRISPR screens have revealed the importance of TNF-α signal transduction mediators, such as TAK1, in facilitating tumor susceptibility to cytotoxic T cells. Here, we demonstrate that inhibition of TAK1 in tumor cells lowers the threshold for TNF-α-induced cytotoxicity. Upon TNF-α signaling, pharmacologic inhibition of TAK1 sensitized tumor cells to RIPK1-dependent apoptosis. However, RIPK1-independent apoptosis occurred upon genetic deletion of Tak1, suggesting a novel scaffolding function of TAK1 is required to induce RIPK1 kinase activity during cell death. Deleting Tak1 impaired in vivo tumor growth, enhanced α-PD-1 immunotherapy, and lead to durable anti-tumor memory, dependent on CD8 T cells and intact TNF-α signaling. Our results collectively demonstrate that compromising TAK1 function within tumor cells leverages the cytotoxic capacity of TNF to enhance anti-tumor immunity and generate deeper and more durable anti-tumor immune responses in preclinical models of cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/57211ff5257cefccbaf3a51da4a814bb6d07d106" target='_blank'>
              Targeting tumor intrinsic TAK1 engages TNF-α-driven cell death through distinct mechanisms and enhances cancer immunotherapy
              </a>
            </td>
          <td>
            Jason D. Huska, Kelly J Doyle, Julie J. Purkal, Cara Hrusch, Ryan C Duggan, Erwin R. Boghaert, A. Souers, D. Phillips, Stephen K Tahir
          </td>
          <td>2025-10-16</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="Cancer‐associated fibroblasts (CAFs) are pivotal stromal components that shape the tumor microenvironment through their remarkable heterogeneity and dynamic functions. This review comprehensively examines the biology of CAFs, starting with their diverse cellular origins and induction mechanisms via key signaling pathways. We highlight the spatial‐temporal heterogeneity of CAF subsets and propose an updated classification system that encompasses eight functionally distinct subtypes based on recent single‐cell transcriptomic studies. The tumor‐promoting roles of CAFs are explored in depth, including their contributions to tumor behavior through novel mechanisms such as neutrophil extracellular traps formation, and multidrug resistance via metabolic reprogramming. A major focus is placed on CAF‐mediated immunotherapy resistance through immune checkpoint regulation, recruitment of immunosuppressive cells, and metabolite secretion. This review also highlights key technologies that are advancing CAF research, including patient‐derived 3D models, artificial intelligence‐enhanced spatial multiomics, clustered regularly interspaced short palindromic repeats (CRISPR)‐engineered mouse systems, and machine learning approaches for analyzing CAF heterogeneity and function. Finally, we evaluate therapeutic strategies targeting CAF activation, secreted factors, and immune crosstalk, while critically analyzing ongoing clinical trials. Overall, this review not only clarifies the biology of CAFs but also provides a translational framework for developing next‐generation stromal‐targeted therapies to overcome treatment resistance in cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e1dae86be5576422570b1acdcb11b97738bdec4b" target='_blank'>
              Cancer‐Associated Fibroblasts: Origin, Classification, Tumorigenicity, and Targeting for Cancer Therapy
              </a>
            </td>
          <td>
            Chang Fan, Wenlong Zhu, Yuan Chen, Wanwan Zhu, Jin Ding
          </td>
          <td>2025-10-28</td>
          <td>MedComm</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 We explore how CD169+ macrophages (MP) and CD8+ T cells coordinate effective anti-tumor immunity in a breast cancer model where mammary stem cells harbor the three cancer driver mutations most frequently associated in human patients (Tp53-/-, MLL3-/-, and PIK3CA). Flow cytometry analysis and tissue section imaging revealed that CD169+F4/80+ MP rapidly infiltrated and outnumbered all other immune cell populations during tumor growth, suggesting they were likely to play an instrumental role in shaping the tumor microenvironment. Selective depletion of these MP in tumor bearing mice resulted in significantly accelerated tumor growth and significantly lower production of effector cytokines (TNF, IFNγ, CCL3) by CD8+ T cells compared to the non-depleted control group. When we deleted STING signaling in CD169+ MP, disrupting a pathway involved in sensing double stranded DNA and producing type I interferon, we also observed faster tumor growth, lower effector function in T cells, and decreased cell surface expression of the integrin CD103 that is associated with tissue residency. Consistent with this result, multiplex immunofluorescent imaging analysis indicated that CD8+ T cells were more clustered in tumors from mice with STING deficient MP. Overall, our data provide evidence for a therapeutically targetable mechanism for aggressive breast cancer in which STING sensing in tumor infiltrating CD169+ MP results in the production of Type I interferons to activate effector CD8+ T cells.



 DOD BC200410, NIH R21 CA290322



 Innate Immune Responses and Host Defense: Cellular Mechanisms (INC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fc9c9d9c6bf7b12b4bd5c0b159dad0dc8b31f36b" target='_blank'>
              CD169+ macrophages orchestrate anti-tumor CD8+ T cell immunity in a preclinical model of breast cancer 3914
              </a>
            </td>
          <td>
            Nicole Couturier, Marie Boutet, Dimitra P. Anastasiadou, George S. Karagiannis, Wenjun Guo, G. Lauvau
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="


 Activation and exhaustion marker expression have become critical for evaluating the efficacy of immune checkpoint inhibitors in cancer therapy. Exhaustion biomarkers, such as Programmed Death-Ligand 1 (PD-L1) and Lymphocyte-Activation Gene 3 (LAG-3), were analyzed in solid tumors alongside co-expression of T-cell activation markers, such as CD86 and Ki67, to gain insights into the immune cell status. Flow cytometry was used to characterize LAG-3 and PD-L1 expression on cytotoxic and memory T cells from patients with various solid tumors, including melanoma, non-small cell lung cancer (NSCLC), and breast cancer, using cryopreserved peripheral blood mononuclear cell (PBMC) samples. The expression of exhaustion markers, LAG-3 and PD-L1, was variable across patients with solid tumors, with elevated levels observed on CD8+ T cells. This suggests an up-regulation in response to persistent tumor antigenic stimulation. The co-expression of exhaustion markers on CD8+ T cells may indicate a role in T-cell dysfunction and immune evasion. These findings highlight the complexity of exhaustion marker expression in immune cells and their influence on immune responses in patients with solid tumors. By integrating LAG-3 and PD-L1 profiling with other markers of immune activation and exhaustion, this study underscores the potential of these markers as predictive biomarkers for immunotherapy response and provides insights into mechanisms of immune evasion in solid tumor cancers.



 Immune Mechanisms of Human Disease (HUM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5345c8124cfc479e7f2de77345d1f38e458a7f71" target='_blank'>
              Activation and exhaustion marker expression on immune cells from patients with solid tumors 9367
              </a>
            </td>
          <td>
            Angelina Bisconte, Rachel Owen, Jackie Benko, Jorge Pardo, Samantha Splitt, Deborah Phippard
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/38bd915a127428183b967cf450cf6cad5748a83e" target='_blank'>
              OCA-B/Pou2af1 Expression in Mouse T Cells Promotes PD-1 Blockade-Induced Autoimmunity but is Dispensable for Anti-Tumor Immunity
              </a>
            </td>
          <td>
            Junhong Du, Asit K. Manna, Erik P. Hughes, Paulla Bisoma, Kimberley J Evason, Arabella Young, W. D. Wilson, Abdelbasset A. Farahat, D. Tantin
          </td>
          <td>2025-10-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Upon activation, B cells integrate signals from antigen and T cell help to choose between a rapid extrafollicular (EF) response and entry into the germinal center (GC). EF differentiation produces short‐lived plasmablasts that provide immediate but relatively low‐affinity antibody, whereas GC entry commits B cells to iterative selection, somatic hypermutation, and affinity maturation, ultimately yielding high‐affinity plasma cells and memory B cells. At the B–T cell border, where both responses originate, B cells also undergo class switch recombination (CSR). In this review, we examine the molecular mechanisms of CSR, highlighting the interplay between the DNA deaminase AID, transcription, and noncanonical nucleic acid structures. We further discuss the differential requirement of glycolysis between the EF versus GC response and how the cytokine IL‐21 fine‐tunes B cell entry into the GC. Together, these perspectives integrate genomic alterations, metabolic demands, and cytokine‐mediated signaling at the critical decision point between EF and GC pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ecc034aac7cb165cdbc5d307ab3c3ccca1cecfd1" target='_blank'>
              Mechanisms Promoting Stability of B Cells
              </a>
            </td>
          <td>
            Vivian L S Kuan, Jayanta Chaudhuri
          </td>
          <td>2025-10-29</td>
          <td>Immunological Reviews</td>
          <td>1</td>
          <td>4</td>
        </tr>

        <tr id="Sepsis is a common and life-threatening condition encountered in intensive care units (ICUs). Mesenchymal stromal cells (MSCs) and their small extracellular vesicles (EVs) have emerged as promising nanotherapeutics, particularly in the context of COVID-19. This study evaluates the efficacy and mechanisms of adipose-derived MSC EVs (ADMSC-EVs) in a lipopolysaccharide (LPS)-induced sepsis model. We quantified M2 macrophages and IL-10 in peripheral blood mononuclear cells (PBMCs) from both septic patients and healthy donors. ADMSCs and their EVs were isolated, and EVs were administered to LPS-challenged mice. Macrophage phenotypes in lung tissue were analyzed using flow cytometry and immunofluorescence. The biodistribution of EVs was traced with PKH67 green fluorescent cell linker dye (PKH-67), and the signaling pathways involved in macrophage reprogramming were examined. ADMSC-EVs efficiently entered macrophages, promoted M2 polarization, suppressed inflammation, and improved survival rates in septic mice. Biodistribution studies demonstrated widespread organ accumulation, with notable localization in the lungs, liver, and kidneys. Mechanistically, the EV cargo miR-21-5p targeted Pellino E3 ubiquitin protein ligase 1 (PELI1), driving M2 polarization in vivo, which was accompanied by increased IL-10 levels. These findings position ADMSC-EVs as a viable cell-free therapeutic approach for mitigating LPS-induced sepsis through the delivery of miR-21-5p to PELI1, thereby supporting further development of EV-based immunomodulatory strategies for sepsis management.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/079e35927153f299495c717d7ee84ca7c453a3b9" target='_blank'>
              Adipose-derived MSC extracellular vesicles ameliorate sepsis by reprogramming macrophages via miR-21-5p targeting PELI1.
              </a>
            </td>
          <td>
            Guannan Zhou, Jieqiong Song, Lizhen Xuan, Zhunyong Gu, Yimei Liu, Cheng Xu, Hongyu He
          </td>
          <td>2025-10-27</td>
          <td>Biomolecules & biomedicine</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Immunotherapy combinations can improve patient outcomes, yet the interactions within the tumor microenvironment (TME) that drive therapeutic synergy are poorly understood. Tumor establishment drives monocyte recruitment and differentiation into tumor-associated macrophages (TAMs), which have essential roles in coordinating immune responses and are thus attractive targets for therapeutic modulation. In a murine model of combination anti-PD-1 and anti-PD-L1 checkpoint blockade, tumor control was associated with increased infiltration of CD8+ T cells and M1-like repolarization of TAMs. Live-cell imaging of the tumor microenvironment revealed stable contacts between tumor-infiltrating CD8+ T cells and TAMs, in which the extent of the contact interfaces increased with combination immunotherapy. Treatment with anti-PD-L1 was able to increase macrophage expression of pro-inflammatory factors and phagocytic activity, suggesting a role for TAMs to reactivate CD8+ T cells in the TME. However, co-treatment with anti-PD-1 was ultimately necessary for tumor control, indicating the need for combination targeting of the TME.



 Mayo Clinic David and Margaret Grohne Cancer Immunotherapy Pilot Award



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/67b4b5c68bd11e510478b663ba12c5b0fe316f16" target='_blank'>
              Macrophage repolarization by immune checkpoint blockade drives T-cell engagement in the tumor microenvironment 2076
              </a>
            </td>
          <td>
            Tina Kwok, Jessica N Lancaster, Haidong Dong, Ildefonso Silva
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Fusobacterium nucleatum (Fn) has been increasingly recognized as a crucial mediator of colorectal cancer (CRC) biology, particularly in microsatellite-stable (MSS) tumors, where immune checkpoint inhibitors (ICIs) have shown limited efficacy. Rather than representing a passive microbial passenger, Fn actively shapes tumor behavior by adhering to epithelial cells, activating oncogenic signaling, and promoting epithelial–mesenchymal transition (EMT). At the same time, it remodels the tumor microenvironment, driving immune suppression through inhibitory receptor engagement, accumulation of myeloid-derived cells, and metabolic reprogramming of tumor-associated macrophages. These mechanisms converge to impair cytotoxic immunity and contribute to both intrinsic and acquired resistance to ICIs. Beyond immune escape, Fn interferes with conventional chemotherapy by sustaining autophagy and blocking ferroptosis, thereby linking microbial colonization to multidrug resistance. Most of these mechanisms derive from preclinical in vitro and in vivo models, where causal relationships can be inferred. In contrast, human data are mainly observational and provide correlative evidence without proving causality. No interventional clinical studies directly targeting Fn have yet been conducted. Its enrichment across the adenoma–carcinoma sequence and consistent detection in both tumor and fecal samples highlight its potential as a biomarker for early detection and patient stratification. Importantly, multidimensional stool assays that integrate microbial, genetic, and epigenetic markers are emerging as promising non-invasive tools for CRC screening. Therapeutic strategies targeting Fn are also under exploration, ranging from antibiotics and bacteriophages to multifunctional nanodrugs, dietary modulation, and natural microbiota-derived products. These approaches may not only reduce microbial burden but also restore immune competence and enhance the efficacy of immunotherapy in MSS CRC. Altogether, current evidence positions Fn at the intersection of microbial dysbiosis, tumor progression, and therapy resistance. A deeper understanding of its pathogenic role may support the integration of microbial profiling into precision oncology frameworks, paving the way for innovative diagnostic and therapeutic strategies in CRC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5de3392ea1b80bc011c9950b5aa6328802a1377a" target='_blank'>
              Fusobacterium Nucleatum in Colorectal Cancer: Relationship Among Immune Modulation, Potential Biomarkers and Therapeutic Implications
              </a>
            </td>
          <td>
            Dalila Incognito, Giuliana Ciappina, Claudia Gelsomino, Antonio Picone, Pierluigi Consolo, A. Scano, T. Franchina, Nicola Maurea, V. Quagliariello, Salvatore Berretta, A. Ottaiano, M. Berretta
          </td>
          <td>2025-10-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>1</td>
          <td>23</td>
        </tr>

        <tr id="Interferon-gamma (IFN-γ), as a pleiotropic cytokine, plays a pivotal role in antitumor immunity. Its remarkable immunostimulatory, antiproliferative, and pro-apoptotic effects make it a promising candidate for tumor immunotherapy. Here, we highlight the dual role of IFN-γ in the tumor microenvironment during tumor development and treatment. IFN-γ can enhance antigen presentation, boost cytotoxic T cell and natural killer cell activity, and inhibit angiogenesis, promoting tumor regression and correlating with favorable therapeutic outcomes. However, prolonged exposure may induce the upregulation of immune checkpoint molecules such as programmed death-ligand 1, trigger T cell exhaustion, and recruit regulatory T cells, phenomena associated with the development of treatment resistance in cancer therapy. This dual nature poses significant challenges for harnessing IFN-γ in tumor treatment, necessitating an in-depth understanding of its mechanisms within specific microenvironments. Although numerous studies have explored IFN-γ-based tumor therapies, their outcomes have been inconsistent. Thus, although IFN-γ-based therapeutic strategies hold considerable promise, their clinical translation requires precise modulation to fully exploit its antitumor effects while mitigating potential protumor risks. See also the graphical abstract(Fig. 1).">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e48bdd0772c494cb7597b77c69e2cc5a685517ff" target='_blank'>
              IFN-gamma in the tumor microenvironment: dual roles in cancer progression and therapy
              </a>
            </td>
          <td>
            Jiahui Cui, Yi Zhang, Li Yang
          </td>
          <td>2025-10-14</td>
          <td>EXCLI Journal</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="The Interferon-Stimulated Gene 15 (ISG15) has a key role during viral infections, since it can modify and regulate the expression of proteins from the host and from viruses. Isg15−/− mice are more susceptible to infectious diseases. ISG15 is induced by type I Interferons (IFN-I) and apart from defense against pathogens, it can also play an important function in cancer or immune-mediated inflammatory diseases. Previous studies reported that ISG15 expression is increased in post-synaptic dendritic cells (DCs) upon interaction with CD4 + T cells. However, data regarding the role of ISG15 in DCs are scarce. The present study assesses the function of ISG15 in DCs activation, migration and ability to mediate T cell activation using bone marrow-derived DCs (BMDCs) and stimulation with lipopolysaccharide (LPS). Activation of DCs was not impaired but tended to be lower in Isg15-deficient mice, as observed by reduced CD40 induction in Isg15−/− BMDCs. Isg15−/− BMDCs induced less proliferation and Granzyme B expression in co-cultured CD8 + T cells. Interestingly, Isg15−/− BMDCs secreted reduced levels of the pro-inflammatory cytokines IL-1β and IL-12 upon LPS stimulation. Mechanistically, our data suggest that ISG15 regulates Caspase-1 activity in DCs leading to lower IL-1 β secretion. In conclusion, this study reveals an essential role for ISG15 modulating DCs inflammatory activity and raises new questions regarding the specific mechanisms of how this protein regulates innate immune responses.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/05fa00535a2acdc99ae44733e69601b7e28b4dad" target='_blank'>
              ISG15 modulates inflammatory profiles and ability to activate CD8 + T cells in bone marrow-derived dendritic cells
              </a>
            </td>
          <td>
            P. Martínez-Fleta, Clara Pertusa, Irene Fernández-Delgado, R. Izquierdo-Serrano, M. Ramírez-Huesca, Nieves Fernández-Gallego, D. Calzada-Fraile, Elena Moya-Ruiz, Raquel Castillo-González, Susana Guerra, E. Martín-Gayo, F. Sánchez-Madrid
          </td>
          <td>2025-10-24</td>
          <td>Cellular and Molecular Life Sciences: CMLS</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="Background: Cerebral malaria (CM) is a severe and often fatal complication of Plasmodium falciparum infection that causes devastating brain injury largely through immune-mediated mechanisms. Pathogenic brain-infiltrating CD8+ T cells are key drivers of CM pathology, yet the intracellular signals enabling their harmful autoimmune-like activity remain poorly defined. Here, we identify protein kinase C θ (PKCθ), a central antigen receptor-signalling mediator, as a critical contributor to experimental cerebral malaria (ECM). Methods/Results: Using a PKCθ null allele mouse strain on a C57BL/6N background, we demonstrate that PKCθ deficiency significantly improves survival in Plasmodium berghei ANKA (PbA)-infected mice without altering parasite burdens in the blood or brain. Mechanistically, loss of PKCθ skews T cell differentiation towards central memory (Tcm) rather than effector memory (Tem) phenotypes, thereby reducing effector differentiation and sequestration of CD8+ T cells in the cerebral microvasculature. This prevents extensive neurovascular damage, preserves neural tissue integrity, and alleviates neurological signs and symptoms. Our findings provide genetic evidence that PKCθ drives CD8+ T cell-mediated brain injury in ECM. Conclusions: These results underscore the potential for repurposing clinically PKCθ inhibitors as host-targeted interventions to protect against cerebral injury and improve outcomes in patients with CM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f72ad9681b0a4fb1435cab237ed155e8996cc887" target='_blank'>
              Inhibition of PKCθ Abrogates CD8+ T Cell-Mediated Neurotoxicity in Murine Cerebral Malaria
              </a>
            </td>
          <td>
            Karin Albrecht-Schgör, Victoria E. Stefan, Martina Steinlechner, Dominik Humer, K. Siegmund, Sebastian Peer, Thomas Gruber, Maja Überegger, Stephanie zur Nedden, Gabriele Baier-Bitterlich, Peter Lackner, Erich Schmutzhard, Nikolaus Thuille, V. Klepsch, G. Baier
          </td>
          <td>2025-10-22</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="TO THE EDITOR, Relapse remains the major cause of treatment failure after allogeneic stem cell transplantation (allo-SCT), often related to impaired immune surveillance by donor-derived T cells. Oxidative stress is a hallmark of allo-SCT leading to accumulation of oxidized DNA lesions, most notably 8-hydroxy-2 ’ -deoxyguanosine (8-ohdg) in reconstituting T cells [1]. High 8-ohdg level correlated with impaired functionality and increased relapse risk [1]. The clinical success of histamine dihydrochloride, an antioxidant agent, in combination with interleukin-2 for relapse prevention in AML highlights the therapeutic relevance of redox modulation to restore T and NK cell functionality [2]. Sustained stimulation of the T cell receptor (TCR) in alloreactive T cells results in mitochondrial hyperreactivity and abundant superoxide generation [3]. Oxidized bases lead to replication stress and double-strand breaks, which not only impair gene expression but also induce premature senescence, a state that limits ef ﬁ cacy of T cell-based therapies. T cell ﬁ tness, which encompasses metabolic resilience and adapt-ability, has emerged as a key determinant of successful immune reconstitution and therapeutic ef ﬁ cacy [4]. In fact, DNA integrity, particularly resistance to oxidative DNA damage, is an under-appreciated facet of T cell ﬁ tness, as DNA damage accelerates T cell aging [5]. In this context, “ DNA ﬁ tness ” emerges as a potential prerequisite for sustained T cell function. The">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6b2ccb5d1ba1f39d638e0ad18a2ddd154ebb1af4" target='_blank'>
              OGG1 activation improves T cell resilience to oxidative stress after allo-SCT and T cell engager exposure
              </a>
            </td>
          <td>
            D. Saul, C. Lischer, H. Bruns, N. Ziegler, A. Kannt, M. Michel, D. Mougiakakos
          </td>
          <td>2025-10-15</td>
          <td>Leukemia</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Gliomas present as highly heterogeneous and aggressive central nervous system (CNS) tumors with challenging diagnosis and management. Traditional and current therapies are lacking efficacy in overcoming the complex and dynamic behavior of gliomas and the local tumor microenvironment. Emerging research highlights the significant role of innate immune receptors including Toll-like, NOD-like and RIG-like receptors, as well as cGAS-STING receptors, scavenger and C-type lectin receptors in glioma development and progression. These receptors can both impact immune modulation as well as facilitate tumor growth through interactions with tumor-associated macrophages, myeloid-derived suppressor cells and cytokine networks, contributing to immune evasion in the tumor microenvironment. Herein, we discuss the main signaling pathways induced through innate immune receptors in gliomas along with their functional properties in glioma pathology while exploring current applications to treatment. Utilizing innate immune receptors as therapeutic targets holds great promise, especially when used along with traditional chemotherapy and radiation schemes, strengthening immune responses. Future studies focusing on the deeper understanding of innate immune receptors signaling and complexity are highly required to enable novel immunoregulatory treatment schemes for gliomas.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b2b7b3e02786ee96fe5c12a17a3e23bd5c3a936a" target='_blank'>
              Innate Immune Signaling in Gliomas: Regulatory Mechanisms and Targeting Potential in Tumor Progression
              </a>
            </td>
          <td>
            Edmund Jung, Sara Al Jadidi, C. Piperi
          </td>
          <td>2025-10-01</td>
          <td>Life</td>
          <td>1</td>
          <td>16</td>
        </tr>

        <tr id="Natural killer (NK) cells serve as pivotal effector cells within the innate immune system, playing an indispensable role against infections and tumors. Individuals with diminished NK cell activity or NK cell deficiency are at a higher risk of developing cancers and experiencing severe viral infections. With global demographic shifts toward aging populations, elucidating the mechanisms of immunosenescence becomes increasingly critical for developing targeted therapeutic interventions against age-related disorders. This review provides a comprehensive summary of the phenotypic characteristics, functional changes, and mechanisms of NK cells in aging and diseases. By synthesizing current research, it highlights key pathways contributing to NK cell immunosenescence in the elderly and explores potential strategies to preserve or restore their cytotoxic and immunoregulatory functions. The review provides novel insights into NK cell immunosenescence and proposes innovative approaches to enhance NK cell activity in aging individuals, offering potential therapeutic avenues for mitigating age-related immune decline.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6176129feabcadd207bec7b9a7e512c4a503122e" target='_blank'>
              Phenotypes, mechanisms, and therapeutic strategies of natural killer cell immunosenescence
              </a>
            </td>
          <td>
            Zixuan Guo, Feng-tian Wu, Yao Chen, Jia Xu, Zhi Chen
          </td>
          <td>2025-10-21</td>
          <td>Immunity & Ageing : I & A</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="


 Melanoma patients treated with anti-PD1 or anti-PD1/anti-CTLA4 present intrinsic or acquired resistance to these immune checkpoint blockade (ICB) treatments. However, the interactions between tumor-stromal-immune cells in the microenvironment (TME) underlying these resistances remain unclear. In this study, we used a cohort of melanoma patients (n = 61) treated with ICB, pre-treatment (n = 33) and post-progression (n = 28), for whole-exome sequencing, single-nucleus RNA sequencing and high-resolution spatial imaging. We developed a framework to analyze response and resistance (intrinsic and acquired) via tumor-intrinsic programs, immune features, and tumor-stromal-immune interactions. Patients with low immune infiltration exhibited enrichment of macrophages associated with hypoxia and angiogenesis phenotypes. Samples with high immune infiltrates displayed an enrichment in lymphocytes, particularly TCF7+ CD8+ T cells. Pre-treatment samples from patients experiencing durable clinical benefit are encriched in memory B cells and plasmablast-like B cells.The presence of Bcells and of follicular dendritic cells in non-lymph node biopsies support the presence of tertiary lymphoid structures within the TME. Lastly, the presence of a TIMD4-expressing macrophage subset correlates with lymphocyte infiltration, indicating its potential role in promoting anti-tumor immunity. Our work defines TME immune profile interaction with tumor-stromal cells associated with clinical outcomes in melanoma.



 NCI HTAN



 Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2a8d3010e6c8bda33a8b18473b82b46e0a2ceaea" target='_blank'>
              Understanding tumor-immune-stromal dynamics driving response and resistance to immune checkpoint blockade in melanoma 4125
              </a>
            </td>
          <td>
            Giuseppe Tarantino, Yiwen He, Priyanka Solanky, Xinyu Cui, K. Pfaff, A.R. Thorner, Timothy R. Blosser, Elliot Boblitt, Allison Frangieh, Tyler J. Aprati, Boyang Zhang, Jiajia Chen, H. Faulkner, Aleigha Lawless, M. Manos, K. Helvie, T. Sharova, Dennie T. Frederick, Sachi Krishna, Chanell Mangum, Domenic Abbondanza, Cai McCann, Bruce Johnson, Alex K. Shalek, Eliezer M. Van Allen, Xiaowei Zhuang, Ryan J. Sullivan, Barbara Engelhardt, Sami Farhi, S. Rodig, F. S. Hodi, Genevieve M. Boland, David R. Liu
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>63</td>
        </tr>

        <tr id="Myeloid-derived suppressor cells (MDSCs) play critical roles in tumor immune evasion. These heterogeneous cells are broadly classified into granulocytic (G-MDSC), monocytic (M-MDSC), and their immature precursors, early-stage MDSCs (e-MDSCs). Elucidating their differentiation and expansion mechanisms is crucial for advancing cancer immunotherapy. This review examines the key signaling pathways (e.g., JAK/STAT, NF-κB, Notch), regulatory cytokines, metabolic factors, and epigenetic modifications central to MDSC biology. A comprehensive understanding of these intricate networks provides valuable insights into tumor immune evasion and facilitates the identification of novel therapeutic targets designed to overcome MDSC-mediated immunosuppression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4682b63ca9757bb9c1ba2dada7a0f722d5dd5cac" target='_blank'>
              Molecular mechanisms governing the differentiation and expansion of myeloid-derived suppressor cells
              </a>
            </td>
          <td>
            Ke Wang, Xiao Wang, Nan Sun
          </td>
          <td>2025-10-17</td>
          <td>Frontiers in Cell and Developmental Biology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Introduction Glioblastoma (GBM) is a highly invasive brain tumor with limited treatment options and poor prognosis. Natural killer (NK) cells are key effectors of antitumor immunity, capable of eliminating cancer stem-like cells. However, GBM creates an immunosuppressive microenvironment that limits NK cell function. Here, we identify cystatin F as an immunosuppressive factor involved in regulating NK cell granule-mediated cytotoxicity. Methods We analyzed cystatin F expression in GBM and its correlation with immune exhaustion markers. NK cell activity was compared between GBM patients and healthy donors. In vitro co-cultures of cystatin F-expressing microglial cells and glioblastoma stem-like cells were used to assess NK cell function. To block cystatin F activation from dimeric to active monomeric form, a small-molecule inhibitor of cathepsin V, the activating protease, was applied. Results Cystatin F expression correlated with immune exhaustion and suppression markers in GBM. NK cells from patients showed reduced cytotoxicity compared to healthy donors. Co-cultures confirmed that cystatin F-expressing microglia impaired NK cell cytotoxicity, while inhibition of cathepsin V restored NK cell function in standard cytotoxicity assays, 3D spheroids, and microfluidic perfused models. Discussion These results indicate that cystatin F mediates NK cell suppression in GBM. Targeting its activation enhances NK cell cytotoxicity, offering a potential strategy to improve NK-based immunotherapy for glioblastoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3bb3c49f85522c7de4609841eca5e88d65fb2178" target='_blank'>
              Targeting cystatin F activation enhances NK cell cytotoxicity in glioblastoma models
              </a>
            </td>
          <td>
            E. Senjor, A. Habič, U. Švajger, Ana Mitrović, M. Proj, A. Porčnik, Borut Prestor, Miha Jerala, Matic Bošnjak, Stanislav Gobec, B. Breznik, Janko Kos, Milica Perišić Nanut
          </td>
          <td>2025-10-28</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="T-cells are a core component of tumor immunotherapy because of their potent ability to identify and kill cancer cells. Yet efficacy is limited by exhaustion, senescence, metabolic dysregulation, an immunosuppressive tumor microenvironment (TME), and limited persistence. This review analyzed these key issues and proposed targeted improvement strategies. Emerging approaches encompass pharmacological modulation of T cell activation and survival pathways, epigenetic reprogramming to reverse exhaustion and senescence, metabolic engineering, combinatorial targeting of immunosuppressive TME components and advanced genetic tools, notably CRISPR-Cas9–based CAR-T optimization, which exemplifies how precise genome editing can enhance therapeutic efficacy. We review the progress and prospects of T-cell improvement strategies in tumor immunotherapy, emphasizing the need for further exploration to enhance the broader application and long-term efficacy of T-cell therapies. This review highlights recent advances and future directions in T-cell engineering, metabolic modulation, and microenvironment targeting, aiming to translate innovations into effective cancer immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/576f0048bd963a53102bad036edb12f448a68a45" target='_blank'>
              Next-generation T cell immunotherapy: overcoming exhaustion, senescence, and suppression
              </a>
            </td>
          <td>
            Guangmei Li, Dengju Li, Xiaojian Zhu
          </td>
          <td>2025-10-13</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 T cells contribute to the pathology associated with rheumatoid arthritis (RA). While T cell co-stimulation modulation with Abatacept (CTLA4-lg) has shown promise in delaying RA onset, the mechanisms driving T cell-mediated progression from pre-disease to active RA remain unclear. We conducted longitudinal scRNA-seq profiling of PBMCs from 45 ACPA+ individuals at risk for RA (ARI), 16 of whom later developed clinical RA (converters) and performed trimodal single cell assay TEA-Seq in a subset of ARI (n = 7) and ACPA- controls (n = 5). We observed extensive transcriptomic changes in CD4 naive and memory cells and an expansion of Tfh17 (PDCD1+CXCR5+KLRB1+RORA+) cells during progression to clinical RA. Trimodal integration revealed upregulation of genes in the calcium–calcineurin–NFAT pathway, enrichment of NFAT motifs, and increased accessibility in an enhancer region of IL21 in the ARI naive CD4 T cells. Our findings indicate that effector CD4 T programs in the converters were biased towards Tph17 development during progression to RA. Additionally, ARI CD4 naive cells exhibited an activation state, with epigenetic imprints linked to Tfh development. Overall, these results suggest that activation and epigenetic reprogramming of naive cells may contribute to specific bias in effector T cell programs during progression to RA disease, providing mechanistic insights for targeting T cells during an at-risk period to potentially prevent or delay clinical RA.



 This work was supported by the Allen Institute.



 Basic Autoimmunity (BA)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/909e41771c510e86442892bab54815a7273f942a" target='_blank'>
              Epigenetic control of pathogenic CD4 T cell polarization during progression to rheumatoid arthritis 3989
              </a>
            </td>
          <td>
            Ziyuan He, Pravina Venkatesan, Adam K. Savage, Marla C. Glass, L. Okada, Upaasana Krishnan, Christy E. Bennett, Nhung T. T. Tran, Yudong D. He, Samir Rachid Zaim, Padmapriyadarshini Ravisankar, Jessica Garber, Palak C. Genge, Kevin J. Lee, C. Phalen, Regina R Mettey, M. Feser, Jane H. Buckner, Ananda W. Goldrath, Thomas F. Bumol, Xiao-jun Li, Michael Holers, Peter J. Skene, G. Firestein, Kevin D. Deane, Troy R. Torgerson, Mark A Gillespie
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>100</td>
        </tr>

        <tr id="Type 2 innate lymphoid cells (ILC2s) are critical mediators of type 2 immunity that play non-redundant context-dependent modulatory functions. Primarily associated with responses against helminths and allergens via the activation of a potent epithelial-ILC2 axis, a growing body of evidence also suggests that a crosstalk between ILC2 and T cells is equally important in maintaining tissue homeostasis. In barrier tissues and secondary lymphoid organs, ILC2s co-localize with T cells, forming hubs where bi-directional signals are exchanged. Here, we describe the diversity of functional interactions between ILC2s and T cells, detailing known contact-dependent and -independent mechanisms, including a relatively new and still poorly defined antigen-presenting function during inflammation. Understanding these complex interactions is necessary to fully elucidate how this specific crosstalk helps maintain tissue homeostasis and regulate inflammatory responses. Identifying the spatial and temporal specificities of these interactions will certainly open new avenues for future targeting of this axis to improve immune-mediated host protection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dc9091d8a7d8543597d9b4583a6f2834ed1e2f0b" target='_blank'>
              Unspoken words: decoding the dialog between type 2 innate lymphoid cells and T cells
              </a>
            </td>
          <td>
            Zahra Jamila Ikra, Qiutong Huang, Huiyang Yu, Gabrielle T. Belz, Craig N. Jenne, Nicolas Jacquelot
          </td>
          <td>2025-10-06</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c454ed40c54564b7e7bad898b56913f7bebc36e6" target='_blank'>
              Multicellular Calcium Waves in Cancer-Associated Fibroblasts Regulate Neuronal Mimicry and Anisotropy Leading to Immune Exclusion
              </a>
            </td>
          <td>
            Giovanni Giangreco, Zoe Ramsden, Antonio Rullan, S. Hooper, David Novo, Joana Leitão Castro, Probir Chakravarty, Marta Milan, Hamid Mohammadi, Sandra Llop, Marc Juarez, Deborah Schneider-Luftman, M. Oliva, Laia Alemany, Mihaela Angelova, A. Olow, Xin Yu, Philip S Hobson, K. Harrington, E. Sahai
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Malignant tumors are a major threat to human health with the immune responses critically influenced by major histocompatibility complex (MHC) class I and II molecules. While MHC-I has been extensively studied for its role in tumor immunity, research on MHC-II, particularly MHC-II function within the tumor microenvironment, has lagged behind research on MHC-I. The expression and regulation of tumor-specific MHC-II (tsMHC-II) in tumor cells not only reflect the immunogenic landscape of the tumor microenvironment but also actively shape antitumor immune responses by modulating CD4+ T cell recognition and activation. Expression of tsMHC-II is tightly controlled by intrinsic oncogenic signaling and extrinsic cytokine stimulation, positioning tsMHC-II as a key determinant of response to immunotherapy, including immune checkpoint blockade. Accordingly, tsMHC-II may serve as a predictive biomarker and a potential therapeutic target in tumor immunotherapy. This review highlights recent advances in the structure and function of MHC-II, the MHC-II regulatory mechanisms in tumors, and the emerging significance of MHC-II in guiding future immunotherapeutic strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c80f9e92f018fb245474012f1fe7574b765d23e2" target='_blank'>
              Biological mechanism and immune response of MHC-II expression in tumor cells
              </a>
            </td>
          <td>
            Mengya Zhou, Siwei Pan, Yanqiang Zhang, Can Hu, Zhiyuan Xu
          </td>
          <td>2025-10-03</td>
          <td>Cancer Biology & Medicine</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Checkpoint inhibitors have revolutionized hepatocellular carcinoma (HCC) treatment, yet their efficacy remains limited in advanced stages, with suboptimal objective response rates. Growth differentiation factor 15 (GDF15), a dual-functional cytokine implicated in tumor progression and immunosuppression, represents a promising therapeutic target. This study aims to develop a novel GDF15-targeted strategy to improve HCC management and synergize with PD-1 blockade. GFRAL-Fc fusion proteins were generated by fusing the extracellular domain of GFRAL with IgG1 Fc. The anti-tumor efficacy and the anti-cachexia ability of GFRAL-Fc was evaluated in a spontaneous HCC model on GDF15 humanized mice. Additionally, the half-life and drug safety were evaluated in mice. To investigate the underlying mechanisms, a CyTOF analysis was utilized to analysis the immunoregulation effects of GFRAL-Fc within HCC. Finally, the anti-tumor effects of GFRAL-Fc in combination with Programmed Death-1 (PD-1) inhibitors were assessed. GFRAL-Fc targets GDF15 to simultaneously prevent GDF15-CD48 interaction-driven ERK activation and block GDF15-GFRAL binding. Treatment with GFRAL-Fc achieved dual antitumor effects: reducing tumor progression and attenuating cancer-associated cachexia. Combination with PD-1 blockade further enhanced antitumor efficacy, resulting in a substantial decrease in tumor nodules. Mechanistic studies revealed that GFRAL-Fc reprograms the immunosuppressive tumor microenvironment by suppressing Treg activation while enhancing CD8+ T cell cytotoxicity. Our findings validate GDF15 targeting as a viable strategy to overcome checkpoint inhibitor resistance in HCC. The GFRAL-Fc fusion protein demonstrates multimodal therapeutic benefits through metabolic regulation and immune remodeling, providing a clinically translatable approach to optimize PD-1-based regimens. This study addresses critical gaps in current HCC management and warrants further clinical validation. Schematic diagram of GFRAL-Fc functional: After binding with GDF15, GFRAL-Fc inhibits the GDF15-GFRAL pathway to suppress cancer-associated cachexia, while also inhibiting the GDF15-CD48 pathway to reprograming the tumor immune microenvironment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f424c4cc08908ec0d690fea5ad9e9738200e0f9" target='_blank'>
              GFRAL-Fc disarms GDF15 to reprogram tumor immunity and amplify PD-1 efficacy in hepatocellular carcinoma
              </a>
            </td>
          <td>
            Gege Shi, Wangqian Zhang, Fei Xie, Jiaxin Shi, Minghui Yan, Lei He, Zhaozhao Li, Yang Xiao, Duo Yu, Haiyan Cao, Haichen Du, Yueyuan Qiu, Kuo Zhang, Shuning Wang, Meng Li, Jieyu Zhang, Zhaowei Wang
          </td>
          <td>2025-10-15</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>20</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a349f447081e148334ada4b0e5ec3e64399cf656" target='_blank'>
              Trophoblast stem cells and syncytiotrophoblasts lack inflammatory responses to LPS but retain robust interferon-mediated antiviral immunity
              </a>
            </td>
          <td>
            Cristine R. Camp, Joshua Baskaran, Matthew Brown, Carly Parker, Paige Drotos, Rachel C. West
          </td>
          <td>2025-10-24</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Objective Regulatory T cells (Tregs) play a pivotal role in tumor immune evasion, and strategies to overcome their immunosuppressive activity are urgently needed. This study investigates the immunomodulatory effects of microwave ablation (MWA) on TNFRSF4+ Tregs, focusing on the OX40L/TNFRSF4 signaling axis as a potential therapeutic target. Methods TNFRSF4+ Tregs were isolated from C57BL/6 mice and subjected to MWA-mimetic thermal stress. In vitro functional assays and in vivo LLC xenograft models were employed, with OX40 agonist intervention. Molecular mechanisms were analyzed via RT-qPCR, Western blot, and immunohistochemistry. The balance of tumor-infiltrating immune cells was quantified by multi-color flow cytometry. Results MWA induced three key effects: (1) Phenotypic shift: decreased CTLA-4+ (P<0.0001) Treg subsets, but increased OX40L+ (P<0.01) in LLC cells; (2) Functional impairment: reduced Treg-mediated support for LLC proliferation, migration, and invasion; (3) Enhanced CD8+ T cell cytotoxicity. In vivo, MWA reshaped the tumor microenvironment by significantly increasing the intratumoral CD8+/Treg ratio (P<0.001), indicating a shift toward an anti-tumor inflammatory state. Mechanistically, MWA suppressed NF-κB/IκBα/TRAF6 signaling, and these effects were amplified by an OX40 agonist, suggesting the pathway is potentially OX40L-dependent. Conclusion This study demonstrates that MWA disrupts Treg immunosuppression, likely by activating OX40L/TNFRSF4 signaling, and favorably alters the balance of effector to suppressor cells, providing a novel rationale for combining thermal ablation with OX40-targeted immunotherapies in cancer treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f38c9a306dd490d7b2909de55961bc75bf9d4ebe" target='_blank'>
              Microwave ablation triggers OX40L-mediated disruption of TNFRSF4+ Treg immunosuppressive activity
              </a>
            </td>
          <td>
            Runqi Guo, Yufeng Wang, Jie Sun, Yuanming Li, Zhixin Bie, Xiaoguang Li
          </td>
          <td>2025-10-23</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="


 Immunosenescence leads to impaired immunity against infections in the elderly. As a key component of adaptive immunity, T cells are crucial for immunity against infection and cancer and exhibit distinct phenotypic changes with age. Characterizing these age-related alterations in T cells is essential for developing strategies to address immune dysregulation in the elderly. In vitro activation model showed that aged mice have a higher frequency of PD1+ exhausted-like CD8 T cells at baseline and higher TCR-induced cell death upon activation. Inhibiting both apoptosis and necrosis rescues TCR activation-induced cell death. Using a murine hepatitis virus (MHV) intranasal infection model, we observed that aged mice had greater weight loss, higher mortality, and impaired CD8 T cell responses during MHV infection. Infected aged mice exhibited increased expression of inhibitory receptors on antiviral CD8 T cells and a decrease in the population of CD8 T cells producing IFN-γ. Single-cell RNA sequencing showed that aging altered the transcriptional profile of antiviral CD8 T cells and reduced T-Bet and ZEB2 expression, key factors for effector CD8 T cell differentiation. Aging also upregulated T cell exhaustion gene signature mediated by the transcription factor TOX. Overall, our findings demonstrate that aging reshapes the molecular program of antiviral CD8 T cells and compromised antiviral T cell immunity in the aged.



 Supported by NIH/ NIA AG-083398; NIAID AI-158294



 Viral Immunology (VIR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/80e47c0f1fb034ad0cc56d0aad4b1018f719c06e" target='_blank'>
              Aging compromises effector differentiation and induces exhaustion-like phenotype in CD8 T cells 2511
              </a>
            </td>
          <td>
            Ziang Zhu, Tuoqi Wu, Chen Yao
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="


 Chronic graft-versus-host disease (cGVHD) is an alloimmune disease that can follow non-self hematopoietic stem cell transplantation, driven by dysregulated T cell and other immune responses. Detailed analysis of naïve and memory T cells with antigen presenting cells has not yet been paired with the role of exhausted T cells in mucosal cGVHD. Using oral mucosa (OM) biopsies collected from patients six months post-transplant, we characterized, at single-cell resolution, T cell exhaustion using transcriptomic and protein level analyses in cGVHD. Single-cell RNA sequencing identified CD8+T cell clusters with apparent dysfunction, including a CXCL13+CD8+ T cell cluster with a dual phenotype characterized by cytotoxic markers (GZMB, PRF1) and exhaustion signatures (TIM3, LAG3). Increased frequency of this cluster correlated significantly with clinical severity score, connecting these cells to disease severity. In unaffected patients, LYVE1+ macrophages and CD1C+ dendritic cells signaling supported immune homeostasis, but these populations were diminished in cGVHD, coinciding with disease progression. CODEX analysis mapped expansion of FOXP3+CD4+T cells and their proximity to CD8+T cells in cGVHD, yet this regulatory influence was insufficient to halt tissue damage. In summary, dysregulated CD8+T cells that combine exhaustion and cytotoxic functions could drive persistent damage and thwart anti-inflammatory signals, underscoring the central role of exhaustion in cGVHD pathogenesis.



 NIH Intramural Program



 Immune Mechanisms of Human Disease (HUM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/afd145d184e9fe7e66457307e5b4674f888ab08a" target='_blank'>
              T cell exhaustion in focus: single-cell mapping of CD8+ T cell dynamics in mucosal chronic graft-versus-host disease 3680
              </a>
            </td>
          <td>
            A. C. Costa da Silva, Rubina Sharma, Noemi Kedei, Frank A Boksa, Damilola F. Killanin, Drashty P. Mody, Marie Kao-Hsieh, David Kleiner, Christopher G. Kanakry, S. Pavletic, J. W. Mays
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>73</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/67b6398ddc5edaa94a066851abec2558753a9728" target='_blank'>
              NLRP1 Shapes Immune and Inflammatory Signatures in Human Melanoma but Not in Mouse Models
              </a>
            </td>
          <td>
            V. P. Targhetta, Raquel de Souza Vieira, Hedden Ranfley, C. N. de Souza Breda, N. O. Câmara
          </td>
          <td>2025-11-26</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Abstract Expression of inhibitory Siglec receptors has been described on T cells of patients with viral infection and cancer. However, the exact function and their role in T-cell activation and control of infections have not been well investigated. Here, we show that Siglec-9 levels increase on T cells in patients with acute severe acute respiratory syndrome coronavirus 2 infection relative to levels on healthy controls. T cells of these patients are inhibited by Siglec-9, and specific blocking with antibodies released this inhibition. To further test the role of Siglec-9 in acute viral infections, we characterized a murine model with T-cell intrinsic Siglec-9 overexpression. We found that Siglec-9 restricted T-cell immunity after acute infection with lymphocytic choriomeningitis virus, thereby dampening T-cell-mediated immune pathology. These results show that inhibitory Siglec receptors including Siglec-9 T cell intrinsically modulate and fine-tune antiviral T-cell activation, proliferation, and effector function.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ed06e49b5229600881efcceffb165b8a257a0279" target='_blank'>
              Increase of Inhibitory Siglec receptors on T cells mitigates severe immune reactions during acute viral infections
              </a>
            </td>
          <td>
            N. Rodrigues Mantuano, A. Bärenwaldt, Mirza Sarcevic, Isabelle V M Siqueira, A. Jauch, Manina Maja Etter, Matthias S Matter, Gregor Hutter, Mike Recher, H. Läubli
          </td>
          <td>2025-10-27</td>
          <td>PNAS Nexus</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a81a04ed656834e3dbf3e26c295c4c2f5db6951" target='_blank'>
              M2 macrophage polarization in allogeneic skin transplantation: from intrinsic mechanisms to clinical prospects for immune tolerance
              </a>
            </td>
          <td>
            Tengxiao Ma, Haoxinai Wang, Yunbin Liu, Lei Li
          </td>
          <td>2025-11-26</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a92502fd070af58b4a67230d880201dd22ee2fc7" target='_blank'>
              CD86 costimulation enhances the antitumor activity of NKG2D CAR-Macrophages and synergizes with Anti-PD-L1 therapy to suppress prostate cancer progression.
              </a>
            </td>
          <td>
            Abdulrahman Ibrahim, Zihao Liang, Wan Liu, Xiaofei Di, Lawan Rabiu, Rong Li, Pengchao Zhang, M. A. Saliu, Maoxuan Liu, Guizhong Zhang, Xiaochun Wan, Dehong Yan
          </td>
          <td>2025-11-25</td>
          <td>Cell communication and signaling : CCS</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e9fce5a4d984852580efd0c55b56d8c29d4c2556" target='_blank'>
              Lipid-Metabolically Active TREM2high Microglia‑Derived Macrophages Predict Poor Prognosis and Represent an Immunotherapeutic Target in Glioma
              </a>
            </td>
          <td>
            Jinxin Li, Xiaotong Yu, Decao Yang, Shaomeng Chen, Jiaxing Xu, Xiaojuan Ma, Chen Huang, Baohui Xu, Lixiang Xue, Yan Wang
          </td>
          <td>2025-10-14</td>
          <td>Journal of Neuroimmune Pharmacology</td>
          <td>1</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c3de68178f204f50d4f5e9e5e298b21f11011eca" target='_blank'>
              Multidimensional single-cell analysis reveals immune dysfunction and inflammatory response in Lymphatic malformations.
              </a>
            </td>
          <td>
            Chunxiao Chen, Wenhao Ju, Xueying Li, Kexin Yao, Jun Cao, Songqi Duan, Xueqi Lv, Tianli Zhang, Sanlin Li, Jiawen Li, Feng He, Baofa Sun, Gang Shen
          </td>
          <td>2025-11-22</td>
          <td>Protein & cell</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Dendritic cells (DCs) are essential regulators of adaptive immunity, functioning as professional antigen‐presenting cells that bridge innate sensing with the induction of adaptive immunity and immune memory. The DC population is heterogeneous, encompassing numerous phenotypic subsets depending on the tissue, pathophysiological condition and species studied, which historically complicated their classification. Advances in bulk or single‐cell transcriptomics and ontogenetic studies have clarified DC heterogeneity and highlighted type 1 conventional DCs (cDC1s) for their unique ability to induce protective CD8+ T cell responses against cancer and intracellular pathogens. Beyond immunity, DCs also maintain tolerance to self and harmless antigens. Contrary to earlier assumptions that tolerogenic DCs are simply immature, recent evidence shows that both immunogenic and tolerogenic maturation involve an extensive and convergent reprogramming of cDC1s during the activation process licensing them for shaping T cell responses, a process referred to as DC maturation. This evolving understanding is reshaping how we study DCs, including the necessity to integrate the timing of DC maturation and their microanatomical redistribution during this process. The novel insights these studies are bringing carry significant implications for vaccines or immunotherapies against intracellular pathogens or cancers, and treatments against allergy or autoimmunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4f0236bce193fec556b42698afce4c36c4c5719f" target='_blank'>
              Identity, Functions, and the Spatiotemporal Maturation of Type 1 Conventional Dendritic Cells
              </a>
            </td>
          <td>
            Ramazan Akyol, Marc Dalod
          </td>
          <td>2025-11-01</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6ff39811b58af3141f8b13471490c1f390abe0d9" target='_blank'>
              Non-canonical inflammasome drives intrinsic anti-microbial responses in human Natural Killer cells
              </a>
            </td>
          <td>
            N. G. Leborgne, Jadie Acklam, Alexander J. Hogg, Zarema Albakova, Karen Hogg, K. Robinson, Grant Calder, Arnel Villamin, Callum Robson, Freya Pealing, Matthew A. Care, Monika Gonka, James M. Fox, James Iremonger, J. Hewitson, David G. Kent, Alison M. Layton, Frances E. Pearson, Max E. Noble, W. Grey, Jillian L. Barlow, Dave Boucher
          </td>
          <td>2025-10-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) is widely considered unresponsive to immunotherapy due to its immunosuppressive microenvironment and limited immune cell infiltration. However, recent single-cell transcriptomic studies reveal the presence of exhausted, potentially antigen-specific T cells in human GBM. We have developed a locally administered, brain-confined cytokine therapy with minimal systemic exposure using an engineered, neonatal Fc receptor (FcRn)-silenced, Compartment-Locked (CL) IL-12Fc fusion protein. This approach thus relies on presence and reactivation of tumor-resident, IL-12-responsive cells. In syngeneic, preclinical GBM models, intratumorally administered CL IL-12Fc induces robust antitumor efficacy, also under conditions of peripheral lymphopenia (induced via systemic temozolomide) or when T cell influx was pharmacologically inhibited. In 3D-perfused, patient-derived GBM explant cultures—with a largely preserved native tumor microenvironment and without addition of autologous peripheral immune cells—CL IL-12Fc triggered pro-inflammatory reprogramming. Proteomics-based secretome analysis revealed significant upregulation of interferon-gamma (IFNγ) pathway signatures. Single-cell RNA sequencing of GBM tissues prior to culture setup confirmed the presence of resident memory T cells in most patients. Notably, single cell transcriptome analysis of post-treatment explants demonstrated a robust IFNγ response in both tumor-associated macrophages, microglia and tumor cells. Our findings demonstrate that CL IL-12Fc can activate local immune responses within human GBM samples, independent of peripheral immune cell recruitment. This localized immune activation is an important prerequisite for the clinical translation of locally confined cytokine therapy. We aim to validate these findings using spatially resolved multiplex immunofluorescence histology. In summary we provide evidence that CL IL-12Fc can facilitate local immune activation without peripheral immune cell requirement.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/060cb1db812334f914a22c2a53795e6b0d1cdc11" target='_blank'>
              IMMU-51. Treatment efficacy in murine and human glioma models with brain Compartment-Locked IL-12 does not per se rely on influx of peripheral immune cells and induces distinct transcriptome and secretome changes
              </a>
            </td>
          <td>
            Sabine Spath, L. Le Large, Michal Beffinger, N. Tatari, M. Ritz, B. Taskoparan, U. Salazar, Sereina Deplazes, Felix Behr, C. Zinner, W. Vader, Carlo Bertozzi, D. van der Meer, G. Hutter, J. vom Berg
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Immunosuppression within the tumor microenvironment (TME) profoundly inhibits anti-tumor immunity, presenting a formidable challenge in cancer therapeutics. Despite this recognized obstacle, multi-targeted immunomodulatory strategies remain elusive. Here we developed a novel mRNA-lipid nanoparticle (LNP) vaccine designed to reprogram key cellular mediators of immune suppression within the TME, including C-C motif chemokine ligand 22 (CCL22), transforming growth factor-β (TGF-β), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), Galectin-3, programmed cell death ligand 1 (PD-L1), indoleamine 2,3-dioxygenase 1 (IDO1), and arginase 1 (ARG1). This immunomodulatory vaccine was evaluated in a cohort of canines with spontaneous neoplasms, encompassing adrenal, hepatic, perianal, vulvar, and pulmonary malignancies. The vaccine demonstrated good tolerability, with only mild adverse events (Grade 1 anorexia, chills, and fatigue) observed in 25% of subjects (2/8). Remarkably, 75% of treated animals (6/8) achieved stable disease, with the median progression-free interval not yet reached a median follow-up of 168 days post-treatment initiation. Two dogs experienced disease progression. The overall disease control rate was 75%. In addition, vaccine administration reversed hematological and biochemical abnormalities and alleviated paraneoplastic syndromes associated with these malignancies. These findings demonstrate that our mRNA-LNP vaccine effectively exerts anti-tumor effects across various cancer types, offering a promising strategy for enhancing anti-tumor immunity in both veterinary and human oncology.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8fef4f03c94eaba07eeff2c05c0e60c396891042" target='_blank'>
              Immunomodulatory vaccine demonstrates therapeutic efficacy across cancer types
              </a>
            </td>
          <td>
            Tiyun Han, Guilai Liu, Chenyi Bao, Jian Zong, Caiyi Fei, Jing Li, Shi Xu, Qingbo Ma, Yingjuan Qian
          </td>
          <td>2025-10-31</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Objectives Dendritic cells (DCs) are pivotal antigen-presenting cells capable of bridging innate and adaptive immunity, making them promising candidates for cancer immunotherapy. While canine mature DCs (cmDCs) have been successfully generated from circulating mononuclear cells (CMCs) in healthy dogs, their derivation and immunomodulatory capacity in tumor-bearing dogs (TbDs) remain poorly characterized. Methods In this study, we evaluated the efficiency of cmDC generation from peripheral blood of both healthy donors (HDs) and TbDs and investigated their functional responses to Toll-like receptor (TLR) agonists and mRNA-based genetic modification. Results CD14+ monocytes were successfully isolated from peripheral blood using immunomagnetic sorting and differentiated into cmDCs using recombinant canine GM-CSF and IL-4. The differentiation efficiency was comparable between the two groups. In both cohorts, cmDCs upregulated key maturation markers (CD1a, CD80, CD83) and restored DLA class II expression in TbDs. Stimulation with LPS and R848 significantly increased CD80 and CD83 expression and triggered IL-12/p70 and IL-8 production, confirming the acquisition of a functional immunostimulatory phenotype. To assess their amenability to genetic engineering, cmDCs were transfected using DE-DOPE/mRNA lipoplexes. These lipoplexes exhibited favorable physicochemical properties and achieved robust mRNA delivery, resulting in 100% GFP-positive cells and >60% viability, outperforming electroporation in terms of cytocompatibility. Conclusions Our findings demonstrate that cmDCs derived from both HDs and TbDs are phenotypically and functionally competent and can be efficiently transfected using a non-viral mRNA delivery system. This strategy offers a viable platform for the development of personalized, DC-based cancer vaccines in canine patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/214b1855d713559c7344f3f9c1196e520714ee7a" target='_blank'>
              Toll-like receptor activation and gene delivery efficiency in canine dendritic cells: a model for comparative oncology
              </a>
            </td>
          <td>
            S. Capellero, R. De Maria, Lisa Adele Piras, L. Marconato, Lorenza Parisi, Eugenio Mazzone, C. Marchiò, E. Berrino, S. Bellomo, A. Sapino, G. P. Stola, Valeria Chiono, L. Nicoletti, Luca Aresu
          </td>
          <td>2025-10-03</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Solid tumors often suppress antitumor immune responses by promoting various dysfunctional CD8+ T cell states, which limit the effectiveness of T-cell-based immunotherapy. However, the mechanisms that promote these states have not been fully characterized. It is demonstrated that spontaneous priming responses during tumor growth can produce memory T cell reservoirs that are conducive to poor proliferative responsiveness during boosting vaccination. Surprisingly, when type I interferon (IFN-I) signaling is impeded, boosting vaccination can elicit robust proliferative responses from tumor-primed memory T cells and promote tumor control. This is observed in multiple tumor types and target antigens. In contrast to conventional memory T cells, tumor-primed memory T cells are unique in their pre-encoded responsiveness to IFN-I and show enrichment of pathways pertaining to DNA repair and cell cycle arrest. Tumor-primed memory T cells up-regulate p21 expression and blockade of either p21 or IFN-I can alleviate this effect to improve their proliferative capacity during boosting vaccination. Characterization of tumor-primed memory T cells revealed transcriptional and phenotypic features of cellular senescence, where higher senescence severity correlated with higher responsiveness to IFNα/β receptor blockade. Overall, IFN-I hyperresponsiveness may be a unique feature of senescent tumor-primed memory T cells that can exacerbate their dysfunction during cancer vaccination.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8cb2455df0fef81e7cabdf5fd3952e0ae44f71bd" target='_blank'>
              Pre-Encoded IFN-I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors.
              </a>
            </td>
          <td>
            Andrew Nguyen, Scott R Walsh, Li Deng, Lan Chen, Yonghong Wan
          </td>
          <td>2025-10-05</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Atherosclerosis remains the primary driver of cardiovascular and cerebrovascular morbidity and mortality. A pivotal event in its pathogenesis is the phenotypic conversion of vascular smooth muscle cells (VSMCs), particularly the transition from a contractile to a macrophage‐like state. Using a murine model of atherosclerosis, we demonstrate that this process is orchestrated by a progressively disrupted perivascular immune milieu characterized by an expansion of CD44⁺ memory CD4⁺ T cells at the expense of CD44− naive CD4⁺ T cells. Within this niche, CD44⁺ natural regulatory T cells (nTregs) actively promote VSMCs macrophage‐like reprogramming, whereas their CD44− counterparts exert an opposing, protective effect. Reciprocally, macrophage‐like VSMCs foster the trans‐differentiation of nTregs into pathogenic Th17 cells, amplifying vascular inflammation. In contrast, induced Treg cells (iTregs) display phenotypic stability and potently inhibit VSMCs macrophage‐like switching, restrict pathological VSMCs migration, and curtail VSMCs survival. Systemic infusion of iTregs selectively remodels the perivascular immune microenvironment toward an antiatherogenic profile. Adoptive transfer of iTregs at early disease stages decreased the abundance of macrophage‐like VSMCs, attenuated plaque burden, and these benefits were partially mediated by transforming growth factor β signaling. Collectively, iTreg‐based cellular therapy represents a promising strategy to intercept VSMCs macrophage‐like transformation and limit atherosclerotic progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f53dac592bfbe7181b6731e2e832bb43126fb9b5" target='_blank'>
              Infusion of Induced Regulatory T Cells Alleviates Atherosclerosis by Reducing Pathological Macrophage‐Like Vascular Smooth Muscle Cells
              </a>
            </td>
          <td>
            Ximei Zhang, Ye Chen, Yesheng Ling, Lin Wu, Ding-hui Liu, Linli Wang, Yong Liu, Guang-yao Shi, Bin Zhou, Bao-shun Hao, Zhenda Zheng, Shujie Yu, Min Wang, Jun Zhao, Donglan Zeng, Julie Wang, Yan Lu, Jun Tao, Wenhao Xia, Song Guo Zheng, Xiaoxian Qian
          </td>
          <td>2025-10-22</td>
          <td>MedComm</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/476c643da3b7bab359ba00f9ad0d1145a5743d99" target='_blank'>
              Mycobacterium tuberculosis-derived linoleic acid increases regulatory T cell function to promote bacterial survival within macrophages
              </a>
            </td>
          <td>
            Hongyu Cheng, Shenzhi Li, Hongjie Liu, Meiyi Yan, Jingxiang Wang, Jingping Huang, Shanshan Liu, Yifan Yang, Xinyu Cao, Pengfei Cui, Yuanna Cheng, Zhonghua Liu, Jie Wang, Xiaocheng Huang, Lin Wang, Lianhua Qin, Ruijuan Zheng, Carl G Feng, Qiang Zou, Yicheng Sun, Zhe Ji, Hua Yang, Baoxue Ge
          </td>
          <td>2025-10-10</td>
          <td>Nature Microbiology</td>
          <td>0</td>
          <td>33</td>
        </tr>

        <tr id="The immunoproteasome (IP) is a specialized form of the 26S proteasome, in which the catalytic subunits β1c, β2c, and β5c of the standard proteasome are replaced by LMP2, MECL-1, and LMP7. The IP is constitutively expressed in hematopoietic cells and its expression in non-hematopoietic cells can be induced by IFN-γ. The IP plays a crucial role in different immune functions, including MHC class-I ligand generation, cytokine production, and T helper cell differentiation. Selective inhibition of the IP has shown therapeutic benefits in treating different autoimmune diseases in pre-clinical animal models. However, the effect of IP inhibition on antibody production in viral infection and vaccination has remained underexplored. In this study, we used ONX 0914, an LMP7/LMP2-selective inhibitor of the IP, to study the effect of IP inhibition on B cells and antibody production. In vitro, continuous exposure to ONX 0914 in a human B cell lymphoma cell line and primary murine B and plasma cells led to poly-ubiquitinated protein accumulation, increased apoptosis, reduced antibody secretion, and impaired immunoglobulin class-switch. However, induction of virus neutralizing antibodies was not affected in IP inhibitor-treated mice. Furthermore, IP inhibition neither impaired vaccine-induced antibody responses, nor affected different B cell populations in two different vaccination models. These findings suggest that IP inhibition does not compromise vaccination efficacy and anti-viral humoral immunity, supporting the potential of IP-targeted therapies for autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f62f1e9c7e2dbbac6994a0363ea3e23614f4d079" target='_blank'>
              Immunoproteasome inhibition triggers protein stress and apoptosis in cells of B cell lineage without impairing vaccination-induced antibody responses
              </a>
            </td>
          <td>
            Dennis Mink, Franziska Oliveri, Julia Otto, Nazlim Kutsi, Carolina Gonzalez Siebold, Tony Muchamuel, Jun Li, Michael Basler
          </td>
          <td>2025-11-24</td>
          <td>Cell Death Discovery</td>
          <td>0</td>
          <td>33</td>
        </tr>

        <tr id="Respiratory viral infections establish tissue-resident memory T cells (TRM) in the lung, which provide optimal protection against subsequent infections, though the underlying mechanisms are incompletely understood. Here, we demonstrate in a mouse model of heterosubtypic influenza infection that lung TRM attenuate inflammation by macrophages during secondary versus primary responses, in part, through production of the immunoregulatory cytokine IL-10. During secondary infections, lung TRM were the predominant producers of early IL-10; inhibiting early IL-10 signaling resulted in increased macrophage-mediated inflammation, morbidity, and lung pathology. Moreover, lung TRM were shown to directly modulate lung macrophage responses and polarization in depletion experiments. Finally, IL-10 enhanced IFN-γ production by lung memory CD8+ T cells. Human influenza-specific TRM isolated from lungs recapitulated robust IL-10 expression associated with augmented effector responses of murine TRM. These data support a dual role of TRM in coordinating in situ secondary responses-augmenting effector responses for robust viral clearance while dampening inflammation to limit tissue damage.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cc6c23ffc8d8e83d96806c3c1229b2a8d9fc04d1" target='_blank'>
              Lung tissue-resident memory T cells optimize protection by IL-10 regulation of innate immunity.
              </a>
            </td>
          <td>
            Alexander Y Yang, Julia Davis-Porada, Daniel H. Paik, Alex B George, Brea H Brown, Paige L Ruschke, Peter A. Sims, Ziv Frankenstein, Anjali Saqi, Donna L. Farber
          </td>
          <td>2025-10-13</td>
          <td>The Journal of experimental medicine</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Immunotherapy remains ineffective in many solid tumors due to poor T-cell infiltration and a metabolically suppressive tumor microenvironment. A dual strategy combining low-level light (LLL) therapy with a nanoscale stimulator of interferon genes (STING) agonist formulation (nanoSTING@Mn) is presented to enhance immune activation and metabolic fitness for durable tumor immunity against T-cell lymphoma (EL4) model. NanoSTING@Mn, composed of ADU-S100 complexed with Mn2⁺ and encapsulated in biomimetic liposomes, potently activates the cGAS-STING pathway, induces a type I interferon response, and promotes lymphocyte infiltration. These monocytes polarize into M1 macrophages, suppressing regulatory T cells. Simultaneously, LLL photo-biomodulation reprograms mitochondrial metabolism in tumor-infiltrating CD8⁺ T and natural killer cells, restoring their durability and leading to complete local tumor eradication. This combination expands a distinct CD8⁺ T-cell subset with Tcf-1⁺ progenitor-exhausted features and elevated memory/effector gene expression, enhancing proliferation and cytotoxicity, as shown by single-cell RNA sequencing. Intranasal nanoSTING@Mn delivery mobilizes these LLL-revived T cells to the lung, where they differentiate into resident memory T cells and establish systemic antitumor immunity. Upon intravenous rechallenge, disseminated tumor cells are eliminated, preventing metastasis and ensuring long-term protection. This synergistic approach offers a scalable platform to boost immunotherapy efficacy and redefines immune-based metastasis prevention strategies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2e9ba5699caa736e818a9807d89458c43c8a2b62" target='_blank'>
              Light Metabolically Reprograms CD8+ T Cells to Potentiate STING-Driven Tumor Eradication and Prevent Metastasis.
              </a>
            </td>
          <td>
            Asmita Banstola, Shilin Gao, ZhengKun Zhang, Yan Dong, Prabhat Upadhyay, Quanwei Zhang, Yongli Li, Zuan-Tao Lin, Zhilong Wang, Mei X. Wu
          </td>
          <td>2025-10-23</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) is a highly treatment-resistant malignancy characterized by its poor prognosis and intrinsic resistance to therapy, driven largely by glioblastoma stem cells (GSCs) and an immunosuppressive tumor microenvironment (TME). This dual resistance plays a significant role in the failure of current treatment strategies. Consequently, there is an urgent need for novel therapeutic approaches that can effectively target GSCs while simultaneously reshaping the TME to promote anti-tumor immunity. In this study, we investigated the dual therapeutic potential of Xevinapant, a lead SMAC mimetic, through a combination of in vitro, in vivo, and single-cell transcriptomic analyses. We found that Xevinapant demonstrated potent anti-tumor activity through inducing dose-dependent apoptosis and significantly reduced cell viability in both human and mouse GSCs. In vivo administration of Xevinapant led to significant tumor suppression and extended overall survival in orthotopic models. Notably, our single-cell RNA sequencing result revealed that Xevinapant activated immune effector cell responses, contributing to the reprogramming of the immunosuppressive TME. Immune cell activation (both lymphoid and myeloid lineages) was further validated by flow cytometry using tumor-derived cells. To overcome potential therapeutic resistance, we derived Xevinapant-specific gene expression signatures and queried the LINCS database to identify small molecules with synergistic effects. Our analysis identified a promising compound ST-059620 that, when used in combination with Xevinapant, enhanced therapeutic efficacy and overcame resistance. Taken together, our findings highlight the dual mechanism of action of Xevinapant in targeting both tumor-intrinsic and microenvironmental resistance mechanisms. These results support the continued clinical development of Xevinapant and provide a strong rationale for combination strategies aimed at improving treatment efficacy in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/14a501e3f81b4b4d8beaca0ed97f02367fa8f4c1" target='_blank'>
              TMIC-25. SMAC Mimetic Targets Glioblastoma Stem Cells and Reprograms the Associated Tumor Microenvironment
              </a>
            </td>
          <td>
            Qiong Wu, Jianan Chen, Anders E. Berglund, Dongliang Du, Robert Macaulay, Arnold B Etame
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Cryptococcal meningitis is a fungal infection in patients with compromised CD4 T cell function. CD4 T cells provide killing signals to macrophages, principally IFNγ, to limit intracellular fungal replication. However, CD4 T cells may also drive inflammatory tissue damage. Yet, it is not fully understood how fungal-specific CD4 T cells infiltrate the brain and how they influence functional phenotypes of CNS-resident myeloid cells. In the current work, we develop a mouse model to track fungal-specific CD4 T cells and determine their influence on microglia. We found IFNγ+ fungal-specific CD4 T cells have limited TCR signalling and characterise a population of inflammatory microglia that upregulate MHCII and IFNγ-regulated genes during infection. Inflammatory microglia have poor fungicidal capacity and significantly expand during infection, a process that depends on CD4 T cell infiltration. Taken together, these data identify the early inflammatory consequences of fungal-specific CD4 T cell infiltration and identify proliferating microglia as important drivers of brain inflammation during infection. Cryptococcal meningitis is a common infection in patients with compromised CD4 T cell function. Using a CD4 T cell activation tracking mouse the authors show the localisation and activation of CD4 T cells in the brain after cryptococcus infection and how these cells interact with MHCII expressing microglia which may increase pathologic brain inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/37f4633c141c3226368499b170bc53f8df43b779" target='_blank'>
              Brain-infiltrating CD4 T cells drive inflammatory microglia proliferation during cryptococcal meningitis in mice
              </a>
            </td>
          <td>
            Sofia Hain, Man Shun Fu, Lucy Wigg, Lorna S. George, D. Lecky, Alexander J Whitehead, Erin Clipston, Ko Sato, Masahiro Ono, Marcel Wuthrich, Bruce Klein, Kazuyoshi Kawakami, J. Rayes, D. Bending, Rebecca A. Drummond
          </td>
          <td>2025-10-09</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="BACKGROUND
Brucellosis poses a significant threat to animal and human health globally. However, how Brucella subverts the immune response to establish persistent infections remains unclear.


METHODS
We utilized single-cell RNA sequencing (scRNA-seq) to decipher the immune landscape of mice infected by Brucella abortus. Flow cytometry, transgenic cell line and mouse, and antibody blockage were utilized to explore the relevant mechanisms.


RESULTS
Brucella infection induced significant changes in the composition and signaling pathways of immune cells, and flow cytometry analysis further confirmed the scRNA-seq data. An in-depth analysis with macrophages, the main target cell for Brucella, demonstrated activation of type I IFN and type II IFN signaling, TNF production, diverse cell deaths, etc. Specifically, Vir-2308 Brucella infection induced IFN-β expression, primarily originating from macrophages. In vitro, a significantly lower level of intracellular Brucella survival was observed in ifnar1-/- macrophages. In vivo, ifnar1 genetic deficiency rendered the mice less susceptible to Brucella challenge with a lower bacterial load and higher levels of macrophages and neutrophils. Interestingly, Brucella infection induced a dramatic reduction of NK cells along with the upregulation of CD94:NKG2A, one typical immune checkpoint module of NK cells. Further blockage of the NKG2A receptor in mice significantly reduced the bacterial load in the tissues, concurrent with a higher ratio of mature dendritic cells and a lower proportion of B cells.


CONCLUSIONS
scRNA-seq revealed that Brucella infection significantly alters the immune microenvironment in mice, providing insight into a better understanding of brucellosis pathogenesis and the immune evasion strategies of this sophisticated pathogen.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/30ce606edc594568f304e17b3f30c914a97c8658" target='_blank'>
              Single-cell transcriptome profiling reveals the immune dysregulation characteristics of mice infected by Brucella abortus.
              </a>
            </td>
          <td>
            Guangzhi Zhang, Qingchun Shen, Jianxin Ye, Yu Feng, Pascal Boireau, Xuezheng Fan, Lang Lv, Yan Li, Xiaofeng Xu, Heleer Cha, Chenguang Shen, Yinghui Zhang, Xiao-wei Peng, Hui Jiang, Jiabo Ding
          </td>
          <td>2025-10-11</td>
          <td>The Journal of infectious diseases</td>
          <td>1</td>
          <td>11</td>
        </tr>

        <tr id="Although chimeric antigen receptor (CAR)-T cells have demonstrated remarkable efficacy against hematologic malignancies, their effectiveness in solid tumors is limited by poor tumor infiltration and severe cytokine release syndrome (CRS). CAR-macrophage (CAR-M) therapy has emerged as a promising alternative, leveraging the innate tumor-homing capacity of macrophages while enabling antigen-specific phagocytosis and immune activation without triggering CRS. Prostate-specific membrane antigen (PSMA) represents an ideal therapeutic target due to its high expression in prostate cancer cells. In this study, we engineered PSMA-specific CAR-M with potent anti-tumor activity against prostate cancer cells both in vitro and in vivo. PSMA-specific CAR-M exhibited strong antigen-dependent phagocytic capability and underwent polarization toward a pro-inflammatory, tumoricidal phenotype upon PSMA recognition. Mechanistically, interaction with PSMA-expressing prostate cancer cells induced metabolic reprogramming, characterized by enhanced glycolytic activity and suppressed oxidative phosphorylation, which reinforced the anti-tumor function of CAR-M. Our findings highlight PSMA-targeted CAR-M therapy as a promising immunotherapeutic approach for prostate cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b18be8ba7a38c7fcc049e00187fed5999372458" target='_blank'>
              PSMA-targeted CAR-macrophages drive glycolytic reprogramming for enhanced prostate cancer immunotherapy
              </a>
            </td>
          <td>
            Yangli Xu, Duoli Xie, Chunhao Cao, Zhuqian Wang, Yue Ju, Lili Guan, Xuelong Li, Shanshan Wu, Luo Zhang, Chao Liang, Xiushan Yin
          </td>
          <td>2025-10-29</td>
          <td>Journal of Hematology & Oncology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="
 The tumor microenvironment of glioblastoma is dominated by immunosuppressive microglia/macrophages that dampen anti-tumor immunity, comprising a major barrier to effective immunotherapy. Developing strategies to reprogram these macrophages is essential to overcome treatment resistance. Bacterial extracellular vesicles (bEVs) are secreted nano-sized (~25–100 nm) particles that modulate myeloid cell activity in a species-dependent manner. We developed a scalable strategy to purify bEVs from the human commensal Escherichia coli Nissle strain consisting of: tangential-flow filtration, Benzonase depletion of free nucleic acids, and size-exclusion chromatography, yielding ~3.5 mg of bEV-associated protein per liter of culture. E. coli Nissle bEVs activated NF-κB and IRF pathways in THP-1 dual-reporter monocyte-derived cells in a dose-dependent manner, with an ED50 approximately seven-fold lower than that of purified LPS or heat-killed bacteria, indicating a distinctly higher potency. We further depleted free LPS that may co-isolate with bEVs, and noted a ~3000-fold reduction in LPS content, with less than 10% protein loss. LPS-depleted bEV bioactivity surpassed LPS amount-matched crude bEVs, supporting that bEV, not residual copurifying LPS, drove the observed in vitro bioactivity. bEVs activated peripheral-blood mononuclear cell-derived CD11b⁺CD68⁺ macrophage-like cells at concentrations as low as 1 ng/mL, while lymphocyte populations experienced minimal effects, in line with bEVs acting primarily on myeloid cells. We next treated M-CSF, IFNγ, and IL-4 polarized human monocyte-derived macrophages with bEVs. In IL-4 polarized (M2-like) macrophages, bEVs induced a more pronounced M1-like reprogramming compared to IFN-γ treatment, increasing CD38, CD80, and CD86 while decreasing CD47 and CD206. This reprogramming persisted even at sub-ED50 concentrations, as low as 0.6 ng/mL. Collectively, this workflow consistently yielded bioactive bEVs that robustly reprogram macrophages. Future work will test the ability of bEVs to reprogram GBM-associated microglia/macrophages, with the ultimate goal of combination with immunotherapies to overcome treatment resistance in the immunosuppressive GBM microenvironment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/314efedf3ab7696248eb4216de5020641b87b2b2" target='_blank'>
              IMMU-16. Development of high-purity bacterial extracellular vesicles for suppressive myeloid cell reprogramming in glioblastoma immunotherapy
              </a>
            </td>
          <td>
            Irem Karaman, Justin Ruiz, O. T. Pumar, Asmita Pathak, Jonathan Mitchell, B. León, Selma Maacha, Wael El-Rifai, Defne Bayik, Dionysios C. Watson
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="


 Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet resistance and immune-related adverse events (irAEs) remain significant challenges. γδ T cells and B cells are recognized as critical players in the tumor microenvironment (TME), but their roles in shaping T cell phenotypes and contributing to ICI resistance are not fully understood. Using syngeneic tumor models in autoimmune-prone NOD mice, which enable simultaneous profiling of tumor immunity and autoimmunity, we investigated mechanisms underlying ICI sensitivity and resistance. In the resistant tumor model, CD8+ T cells exhibit a naïve phenotype, with elevated TCF-1 expression and reduced activation markers such as PD-1 and CTLA-4. In contrast, activated CD8+ T cells dominate the sensitive tumor model, highlighting T cell phenotypes as key drivers of ICI responses. Further analyses implicated γδ T cells and B cells in these divergent responses. Depleting γδ T cells in the resistant model significantly improved tumor control, underscoring their role in mediating resistance. Conversely, CD8+ T cell activation was enhanced in B cell-deficient mice, suggesting B cells may restrict antitumor immunity. Together, these findings provide critical insights into the interplay between T cells, γδ T cells, and B cells within the TME and highlight potential therapeutic strategies to overcome ICI resistance without inducing irAEs.



 National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number: T32AI138945



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a88c64fd65f389029580f6961ad4a61916ee0e46" target='_blank'>
              The Interplay Between γδ T cells and B cells Contributes to Immune Checkpoint Inhibitor Resistance 3426
              </a>
            </td>
          <td>
            Camille Hansen, Arabella Young
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="


 Persistent antigen exposure, a hallmark of chronic infections and tumors, drives the formation of a distinct population of CD8+ T cells, known as exhausted CD8+ T (TEX) cells, with increased expression of immune checkpoint molecules and reduced effector function. Immune checkpoint inhibition (ICI) therapy has emerged as a powerful tool to reinvigorate the function of TEX cells. However, despite the immunostimulatory effects of radiotherapy (RT), combining RT with ICI has yielded modest clinical benefits in cancer patients. While the success of ICI therapy largely depends on the presence of progenitor TEX cells, the impact of high-dose ionizing radiation (IR) on the TEX population, particularly enriched within the treatment field, remains understudied. Here, we show that chronically infected mice with LCMV-Clone 13 subjected to sublethal whole-body irradiation (WBI) exhibited a lasting numerical decline and impaired antigen-specific function in their TEX cells. Using single-cell RNA sequencing and multiparameter flow cytometry, we observed that WBI gradually altered the subset composition of surviving TEX cells, highlighted by the loss of progenitor and effector-like TEX cells while terminally-exhausted TEX cells were enriched. Lastly, WBI rendered ICI therapy less effective in rescuing TEX cells and decreasing viral burden. These findings provide important insights into how high-dose IR alters the fate of TEX cells, potentially impairing their responsiveness to ICI therapy.



 Supported by NIH Grants GM134880, AI114543



 Lymphocyte Differentiation and Peripheral Maintenance (LYM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ef55b305a83cb203c9064f70e6ab8c59e03b2320" target='_blank'>
              Ionizing radiation impairs the efficacy of immune checkpoint inhibition by driving terminal exhaustion of progenitor exhausted CD8+ T cells 4054
              </a>
            </td>
          <td>
            Mohammad Heidarian, S. Kannan, Xin Zhao, M. Mix, , John T. Harty, V. Badovinac
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>54</td>
        </tr>

        <tr id="Decades of experimental work have helped define the heterogeneity of the various cell types that compose the immune system. The different cell types arise from distinct hematopoietic stem and progenitor cells in a coordinated fashion during ontogeny, providing a set of diverse cells that contribute to host defense. Cells can also differentiate into different subsets in response to the cytokine and tissue environment, creating a level of cellular heterogeneity that helps direct the nature and magnitude of the immune response. Here we are discussing a variation whereby cellular heterogeneity arises due to the expression of X‐linked immune genes that escape X chromosome inactivation, giving an advantage to a subset of cells more prone to respond to stimulation by external (pathogens) but also internal signals (i.e., mechanosensing). Interestingly, these inflammatory subsets are much more likely to be differentially enriched in patients with autoimmunity or inflammatory diseases which are well known to be predominant in females. We are using plasmacytoid dendritic cells (pDCs) as a model cell type, as these cells are a rare but critical subset of innate immune cells, with a rapid and massive capacity to produce type I IFNs (IFN‐I) upon sensing of nucleic acids from pathogens, but also from the self, and these cells have been linked to the pathogenesis of many autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/98b5143104584df960a1c460b9d9fe7799416cad" target='_blank'>
              Escape From X Chromosome Inactivation as a Driver of Plasmacytoid DC Heterogeneity in Health and Disease
              </a>
            </td>
          <td>
            Franck J. Barrat, J. Guéry
          </td>
          <td>2025-11-01</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="


 Pediatric high-grade gliomas (pHGG) are characterized by an immunologically cold and highly immunosuppressive tumor microenvironment (TME). It is dominated by M2-like tumor-associated macrophages (TAMs), which impair CAR T-cell function and persistence. However, broad myeloid targeting can be detrimental, as recent evidence shows that inflammatory macrophages are essential to support CAR T-cell activity. We therefore identified CD123 as selectively expressed on immunosuppressive TAMs, making it a promising target to remodel the TME. Meanwhile, B7-H3 is a tumor-associated antigen that is broadly expressed in pHGGs, making it an ideal target for CAR T-cell therapy. We now hypothesize that dual targeting of CD123+ TAMs and B7-H3+ tumor cells would synergistically deplete suppressive myeloid populations, restore T-cell function, and enhance anti-tumor efficacy.



 To evaluate the therapeutic potential of CD123 and B7-H3 dual CAR T-cell therapy in modulating the TME, preserving supportive myeloid subsets, and enhancing anti-tumor efficacy in pHGG.



 Using immunocompetent pHGG models, we tested CD123 and B7-H3 CAR T-cells through in vitro cytotoxicity, antigen stimulation, and co-cultures with bone marrow–derived M1 or M2 macrophages. In vivo, CD123 CAR T-cells were administered intratumorally as monotherapy or in combination with B7-H3 CAR T-cells. Endpoints included TAM depletion, phenotypic and transcriptomic TME remodeling, tumor progression, and survival.



 CD123 CAR T-cells exhibited minimal cytotoxicity against B7-H3+ glioma cells but selectively depleted M2-like TAMs in vitro and in vivo. M2 macrophages suppressed B7-H3 CAR T-cell persistence in vitro; this suppression was reversed by co-treatment with CD123 CAR T-cells. Dual CAR T-cell therapy significantly enhanced anti-tumor activity, reduced myeloid and microglial infiltration, and extended survival in vivo.



 Targeted depletion of CD123+ TAMs enhances B7-H3 CAR T-cell efficacy by mitigating immunosuppressive signaling while preserving beneficial myeloid support. This dual-targeting strategy offers a mechanistically guided approach to overcoming TME-driven resistance in DIPG and other pHGG.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/43e9945f878d4e3f16528ee181777513363175aa" target='_blank'>
              EXTH-114. Dual CD123 and B7-H3 CAR T Cells Potentiate Immune Responses and Remodel the Tumor Microenvironment in Pediatric Gliomas
              </a>
            </td>
          <td>
            Khatereh Khorsandi, Kaleem L Coleman, Paulina Velsquez, Dalia Haydar
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Natural killer (NK) cell function is impaired in patients with chronic hepatitis B (CHB) infection; however, the underlying mechanisms are not fully understood. Here, we collected the blood samples from healthy donors (HDs) and patients with CHB, and then analyzed the characteristics of NK cells by RNA-seq analysis, flow cytometry, Seahorse assay. HBV-carrier mice were used to confirm the findings in vivo. We found that the dysfunction of NK cells in peripheral blood of patients with CHB was associated with the disturbance of glycolysis. Further investigation showed chronic HBV infection impaired the activation of mammalian target of rapamycin (mTOR) in NK cells, resulting in decreased expression of molecules involved in glycolysis, including HIF-1α and GLUT1. Mechanistically, we found that HBsAg suppressed IL-15-triggered mTOR activity by competitively binding to the IL-15 receptor β (IL-15Rβ, CD122) on NK cells, leading to the decreased expression of HIF-1α and its downstream genes. Significantly, HBsAg neutralizing antibody intravenous injection or mTOR agonist MHY1485 intraperitoneal injection restored the IL-15/mTOR signaling in NK cells of HBV-carrier mice, resulting in NK cell activation and HBV clearance. Further, transferring MHY1485-pretreated NK cells isolated from HBV-carrier mice displayed augmented anti-HBV effects in recipient HBV-carrier mice. These findings reveal a new mechanism by which chronic HBV infection induces NK cell dysfunction, and highlight the potential of mTOR activation and HBsAg clearance as therapeutic strategies for CHB treatment via recovering NK cell immune functions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/db9d073c5d94a52821dfc4a44cc1e423ba2d752b" target='_blank'>
              Chronic HBV infection impairs the glucose metabolism and effector function of NK cells via HBsAg/IL-15/mTOR axis
              </a>
            </td>
          <td>
            Yating Yu, Zixuan Wang, Ailu Yang, Yucan Wang, Cuiping Bao, Li Zhuo, Qiuju Han, Huajun Zhao, Jian Zhang
          </td>
          <td>2025-10-13</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="


 CD8 T cells are a critical component of the immune response to infections as well as in prevention and restriction of cancer growth. Across multiple solid cancer types, tumor infiltration of CD8 T cells is associated with improved patient survival. CD8 T cell cytotoxicity and cytokine production have been characterized as the primary mechanisms by which these cells execute their immune function. However, basal cell motility, defined as random walk and exploratory spread, is an essential and underappreciated aspect of the CD8 T cell-mediated antitumor response. Cell motility enables effector CD8 T cells to search for and reach their cell targets within a solid tumor microenvironment. Here, we investigate the impact of IL-21 on effector CD8 T cell motility. We show that compared to effector CD8 T cells expanded in the presence of IL-2 alone, those expanded in IL-2 and IL-21 exhibit increased cell motility in vitro and in vivo. We also show that IL-21 enhances mitochondrial respiration and mitochondrial calcium in effector CD8 T cells. Our data suggests that increased mitochondrial calcium and mitochondrial ATP promote CD8 T cell motility through IL-21-mediated STAT3 activity. Therefore, IL-21 plays an important role in effector CD8 T cell mitochondrial fitness, cytoskeleton stiffness, and cell motility, which can be leveraged in the design of adoptive T cell therapies for the treatment of solid tumors.



 Supported by NIH R01 CA260909; T32AI007405.



 Cytokines and Chemokines and Their Receptors (CCR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c85e17d7c962d1daada79818491cc536bfb732e9" target='_blank'>
              Enhancement of effector CD8 T cell motility by IL-21 through STAT3 4131
              </a>
            </td>
          <td>
            Maureen Hoen Rauhut, Fahiima Abdullahi, Felipe Valença-Pereira, Mercedes Rincon
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 We are witnessing a significant increase in complex T cell-mediated immune disorders, such as food allergies and autoimmune disease. This trend suggests that the activation threshold for T cells may be altered, and understanding how to modulate this threshold has profound implications for disease treatment. In this study, we demonstrate that the effector program of CD8? T cells (including naïve, circulating memory, and tissue-resident cells) induced by TCR and cytokine stimulation is regulated by the class II histone deacetylase, HDAC5. HDAC5 exhibits little to no deacetylase activity against histone tails, but can function in the cytoplasm as a scaffolding protein or to directly deacetylate protein targets. Using small interfering RNA (siRNA) in cell lines of primary human CD8+ cytotoxic intraepithelial lymphocytes (IE-CTLs), we show that the loss of HDAC5 decreases their activation. Furthermore, inhibiting HDAC5 activity with the HDAC4/5 inhibitor LMK235 reduces the activation potential of ex vivo isolated human intestinal IE-CTLs following stimulation, suggesting that HDAC5 enzymatic activity is required for this effect. Finally, our data indicate that HDAC5 inhibition broadly impacts CD8? T cell activation, including in circulating memory and naïve subsets. This work identifies HDAC5 as a critical enzyme regulating the activation of CD8? T cells and highlights the potential of targeting HDAC5 to modulate CD8? T cell activation thresholds in inflammatory disorders.



 Supported by NIH BIBIB 2 T32 EB 9412; NSF Graduate Research Fellowship Program; University of Chicago Celiac Disease Research Center.



 Immune Response Regulation: Molecular Mechanisms (IRM)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c3f63a425ec70d967412fb047c150bfd3ab601d0" target='_blank'>
              HDAC5 regulates the activation of cytotoxic CD8+ T cells 4190
              </a>
            </td>
          <td>
            Megan Borregard, C. Ciszewski, Yandong Zhang, Hening Lin, B. Jabri
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>70</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3835e8cea6c320bb95706e08cb3361a64f4ee503" target='_blank'>
              Inhibition of SHP-1 /2 blocks antigen cross-presentation by human macrophages and dendritic cells
              </a>
            </td>
          <td>
            Alexine S. de Wit, Harry Warner, Huang Huang, M. Verdoes, Geert van den Bogaart, Frans Bianchi
          </td>
          <td>2025-10-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="
 Brain metastases (BM) from lung adenocarcinoma represent a formidable clinical challenge due to limited therapeutic efficacy. To gain insight into complex tumor microenvironment (TME) of BM, we analyzed single-cell RNA-sequencing data comprising 66,769 cells from primary tumors (PTs; 44,355 cells) and matched BM lesions (22,414 cells). Our analysis revealed a profound shift in cellular composition during metastasis: while T cells predominated PT (44.12%), tumor cells became the most abundant population in BM (55.17%), with corresponding reductions in T cells (27.57%) and macrophages (19.3%). Cell–cell communication analysis identified fibroblasts as central mediators in both PT and BM, with a transition from collagen signaling in PT to thrombospondin signaling in BM, facilitating interactions with tumor cells, B cells, and oligodendrocytes. Ingenuity Pathway Analysis revealed enrichment of collagen-related genes in fibroblasts (MFAP4, COL15A1, FBLN1, FBLN2) and Th1/Th2 pathway genes in T cells (IKZF1, SH2D1A, RASGRP1, SKAP1). Subclustering uncovered seven distinct fibroblasts subpopulations and a notable shift from PT-enriched C0 to BM-enriched C1, suggesting dynamic phenotypic adaptation. Pseudotime trajectory analysis further clarified fibroblasts differentiation states. T-cell subclustering revealed a significant increase in immunosuppressive regulatory T cells (84.1%) and proliferating CD4+ T cells (10.5%) in BM, highlighting mechanisms of immune evasion. COL15A1 expression correlated with poor patient survival and emerged as a promising therapeutic candidate, showing increased sensitivity to Dabrafenib, Trametinib, Piperlongumine, Cabozantinib, Staurosporine, and Vemurafenib. Additional gene drug associations were observed, with FBLN1, RASGRP1, MFAP4, SH2D1A, and IKZF1 linked to potential sensitivity to Erlotinib, Afatinib, Fluorouracil, and Brefeldin A. These findings provide a high-resolution map of the BM TME and highlight COL15A1 and related pathways as potential targets for precision therapy in patients with BM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fc3a5b204d80d9cd5d66d31480f9cf9dd3274795" target='_blank'>
              TMIC-44. Fibroblast reprogramming and immune evasion define the tumor niche in brain metastases
              </a>
            </td>
          <td>
            Sanskriti Dey, J. Chuang, Chih-Yang Wang
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) remains one of the most lethal primary brain tumors, characterized by profound immunosuppression and resistance to conventional immunotherapy. A hallmark of the GBM microenvironment is the prevalence of functionally exhausted T cells, marked by sustained expression of inhibitory receptors such as PD-1 and impaired effector function. These exhausted T cells represent a major barrier to durable anti-tumor immunity and effective immunotherapeutic intervention. To address this, we explored PD1-IL2v, an engineered immunocytokine designed to selectively stimulate PD-1⁺ cells with IL-2 signaling while minimizing activation of regulatory T cells. Using both the immunogenic GL261 and the immune checkpoint-resistant SB28 murine models of GBM, we administered PD1-IL2v either systemically or directly into the tumor. Flow cytometry was employed to assess changes in tumor-infiltrating lymphocytes, with particular focus on exhaustion and effector phenotypes. Notably, local administration of PD1-IL2v, but not systemic delivery, effectively reactivated CD8⁺ T cells within the tumor microenvironment. PD1-IL2v treated mice exhibited enhanced cytokine production, increased proliferation, and restoration of cytotoxic activity in T cells. Phenotypic profiling of tumor infiltrating lymphocytes (TILs) revealed an expansion of a stem-like subset of exhausted T cells (PD-1⁺TCF1⁺), alongside the emergence of a novel, differentiated population with superior effector functions, termed “better-effector” T cells. Therapeutic intervention with PD1-IL2v led to complete tumor rejection in a subset of animals, and increased infiltration of functional T cells into the tumor core. Our findings underscore T cell exhaustion as an untapped reservoir of tumor-reactive T cells that can be therapeutically reinvigorated using PD1-IL2v. This approach not only restores anti-tumor immunity but also induces superior effector populations capable of driving tumor regression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1d2a360e4ecb23a3988292b555a7155b5788a697" target='_blank'>
              IMMU-26. Reinvigorating exhausted T cells in glioblastoma via PD1-IL2v immunocytokine therapy
              </a>
            </td>
          <td>
            U. Salazar, B. Taskoparan, Sereina Deplazes, V. Nicolini, Laura Codarri-Deak, H. Okada, C. Klein, Johannes vom Berg
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Abstract Microglia, the immune cells of the central nervous system (CNS), quickly respond to neurodegeneration by proliferating and migrating to areas of disease, phagocytosing debris, and releasing cytokines to initiate inflammation. Critically, the mechanisms underlying these microglial functions remain only partly understood. One molecular regulator of interest is complement protein C1q, the initiator molecule of the complement cascade that increases 300-fold in healthy aging and accumulates with neurodegeneration. We have previously reported that exogenous C1q treatment alters inflammatory gene expression and cell function in human induced pluripotent stem cell-derived microglia (iMG). Here, we test the hypothesis that C1q induced cell changes are modulated by novel C1q receptor, CD44. We first used validated expression of five recently identified C1q receptors at the RNA and protein levels, and then we used proximity ligation assay to validate C1q-receptor binding on the iMG cell surface. CD44 was selected as an initial target and thus CD44 knockout iMG were generated to test whether the C1q response is dependent on CD44. While the C1q-induced inflammatory response was not dependent on CD44, we demonstrate that C1q-CD44 interactions regulate changes in microglial phagocytosis, proliferation, and migration. These data suggest C1q interacts with CD44 on iMG to modulate microglial functions that are critical to health and disease. This data informs future work which will test how C1q-CD44 interactions are altered in neurodegenerative disease and if these interactions could be modulated as a therapeutic target.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8b289d13959c42994aa13fbceb63e5c128433ea8" target='_blank'>
              C1q-CD44 interactions regulate microglial phagocytosis, proliferation, and migration
              </a>
            </td>
          <td>
            Pooja S Sakthivel, Alyssa Villegas, Anita Lakatos, Meghana Kaipa, Julian M. Lopez, Ashley Ling, Zeina H. Elrachid, Josh Karam, Aileen J. Anderson
          </td>
          <td>2025-10-23</td>
          <td>Research Square</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Chronic liver diseases (CLDs), encompassing a spectrum of etiologies including metabolic dysfunction, alcohol abuse, and viral infections, represent a significant global health burden. The progression of these diseases to fibrosis, cirrhosis, and hepatocellular carcinoma is underpinned by complex immunological mechanisms in which liver-resident macrophages (LRMs) are central players. LRMs are not a monolithic population but a heterogeneous consortium of cells, primarily comprising embryonically-derived, self-renewing Kupffer cells and dynamically recruited monocyte-derived macrophages. These subsets, along with newly identified populations like lipid-associated macrophages and scar-associated macrophages, exhibit distinct origins, phenotypes, and functions that profoundly influence the trajectory of liver injury and repair. A new generation of immunomodulatory therapies is being developed to specifically target the pathways that govern LRM function. However, clinical responses to these agents have been variable, a phenomenon largely attributable to their differential effects on the diverse LRM subsets and the profound heterogeneity of the patient population. This review elucidates the complex heterogeneity of LRMs in the context of different CLDs. We dissect the mechanisms by which emerging immunomodulatory therapies—including PPAR agonists, chemokine receptor antagonists, and intracellular signaling inhibitors—alter the balance, phenotype, and functional output of distinct LRM populations. By integrating findings from preclinical models with outcomes from recent clinical trials, we illustrate how the specific modulation of LRM subsets correlates with therapeutic efficacy or failure. Furthermore, we discuss the critical role of LRMs in the progression to hepatocellular carcinoma and the implications for immune checkpoint inhibitor therapies. Finally, we outline the key challenges in translating these findings into clinical practice and highlight future research priorities, emphasizing the need for single-cell technologies, investigation of the gut-liver axis, and development of combination therapies. A deeper understanding of LRM biology is paramount to advancing a precision medicine approach, ultimately paving the way for more effective and personalized treatments for patients with CLD.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ed65ec692e297444f6ff1e7147beb4319d35a2a7" target='_blank'>
              Decoding the heterogeneity of liver-resident macrophages in chronic liver diseases: therapeutic responses to immunomodulatory strategies
              </a>
            </td>
          <td>
            Renbin Ouyang, Xiaocheng Li, Jianhua Hao, Jie Lin, Hui Lan, Jing Peng, Xinmin Li, Zhiliang Tian, Yu Sun
          </td>
          <td>2025-11-10</td>
          <td>Frontiers in Pharmacology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="


 Despite significant advancements in targeted therapies and immunotherapies, a substantial proportion of non-small cell lung cancer (NSCLC) patients remain unresponsive to treatment. One contributing factor is tumor-induced immunosuppression, which impairs effective T cell responses. Natural killer (NK) cells, while playing a pivotal role in antitumor immunity, have been shown to negatively regulate adaptive immune responses in various contexts. In this study, we characterized the phenotype of NK cells within the NSCLC microenvironment and investigated their potential contribution to immune suppression. CD3- CD56+ NK cells were isolated from tumor resection specimens and profiled using single-cell RNA sequencing and CITE-seq. Identified NK cell clusters were subsequently quantified in tumor-infiltrating lymphocyte (TIL) cultures exhibiting different expansion rates. Our analyses identified a tumor-specific NK cell subset associated with reduced recurrence-free survival (RFS). This subset was preferentially enriched in TIL cultures with low expansion rates compared to those with high expansion rates, suggesting a potential role in limiting T cell proliferation. Future investigations will focus on confirming the regulatory role of this NK cell subset and elucidating the mechanisms underlying its suppressive function.



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/96876b361473daba1aa036fd63568ae3002f5c55" target='_blank'>
              Immunoregulatory NK cells in non small cell lung cancer (NSCLC) 3221
              </a>
            </td>
          <td>
            Jules Sotty, D. Chung, Nicolas Jacquelot, Jehan Vakharia, Azin Sayad, Ben X Wang, P. Ohashi
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="


 Post-Acute Sequelae of COVID-19 (PASC) are rapidly evolving into a major public health concern. However, the link between acute infection and chronic disease remains unclear. With insights from 3 PASC patient cohorts, we established a clinically relevant mouse model and identified an aberrant immune-epithelial progenitor niche unique to the fibroproliferation in respiratory PASC. Using spatial transcriptomics and imaging, we found that lung-resident CD8+ T-cell (TRM)-derived IFN-γ and TNF stimulated local macrophages to chronically release IL-1β, promoting the accumulation of dysplastic epithelial progenitors to drive fibrosis. Neutralization of IFN-γ and TNF, or IL-1β activity improved alveolar regeneration and pulmonary function, presenting a therapeutic strategy to rescue post-viral disease in the aftermath of infection. We believe that the accumulation of CD8+ TRMs occurs due to an evolutionary need of the epithelium to maintain memory of injury and ensure rapid protection at these vulnerable sites in case of subsequent viral exposures. Dysregulation of this immune-epithelial crosstalk however, results in pathological remodelling of the lungs as observed in PASC. Thus, we are exploring the role of epithelium and the molecular basis of this crosstalk to identify key mediators to ultimately uncouple the protective and pathological functions of CD8+ TRMs post-infection to promote functional lung recovery without compromising immunity to future infections.



 Harish Narasimhan: F31HL170746 and T32AI007496 Jie Sun: AI147394, AG069264, AI112844, HL170961, AI176171 and AI154598



 Viral Immunology (VIR)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/543188223d45038e3c98aeb834d328a6cf25d7e3" target='_blank'>
              An aberrant immune-epithelial progenitor niche drives post-viral sequelae 3466
              </a>
            </td>
          <td>
            H. Narasimhan, Jie Sun
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="


 Immune checkpoint inhibition (ICI) has dramatically advanced cancer treatment but is associated with adverse outcomes including ICI-induced myocarditis. Recent work demonstrated that T cells restricted to cardiac antigens are indispensable, yet how these cells provoke fatal cardiac damage remains poorly defined. To interrogate the mechanisms underlying myocarditis, we derived a transgenic mouse line with cardiomyocyte-restricted ovalbumin expression. Transfer of naïve OTI T cells into transgenic recipients did not induce pathology, but the addition of ICI led to myocarditis. Critically, PD-1 blockade alone proved sufficient. Our findings suggest that PD-1 blockade facilitates de novo CD8 T cell priming, independent of conventional microbial stimuli. Current work aims to determine if ICI obviates the need for classical 2nd and 3rd priming signals. Additionally, we characterized diseased hearts following CD8 T cell priming and subsequent cardiac infiltration. T cells constitute half of the infiltrating immune cells, while inflammatory monocytes/macrophages and DCs dominate the non-lymphocyte population. Elevations in innate cytokines IL-1β and IL-6 were also identified. We then targeted T cell-mediated innate inflammation to ameliorate disease. Thus, these studies use a novel mouse model to 1) underscore the role for CD8 T cells, 2) reveal a noncanonical activation pathway of CD8 T cells during PD-1 blockade, and 3) posit a role for innate inflammation as a driver of pathology.



 Supported by AHA predoctoral fellowship (24PRE1198808); NIH/NIAID AI123176; NIH/NHLBI HL156852



 Basic Autoimmunity (BA)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a3a81d81333df1541d1c40b6e6fdc183b42d1e5e" target='_blank'>
              Immune checkpoint blockade induces de novo CD8 T cell priming and innate inflammation leading to myocarditis 3714
              </a>
            </td>
          <td>
            Kathrynne A. Warrick, Jeffery D. Molkentin, C. Pasare
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="Background/Objectives: In children developing B-cell acute lymphoblastic leukemia (B-ALL), an immune evasion event takes place where otherwise “silent” preleukemic cells undergo a malignant transformation while escaping immune control, often through unknown mechanisms. Methods and Results: Here, we identify the upregulation of PD-1 expression in preleukemic cells, triggered by Pax5 inactivation in mice and correlating with the time of conversion to leukemia, as a novel marker that favors leukemia evasion. This increase in PD-1 expression is apparent across diverse molecular B-ALL subtypes, both in mice and humans. PD-1 is not required for B-cell leukemogenesis, but, in the absence of PD-1, tumor cells express NK cell inhibitory receptors, highlighting the necessity for leukemic cells to evade the host’s NK immune response in order to exit the bone marrow. PD-1 expression reduces natural antitumor immune responses, but it sensitizes leukemic cells to immune checkpoint blockade strategies in mice and humans. PD-1 targeting confers clinical benefits by restoring NK-mediated tumor cell killing in vitro and eliminating tumor cells in vivo in mice engrafted with B-ALL. Conclusions: These results identify PD-1 as a new therapeutic target against leukemic progression, providing new opportunities for the treatment and possibly also the prevention of childhood B-ALL.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1b41b3b2aebacf7f7340a2020174ac633c1537ec" target='_blank'>
              PD-1 Expression Promotes Immune Evasion in B-ALL
              </a>
            </td>
          <td>
            Ana Casado-García, Gonzalo García-Aguilera, Julio Pozo, Ninad Oak, S. Barrena, Belén Ruiz-Corzo, Jaanam Lalchandani, Ana Chamorro-Vera, Ana Castillo-Robleda, Beatriz Soriano, Silvia Alemán-Arteaga, Elena G. Sánchez, Jorge Martínez-Cano, Andrea López-Álvarez de Neyra, Paula Somoza-Cotillas, Oscar Blanco, Susana Riesco, Pablo Prieto-Matos, Francisco Javier García Criado, M. B. García Cenador, C. Cobaleda, Carolina Vicente-Dueñas, Kim E. Nichols, Alberto Orfao, Manuel Ramírez-Orellana, I. Sánchez-García
          </td>
          <td>2025-11-12</td>
          <td>Hematology Reports</td>
          <td>0</td>
          <td>47</td>
        </tr>

        <tr id="Cluster of differentiation 47 (CD47), an immune checkpoint commonly referred to as the “don’t eat me” signal, plays a pivotal role in tumor immune evasion by inhibiting phagocytosis through interaction with signal regulatory protein alpha (SIRPα) on macrophages and dendritic cells (DCs). Although early enthusiasm drove broad clinical development, recent discontinuations of major CD47-targeted programs have prompted re-evaluation of its therapeutic potential. The purpose of this commentary is to contextualize the setbacks observed with first-generation CD47 inhibitors and to highlight strategies aimed at overcoming their limitations. Clinical challenges, including anemia, thrombocytopenia, suboptimal pharmacokinetics, and limited single-agent efficacy, underscore the need to develop safer, more selective approaches. Emerging next-generation strategies, such as SIRPα-directed agents, bispecific antibodies, and conditionally active therapeutics, are designed to enhance safety and tumor selectivity and reduce systemic toxicity. In addition, spatial profiling and biomarker-driven patient selection are advancing toward guiding rational therapeutic combinations, including with “eat-me” signals (e.g., calreticulin [CALR]) or DNA damage response therapies (e.g., poly(ADP-ribose) polymerase [PARP] inhibitors). Rather than signaling failure, these developments underscore the need for precision, context-specific applications, and adaptive trial designs to realize the durable therapeutic promise of CD47 blockade in cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6db3989cf98c5088a39820847a95a9d8b5760515" target='_blank'>
              CD47-Targeted Therapy in Cancer Immunotherapy: At a Crossroads of Promise and Challenge
              </a>
            </td>
          <td>
            Xuejun Guo, Yilin Fu, Natalia Baran, Wenxue Ma
          </td>
          <td>2025-10-22</td>
          <td>Oncology Research</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="STAT3 is pivotal for governing myeloid responses to inflammatory stimuli to prevent hyperinflammation in vivo, yet whether STAT3 mediates pathogen control and clearance by myeloid cells remains unclear. In this study, we identified significant enrichment of IFN-stimulated transcriptional pathways in Stat3-deficient bone marrow-derived macrophages (BMDMs) at steady state. This was accompanied by activation of autocrine type I IFN (IFN-I) and aberrant autocrine IL-6 signaling associated with increased STAT1 activity. Despite exaggerated baseline IFN-STAT1 signaling, Stat3-deficient BMDMs were significantly impaired in their ability to induce expression of key pathogen defense genes and specific immune mediators upon LPS stimulation. STAT3 was also required in Citrobacter rodentium-infected BMDMs for expression of pathogen defense genes and effective bacterial killing. Moreover, bone marrow chimeric mice with 20% Stat3-deficient hematopoietic cells were more susceptible to infection with C. rodentium and showed increased bacterial dissemination and reduced production of specific cytokines. IL-6 blockade subdued the intrinsic IFN response and rescued expression of select pathogen defense genes in Stat3-deficient BMDMs upon LPS stimulation yet was unable to restore bacterial killing activity. Taken together, our results identify novel functions for STAT3 in orchestrating an optimal microbial defense response and suggest this is regulated by discrete mechanisms including modulation of autocrine IL-6 signaling in macrophages.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f2fb8ade12d78988b7357e5a9ba0e554b3150002" target='_blank'>
              STAT3 mediates an inflammation-induced microbial defense response and regulates pathogen control and clearance by macrophages.
              </a>
            </td>
          <td>
            B. Patel, Xiaofeng Zheng, Laura M. Kahn, Sarah M. Schneider, Josué E. Pineda, Morgan N. Riba, Khaoula Ouchen, Sara Meril, Ariel P Nash, Jing Wang, S. Watowich
          </td>
          <td>2025-11-11</td>
          <td>Journal of immunology</td>
          <td>0</td>
          <td>57</td>
        </tr>

        <tr id="Effector T cells are central to immune defense against Mycobacterium tuberculosis (Mtb), exerting complex and multifaceted roles that contribute to both protection and immunopathology. CD4+ T cells activate macrophages, maintain granulomas, and coordinate broad immune functions through diverse subsets, including cytokine-producing, cytotoxic, and regulatory cells. CD8+ T cells target infected cells through cytolytic activity and cytokine secretion, while unconventional T cells provide rapid, innate-like responses, particularly at mucosal sites. Recent advances in single-cell and spatial transcriptomics have revealed heterogeneity, functional plasticity, and spatial compartmentalization among T-cell subsets. Tissue-resident memory T cells in the lung parenchyma have emerged as key predictors of protective immunity. These insights are reshaping our understanding of T-cell-mediated control of Mtb and highlight the limitations of interferon (IFN)-γ-centric vaccine strategies. Future strategies must aim to elicit a broader range of T-cell responses, promote effective tissue localization, enhance polyfunctionality, and overcome regulatory or exhaustion-associated dysfunctions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bc0156b9542ecfa4c556d034e4b45afc8d02e45d" target='_blank'>
              Effector Functions of Conventional and Unconventional Mycobacterium tuberculosis (Mtb)-Specific T Cells.
              </a>
            </td>
          <td>
            S. Panda, Kendall Kearns, C. L. Lindestam Arlehamn
          </td>
          <td>2025-11-03</td>
          <td>Cold Spring Harbor perspectives in medicine</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="
 Glioblastoma (GBM) remains a paradigm of immunotherapy resistance, characterized by minimal effector T cell infiltration and failure to respond to immune checkpoint blockade (ICB) therapies such as anti-PD-1. In contrast, autoimmune states such as experimental autoimmune encephalomyelitis (EAE)—a murine model of multiple sclerosis—elicit robust, antigen-specific T cell responses within the central nervous system. We hypothesized that proinflammatory mechanisms sustaining autoimmunity in EAE could be co-opted to overcome immune tolerance in GBM. Single-cell RNA sequencing was used to profile T cell phenotypes from EAE and syngeneic GBM (CT-2A) models. EAE was induced in tumor-bearing mice, and tumor-specific EAE variants were generated using tumor cell lysate immunization. Cytokine expression was profiled via Luminex and white matter changes were visualized with diffusion tensor imaging and T2 mapping. Functional studies included adoptive transfer of CD3+ T cells or regulatory T cells, and hydrogel-based delivery of IL-6, IL-23, and anti-TGF-β to tumor-draining lymph nodes (TDLNs). T cell bioenergetics were assessed via Seahorse metabolic profiling and flow cytometry. EAE induction in GBM-bearing mice significantly improved survival and increased intratumoral Th1 and Th17 T cell infiltration. Tumor lysate immunization reproduced these effects and sensitized tumors to anti-PD-1 therapy. IL-6, IL-23, and IL-1β were identified as shared inflammatory mediators in both EAE and tumor-immunized states. Targeted lymphoid conditioning via hydrogels loaded with recombinant IL-6, IL-23, and anti-TGF-β reprogrammed TDLNs, enhanced T cell activation and oxidative phosphorylation, and extended survival (P<0.0001). Therefore, autoimmune inflammatory circuits can be repurposed to recondition the immunosuppressive GBM TME. Lymphoid niche modulation using a combination of IL-6, IL-23, and TGF-β blockade offers a novel strategy to sensitize GBM to currently available immunotherapeutic strategies such as anti-PD-1.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ec557fff3154e9f6980a04bed886b991ce663c85" target='_blank'>
              IMMU-13. Leveraging the immune milieu of experimental autoimmune encephalomyelitis to perpetuate an anti-tumor T cell response in glioblastoma
              </a>
            </td>
          <td>
            John Choi, Lily H Kim, John Klich, Andrew Tran, Peggy Ho, Rohit Verma, Kwang Bog Cho, Si Yeon Lee, Gordon Li, Lawrence Steinman, Michael Lim
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 Glioblastoma (GBM), the most common and malignant primary brain tumor, exhibits profound immune suppression, hindering immunotherapy efficacy. GBM-derived extracellular vesicles (EVs) play a major role through the immunosuppressive polarization of myeloid cells. Inhibition of EV-myeloid cell interactions thus represents a novel target to mitigate GBM-mediated immune suppression. However, there are multiple mechanisms of EV-target interaction, and downstream pathways of GBM-EV signaling are poorly understood. We explored two pharmacological agents targeting different mechanisms of EV uptake: Methyl-B-cyclodextrin (MBCD), which disrupts lipid rafts, and cytochalasin D, which inhibits actin polymerization. Our results showed immunosuppressive myeloid cell (CD11b+/ CD15-/ HLA-DRlow/ CD14high) populations increased upon GBM-EV treatment. Following cytochalasin D treatment, fewer immunosuppressive myeloid cells were observed (7.40%±1.01 vs. untreated 9.66%±2.86), with rescuing T cell proliferation. Conversely, MBCD treatment increased immunosuppressive myeloid cell levels (10.42%±2.38 vs. untreated 8.87%±3.97) without impacting T cell proliferation. This study demonstrates the feasibility of pharmacologically targeting EV-myeloid cell interactions to rescue tumor mediated immune suppression by inhibiting actin-dependent endocytosis with cytochalasin D. The converse results using MBCD treatment indicate differential importance of different EV uptake pathways in monocyte regulation.



 Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c83aad2ce4bc7312164a625b88f12016523ef26e" target='_blank'>
              Selective Targeting of EV Uptake Pathways in Glioblastoma to Combat Tumor-Induced Immune Suppression 4324
              </a>
            </td>
          <td>
            Minori Aoki, Mohammad Asad, Julio Inocencio, Stefan Mitrasinovic, C. Crisman, Ian Parney, Patrick Lasala, Vijay Agarwal, Emad Eskandar, B. Himes
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Dendritic cells (DCs) demonstrate remarkable functional and metabolic heterogeneity that governs the balance between immune tolerance and autoimmune pathogenesis. Under homeostatic conditions, tolerogenic DC subsets maintain immunological equilibrium through distinct metabolic programs and the production of immunoregulatory metabolites, promoting T cell anergy and regulatory T cell (Treg) differentiation. In contrast, autoimmune conditions trigger pathogenic metabolic rewiring, shifting DCs toward glycolysis and enhanced lipid synthesis, which drives DC hyperactivation and breakdown of self‐tolerance. This metabolic reprogramming is coordinately regulated by external microenvironmental cues and internal signaling pathways, leading to heterogeneous DC responses in diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and psoriasis. Targeting metabolic regulators offers promising therapeutic strategies to restore immune tolerance and prevent harmful autoimmunity and inflammation. The review highlights the intricate interplay between DC metabolism and function, emphasizing how metabolic heterogeneity underpins their dual roles in immune regulation and autoimmunity. Future exploration of subset‐specific metabolic preferences and spatiotemporal metabolic dynamics will facilitate the development of precision immunotherapies for autoimmune diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a97f07a5b7ac318a1833bd58333831f7827e042e" target='_blank'>
              Functional and Metabolic Heterogeneity of Dendritic Cells in Self‐Tolerance and Autoimmunity
              </a>
            </td>
          <td>
            Jianru Chen, Juan Liu, Xuetao Cao
          </td>
          <td>2025-11-01</td>
          <td>Immunological Reviews</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Chimeric antigen receptor (CAR)-T cell therapy, despite revolutionizing hematologic malignancies, remains limited in solid tumors due to immunosuppressive microenvironments and systemic toxicities from combination immunotherapies. Recent engineering innovations demonstrate that physically linking anti-PD-L1 antibodies to interleukin-12 within CAR-T cells creates tumor-localized immunomodulation, concentrating therapeutic activity at PD-L1-positive sites while minimizing systemic exposure. In preclinical models, PD-L1-binding IL-12 fusion proteins achieved superior antitumor responses (100% vs. 50% complete responses) compared to non-binding controls, with significantly reduced inflammatory toxicity. Spatial proteomic analysis revealed comprehensive tumor microenvironment remodeling including enhanced CD8 + T cell infiltration and reduced immunosuppressive myeloid populations. Validation in human CAR-T cells targeting TAG72-positive ovarian cancer confirmed appropriate PD-L1 binding and enhanced cytotoxicity. This rational engineering strategy addresses multiple barriers simultaneously through molecular sequestration, offering a promising platform applicable to alternative checkpoint-cytokine combinations and other cellular therapeutics. Clinical translation represents a critical next step for extending CAR-T efficacy to solid malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f7a6546fc7d661b815d3d60a952bbd89932e2713" target='_blank'>
              Tumor-localized immunomodulation: a critical advance in engineering CAR-t cells for solid malignancies
              </a>
            </td>
          <td>
            Maryam Abid, Ursula Abu Nahla, Muhammad Nabeel Saddique
          </td>
          <td>2025-11-04</td>
          <td>Annals of Medicine &amp; Surgery</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="
 The immunosuppressive tumor microenvironment is a major challenge in GBM. We are developing oncolytic Zika virus (ZIKV) as a treatment that targets treatment-resistant glioma stem cells and ignites CD8+ T-cell dependent anti-tumor immune response. We previously demonstrated that ZIKV infection significantly improves survival in multiple mouse models of GBM (Nair et al, JCI insight, 2021). However, myeloid driven immunosuppression remains a critical barrier. While Siglec-15 has recently been described as a myeloid immune checkpoint in other cancers (Wang et al, Nat Med, 2019), it is relatively unexplored in GBM. An antibody against Siglec-15 is in a phase II clinical trial for metastatic solid tumors (NCT04699123), but not tumors of the central nervous system. In human GBM specimens, we observed that Siglec-15 is highly expressed on myeloid (16-23%) and tumor cells (18-19%). Here, we use therapeutic and genetic approaches to target Siglec-15, as well as immunotherapy-resistant mouse models of GBM. In CT2A-bearing mice, long-term survival (90 days) increased from 40% (only ZIKV) to 60% (anti-Siglec-15+ZIKV). Adding antibody against PD-1 further improves the long-term survival (83%). In the immunotherapy-resistant SB28 model, triple therapy (anti-Siglec-15+ZIKV+anti-PD-1) led to 76% long-term survivors and greater CD8+ T-cell activation (1.7-fold). Upon re-challenge of cured mice, we detected an increase in CD8+ brain resident memory T-cells (11-fold) and CD8+ effector memory T-cells (11-fold), and 80% of mice survived. These findings with antibody against Siglec-15 were further confirmed using Siglec-15 knockout mice. Mechanistically, using bone marrow derived myeloid cells and T-cell proliferation assays, we determined that depletion of Siglec-15 improves phagocytosis of tumor cells (CT2A; 25.2% and SB28; 6.9%) and significantly improves T-cell activation (81%) and T-cell proliferation (86.8%), and these findings may explain why we observed improved outcomes. These results suggest the potential of this triple therapy in overcoming the problem of the immunosuppressive tumor microenvironment in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a95001b5599103be9128f5ed56fc151095bff75" target='_blank'>
              TMIC-21. Dual blockade of Siglec-15 and PD-1, combined with oncolytic Zika virus therapy, confers protection against immune-resistant gliomas
              </a>
            </td>
          <td>
            Ashwani Kesarwani, Sonam Verma, Amber Neil Griffith, Tong Hu, Fei Shu, Amanda Andrade de Costa, Y. Li, Mridu Kanga, Brett H Herzog, D. DeNardo, Mai Dang, Jingqin Luo, Pei-Yong Shi, Xuping Xie, Jun Wang, Lieping Chen, Albert Kim, Peggy L. Kendall, Michael S Diamond, Milan G Chheda
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>70</td>
        </tr>

        <tr id="STACT is a modular, genetically engineered live attenuated S. Typhimurium bacterial platform that enables tissue-specific localization and cell-targeted delivery of large, multiplexed payloads via systemic administration. It has been engineered to minimize systemic toxicity and to enrich in the tumor microenvironment (TME) via metabolic dependency and showed a decreased systemic inflammatory cytokine profile compared to its parent strain VNP20009. ACTM-838 utilizes the STACT platform to deliver IL-15/IL15Rα and a constitutively active STING to tumor-resident phagocytic antigen-presenting cells. Upon intravenous (IV) dosing to tumor-bearing mice, ACTM-838 distributed and enriched in the TME, exhibited specific uptake in tumor-resident phagocytic cells and led to expression of human IL-15/IL15Rα and murine IFNα in the tumor. ACTM-838 induced comprehensive TME changes to an immune permissive anti-tumor phenotype with a decrease in exhausted T-cells and Tregs and an increase in cytolytic T-cells and MHCII-high proliferating myeloid cells. ACTM-838-treated tumors exhibited upregulated anti-tumor innate and adaptive immunity expression profiles, T-, NK- and B-cell infiltration and downregulated cell cycle, DNA damage and TGFβ responses. Single-cell RNAseq and flow cytometry data confirmed activation and infiltration of both innate and adaptive immune cells. ACTM-838 showed durable anti-tumor efficacy in multiple murine tumor models and synergized with anti-PD1 therapy in combination.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fdc45e3f7f02c73e89e5ca3fbdf0ef5ae7e3ad3f" target='_blank'>
              ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response.
              </a>
            </td>
          <td>
            Kyle Cron, Ping Fang, Oanh Pham, Julie Janes, J. Brandenburg, William Lu, Jonathan Zhu, Bret Peterson, Sara Tribble, Haixing Kehoe, Anastasia Makarova, Alex Iannello, Jean Chan, J. Skoble, Hailey He, Chris Rae, Christopher Thanos, A. Udyavar
          </td>
          <td>2025-10-06</td>
          <td>Oncotarget</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Resident memory CD8+ T cells (Trms) are essential for protecting barrier nonlymphoid tissues (NLTs) against reinfection, yet the involvement of dendritic cells (DCs) in this process and the nature of Trm-DC interactions within these tissues remain poorly understood. Our study demonstrates that upon reactivation, memory CD8+ T cells located in the skin-independently of circulating memory counterparts-initiate the infiltration and maturation of plasmacytoid DCs (pDCs) in the tissue. This, in turn, promotes the maturation of conventional type 1 DCs (cDC1s) through type I IFN (IFN-I) signaling in a pDC-dependent manner. Depletion of pDCs or blocking IFN-I signaling disrupts this axis, severely impairing Trm-driven protection against secondary infections with vaccinia virus (VACV) in the skin. Notably, this pDC-dependent, IFN-I-mediated pathway is also essential for Trm-mediated protection against secondary respiratory infections with influenza A virus (IAV). Our findings uncover a crucial collaboration between Trm, pDCs, and cDC1s, offering new insights for enhancing vaccines.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fe1fd70d582b73456d2a4754cfa0b98111080ee7" target='_blank'>
              pDCs amplify tissue-resident memory CD8+ T cell responses during viral reinfection.
              </a>
            </td>
          <td>
            Elena Hernández-García, Miguel Galán, Sofía C Khouili, Elena Moya-Ruiz, Ana Redondo-Urzainqui, F. J. Cueto, Saraí Martínez-Cano, Manuel Rodrigo-Tapias, E. Tomasello, Santos Mañes, Marc Dalod, D. Sancho, S. Iborra
          </td>
          <td>2025-11-25</td>
          <td>The Journal of experimental medicine</td>
          <td>0</td>
          <td>41</td>
        </tr>

        <tr id="


 Lupus is a complex autoimmune disease that involves dysregulation of the B cell compartment. Potential mechanisms for this dysregulation include abnormalities in immune dampening pathways, such as the programmed cell death 1 receptor (PD-1). Though PD-1 functions as a negative regulator in T cells, its role in B cells is not clear. We used comprehensive flow and mass cytometry to examine the expression of PD-1 on peripheral blood B cells from lupus and healthy controls in two large patient cohorts. PD-1 was increased on antigen experienced B cells including double negative, memory, and CD11c+ age-associated B cells. Heterogeneity in patient PD-1+ B cells was uncovered, including an enriched PD-1+CD11c+CXCR3+ B cell subset which we speculate may be pathogenic due to their potential to migrate to sites of inflammation, and a diminished PD-1+PD-L1+ B cell subset which we expect is an immunosuppressive phenotype. PD-1 expression was higher in patients with elevated anti-dsDNA, high disease activity and increased with in vitro stimulation (anti-BCR and TLR9). Surprisingly, PD-1+ B cells proliferated more than PD-1- B cells, and PD-1 blockade with an anti-PD-1 antibody further increased proliferation. Our results suggest that PD-1 function in B cells is different than its inhibitory signaling role in T cells. Further, the expansion of PD-1 expressing B cells in lupus, especially in patients with high disease activity, highlights a new potential pathogenic B cell population.



 Supported by T32ES007026; Public Health Sciences Pilot Award; NIH Accelerating Medicines Partnership (RA/SLE Network)



 Basic Autoimmunity (BA)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5935df81b4ecf4492f3d3f23ff65634bbec5dc4d" target='_blank'>
              PD-1 expressing B cells are expanded in lupus 4452
              </a>
            </td>
          <td>
            Melanie Perkins, Nida Meednu, Daria Krenitsky, Alice Horisberger, A. Griffith, Joshua Keegan, Fan Zhang, James A. Lederer, , Lisa A. DeLouise, J. Anolik
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="
 Despite groundbreaking advances in Oncology over the past decade including the advent of immunotherapy, Glioblastoma (GBM), is still a therapeutic challenge with poor patient outcomes and an urgent need for effective therapies. SLIT2 is a secreted polypeptide that guides migration of cells expressing ROBO1&2 receptors and is key for axonal guidance and angiogenesis. In primary brain tumors, SLIT2 expression increases with malignant progression with highest levels observed in Grade IV GBM patients when compared to Low Grade Gliomas, where it also correlates with poor prognosis. Mechanistically, SLIT2-ROBO1/2 signaling promotes the recruitment and polarization of tumor-associated microglia/macrophages (TAMs) to the tumor microenvironment (TME) via PI3Kgamma, leading to dysmorphic angiogenesis, T cell exclusion and immunosuppression. Despite key functions in the TME, targeting SLIT2 in Oncology has been limited by the lack of validated blocking reagents with proper penetration and signaling inhibition potential. We have developed high-affinity human monoclonal antibodies recognizing both human and murine ROBO1&2 (Anti-Robo1/2 mAbs) which are capable of inhibiting microglia and macrophage migration and polarization in vitro. Treatment of immunocompetent preclinical GBM models with Anti-Robo1/2 mAbs leads to reduced TAM infiltration and tumor-supportive polarization, with profound changes in the GBM microenvironment. We observed vascular normalization, reduced hypoxia and increased infiltration and anti-tumor effective function of CD8+ T cells. Furthermore, inhibiting SLIT2-ROBO1/2 signaling also acted in the meningeal compartment, normalizing the meningeal lymphatic vasculature of GBM-bearing mice, improving antigen and immune cell drainage to deep cervical lymph nodes and improving anti-tumor immune responses. By modifying the tumor immune micro- and macroenvironment, Anti-Robo1/2 mAbs prolong tumor bearing-mice survival and renders immunotherapy-resistant tumors sensitive to checkpoint inhibition therapy. Altogether, our data suggest that Anti-Robo1/2 mAbs are a potential novel immunotherapeutic agent for GBM by simultaneously targeting TAMs and meningeal lymphatics, allowing for improved efficacy of currently available T cell-based immunotherapies in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/24418a1c70ccbfe4767c318dc6a36b731f7649c6" target='_blank'>
              TMIC-41. Anti-Robo1/2 monoclonal antibodies as a novel macrophage-based immunotherapy for glioblastoma
              </a>
            </td>
          <td>
            Luiz Henrique Medeiros Geraldo, Maria Luiza Lopes de Oliveira, Levi Blazer, E. Sulman, Jose Ricardo McFaline Figueroa, Sachdev Sidhu, Amanda Lund
          </td>
          <td>2025-11-01</td>
          <td>Neuro-Oncology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="


 Inducing robust mucosal memory T cells in the lung is critical for developing vaccines against respiratory pathogens like Influenza A virus (IAV). Lung tissue-resident memory (TRM) cells serve as the first defense against IAV but undergo rapid attrition, challenging T cell-based mucosal vaccine strategies for durable immunity. This study examined the impact of combination adjuvants targeting distinct innate receptors on CD8 T cell differentiation and TRM persistence. Intranasal delivery of Adjuplex (ADJ) combined with either TLR4 agonist GLA or STING agonist CDN induced strong expansion of mucosally-imprinted CD8 T cells in lungs and airways. ADJ+GLA predominantly generated Type III T cells, while ADJ+CDN favored Type I T cells. ADJ+GLA vaccination led to the persistence of greater number of lung TRMs, correlated with sustained IL-7R expression and lower viral titers (180d p.v.). Also, ADJ+GLA but not IAV induced stem-like, functionally plastic Type III TRMs provided durable immunity to IAV. In Tbx21 conditional KO mice, ADJ+GLA increased IL-17A+, RORγt+, ICOS+, and CD127+ CD8 T cells, suggesting the roles of RORγT and T-bet in vaccine-induced TRM development. Ongoing studies aim to elucidate the precise role of T-bet and RORγT in durable TRM formation. In summary, innate receptor engagement shapes T cell differentiation and lung TRM durability. Our findings highlight Type III programming as a promising avenue for mucosal vaccine design against respiratory viral pathogens.



 This work was supported by Public Health Service Grants UO1AI12499 and R21AI173757 from the National Institutes of Health and the John E. Butler Professorship to MS.



 Vaccines and Immunotherapy (VAC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/38455ec87f8c161d0e6405c997dadf4ef1b047d7" target='_blank'>
              Innate immune receptor engagement governs functional differentiation of effectors and persistence of tissue-resident memory T cells 4002
              </a>
            </td>
          <td>
            Hongtae Park, Brock Kingstad-Bakke, Thomas Cleven, Hailey E. Bussan, Cynthia Pryde-Aguilar, Myunghwan Jung, M. Suresh
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Autologous hematopoietic stem and progenitor cell (HSPC) transplantation is performed after myeloablation in cancer treatment to restore blood cell production and support immune recovery. Despite its success in achieving survivorship, many recipients later suffer from recurrent infections and pulmonary complications. The mechanisms driving the complications after HSPC transplantation later in life are unknown. However, the induction and/or maintenance therapeutics might be driving the negative outcomes in treated patients. We investigated the effects of the cancer therapeutics topotecan and 13-cis-retinoic acid (13cisRA) on cell phenotype and functions of HSPCs isolated from cord blood and primary monocytes from adult donors. In HSPCs, 13cisRA reduced autophagy and lysosomal activity, triggered a DNA damage response through increased γH2A.X and CDKN2 expression (including the spliced p14ARF isoform), and upregulated the epigenetic regulator SIRT3. 13cisRA also activated primary monocytes, inducing CXCL8 and CCL2 production. By contrast, topotecan had no effects on mature monocytes but induced DNA damage, metabolic remodeling, and epigenetic alterations in HSPCs. These changes included increased CDKN1A expression, higher γH2A.X-positive cell frequency, autophagy activation, and SIRT1 upregulation. The differential effects of 13cisRA and topotecan on HSPCs and monocytes might underlie the long-term complications of autologous HSPC transplantation. By modulating DNA damage, autophagy, and epigenetic pathways, these therapies could influence hematopoietic recovery and immune reconstitution, offering insights for improving transplantation outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/40700a18bb2f4d01f77bdd0f2f20d9027b11e468" target='_blank'>
              High-Risk neuroblastoma therapeutics Topotecan and 13-cis-Retinoic acid modulate autophagy and induce DNA damage response in hematopoietic stem cells and monocytes
              </a>
            </td>
          <td>
            Petra Lázničková, Federico Tidu, Jiří Hrdý, K. Boráková, Marcela Hortová Kohoutková, J. Frič
          </td>
          <td>2025-10-13</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="HBV is an enveloped DNA virus that exclusively infects hepatocytes of humans and some non‐human primates. During its viral life cycle, HBV and its structural components can directly regulate the metabolism of hepatocytes, which may reshape the liver immune microenvironment. CD8+ T‐cells, well known as cytotoxic T lymphocytes for their antiviral immunity, can undergo metabolic reprogramming during chronic HBV infection. Increasing evidence demonstrates that metabolic reprogramming promotes T‐cell exhaustion, which is a hallmark of HBV infection. Additionally, complicated metabolites (e.g., glucose, lipids, amino acids and nucleic acids) secreted from hepatocytes or T‐cells contribute to the communication between these two cell types, which may facilitate HBV infection and hinder antiviral immune response. In recent years, supplementation of certain specific metabolic substrates or targeting metabolic enzyme genes has been reported to mitigate HBV replication and induce antiviral immune response, holding promise as effective strategies for curing chronic HBV infection. This review provides a thorough overview of recent advances in the metabolic characteristics of hepatocytes and T‐cells during HBV infection, discusses the relationship between CD8+ T‐cell exhaustion and metabolic reprogramming, and emphasises the therapeutic potential of metabolic approaches in the HBV clinical landscape.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/09b14a8fcc73cd7d24ed36fdf1bbd15eb3bb6e4a" target='_blank'>
              Metabolic Reprogramming and CD8+ T‐Cell Exhaustion During Chronic HBV Infection
              </a>
            </td>
          <td>
            Haohao Li, Weiwei Mu, Alison Zhao, Su Xiao, Chenxin Huo, Huajun Zhao, Hongchun Wang, Ronghui Li, Qiuju Han
          </td>
          <td>2025-10-17</td>
          <td>Liver International</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="


 CD8+ T cells play a pivotal role in protective immune responses against intracellular pathogens and tumors. Most CD8+ T cells activated during a primary immune response will contract and die, however, a small percentage persist to form long-lived memory populations (CD8+ Tmem). CD8+ Tmem rapidly deploy their effector functions (i.e., cytotoxicity, cytokine secretion) to respond to subsequent antigen challenges. While these canonical roles are critical, previous studies have suggested that CD8+ T cells can confer protection in the absence of their cytotoxic machinery. The underlying mechanisms for such non-canonical roles remain ill-defined. Our studies have discovered that CD8+ Tmem engage myeloid cells, namely dendritic cells (DCs), in a cognate fashion to drive robust innate inflammatory responses indicative of both NF-kB and IRF activation. These responses appear to be driven by TNFSF ligand-receptor interactions between CD8+ Tmem and DCs, respectively. The ability to induce innate inflammation is directly correlated with the expression of certain TNFSF ligands, and lack of inhibitory molecules, on CD8+ Tmem. These data suggest an evolutionary adaptation wherein CD8+ Tmem facilitate protective responses not only through direct effector functions, but also by inducing broad innate inflammation. Thus, we propose memory CD8+ T cells as surrogate microbes that can initiate proinflammatory and anti-viral responses through previously unexplored mechanisms.



 Cincinnati Children’s Research Foundation



 Immune Response Regulation: Cellular Mechanisms (IRC)
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cf8f9321a00c72bc1594dfeaba5a6a038af8275a" target='_blank'>
              Memory CD8+ T cell-induced activation of the innate immune system drives inflammation and anti-viral immunity 3109
              </a>
            </td>
          <td>
            Charles N. Vallez, Satomi Ando, Koichi Araki, C. Pasare
          </td>
          <td>2025-11-01</td>
          <td>The Journal of Immunology</td>
          <td>0</td>
          <td>29</td>
        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

</body>

<script>

  function create_author_list(author_list) {
    let td_author_element = document.getElementById();
    for (let i = 0; i < author_list.length; i++) {
          // tdElements[i].innerHTML = greet(tdElements[i].innerHTML);
          alert (author_list[i]);
      }
  }

  var trace1 = {
    x: ['2025'],
    y: [13],
    name: 'Num of citations',
    yaxis: 'y1',
    type: 'scatter'
  };

  var data = [trace1];

  var layout = {
    yaxis: {
      title: 'Num of citations',
      }
  };
  Plotly.newPlot('myDiv1', data, layout);
</script>
<script>
var dataTableOptions = {
        initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;

                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);

                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';

                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    scrollX: true,
    scrollCollapse: true,
    paging: true,
    fixedColumns: true,
    columnDefs: [
        {"className": "dt-center", "targets": "_all"},
        // set width for both columns 0 and 1 as 25%
        { width: '7%', targets: 0 },
        { width: '30%', targets: 1 },
        { width: '25%', targets: 2 },
        { width: '15%', targets: 4 }

      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  }
  new DataTable('#table1', dataTableOptions);
  new DataTable('#table2', dataTableOptions);

  var table1 = $('#table1').DataTable();
  $('#table1 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table1.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
    }
  });
  var table2 = $('#table2').DataTable();
  $('#table2 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table2.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
    }
  });
</script>
<style>
  .child-row-content {
    text-align: justify;
    text-justify: inter-word;
    word-wrap: break-word; /* Ensure long words are broken */
    white-space: normal; /* Ensure text wraps to the next line */
    max-width: 100%; /* Ensure content does not exceed the table width */
    padding: 10px; /* Optional: add some padding for better readability */
    /* font size */
    font-size: small;
  }
</style>
</html>







  
  




  



                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8v12Z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "..", "features": ["navigation.top", "navigation.tabs"], "search": "../assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    

      <script src="../assets/javascripts/bundle.c8d2eff1.min.js"></script>
      
    
<script>
  // Execute intro.js when a button with id 'intro' is clicked
  function startIntro(){
      introJs().setOptions({
          tooltipClass: 'customTooltip'
      }).start();
  }
</script>
<script>
  

  // new DataTable('#table1', {
  //   order: [[5, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });

  // new DataTable('#table2', {
  //   order: [[3, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });
  new DataTable('#table3', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
  new DataTable('#table4', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
</script>


  </body>
</html>